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Abstract  
 
Background  
Cardiovascular mortality in patients with RA is 50% higher than the general population. 
Although well established that the incidence of CVD is increased, the precise cause is unclear. 
There is increasing recognition that systemic inflammation is a major driver of increased CV 
risk. IL-6 is implicated in CVD in the general population but its role in CVD in RA is undefined. 
Of the two modes of IL-6 signaling, evidence demonstrates that trans-signaling is pro-
inflammatory whereas classical signaling has regenerative or anti-inflammatory effects. The 
aim of this thesis is to examine the role of IL-6 trans-signaling in CVD in RA by experimental 
and translational studies. 
 
Methods  
Myography was used to determine the effect of IL-6 trans-signaling blockade, using 
sgp130Fc, on aortic constriction in mice with CIA. Serum CCL2 and VCAM-1 were measured. 
The effect of IL-6 trans-signaling, using Hyper-IL-6, on atherosclerotic plaque size and fibrous 
cap thickness was assessed in ApoE-/- mice. Arterial and plaque VCAM-1 expression was 
assessed. The relationship between sIL-6R-regulated CVD Candidate Proteins (SCCPs) and 
CVD in established RA was investigated in a cross-sectional study. An observational 
longitudinal study investigated whether SCCPs were associated with presence and 
progression of subclinical atherosclerosis in early RA, using carotid ultrasound to measure 
CIMT.  
 
Results  
Sgp130Fc reduced arthritis severity and restored vascular dysfunction in CIA.  This was 
associated with reduced serum CCL2 and VCAM-1. In ApoE-/- mice, Hyper-IL-6 increased 
plaque size and VCAM-1 expression in the brachiocephalic artery.  In established RA, VCAM-
1 correlated with disease activity and CV risk. In early RA, baseline RA disease activity was 
associated with CIMT change at 6 months. Patients that were ‘rapid progressors’, in terms of 
CIMT change at 12 months, had higher baseline VCAM-1, HbA1c, total cholesterol:HDL ratio 
and LDL cholesterol.  
 
Discussion  
IL-6 trans-signaling appears to play a pivotal role in vascular dysfunction and atherosclerosis 
in mouse models. In early RA, proteins regulated by IL-6 trans-signaling are associated with 
progression of subclinical atherosclerosis. Inflammation from RA onset in CVD susceptible 
individuals may accelerate atherosclerosis. Findings suggest that IL-6 trans-signaling 
blockade may be beneficial to RA patients, and perhaps for atherosclerosis in the general 
population.  
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1 Chapter 1- General Introduction 
 
1.1 Rheumatoid arthritis  
 
Rheumatoid arthritis (RA) is an inflammatory chronic polyarthritis that leads to joint 
destruction, deformity and loss of function. It is the most common inflammatory 
arthritis globally, affecting approximately 1% of the UK population (Symmons et al, 
2002). It is a systemic disorder but is predominantly characterised by symmetrical 
persistent synovial inflammation in diarthrodial joints (Tak and Bresnihan, 2000). 
Within the joint the inflamed synovial lining proliferates and forms pannus which 
erodes into cartilage and bone, leading to joint damage (Bartok and Firestein, 2010).  
Its consequences include pain, disability and increased mortality. Costs of RA in the 
UK, including indirect costs and work related disability, have been estimated at £3.8-
£4.75 billion per year (Pugner et al, 2000). Although its course is heterogeneous and 
variable, within two years of diagnosis patients usually experience moderate 
disability and after 10 years 30% are severely disabled (National Collaborating Centre 
for Chronic Conditions 2009). Extra-articular manifestations can include vasculitis, 
scleritis, pulmonary fibrosis, rheumatoid nodules, amyloidosis, serositis and 
lymphadenopathy (Cojocaru et al, 2010).  Systemic manifestations include anaemia, 
fatigue, depression, osteoporosis and cardiovascular disease (CVD) (Choy, 2012), the 
latter being responsible for the increased mortality in RA (Meune et al, 2009).   
 
1.2 Aetiology of RA  
 
The aetiology of RA is unknown, although some environmental and genetic factors 
have been associated with its development. These include specific human leucocyte 
antigen (HLA) alleles, smoking and viral infection. HLA-DR4 correlates strongly with 
RA (Fugger and Svejgaard, 2000). However, concordance rates in monozygotic twins 
are only around 15% (Silman et al, 1993), suggesting that environmental factors play 
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a large role. Smoking also appears to increase the risk of developing RA and to have 
an adverse effect on disease progression (Masdottir et al, 2000).  Numerous 
infectious agents have been suggested as potential causes or triggers for RA, 
including Epstein–Barr virus (EBV), mycoplasma organisms (Schaeverbeke et al, 
1997) and peridodontopathic bacteria (Routsias et al, 2011). Bacterial and viral 
products, such as EBV, have been found in the joints of RA patients at synovial biopsy 
(Takei et al, 1997). However, it has also been postulated that this may be due to 
persistence of infection due to altered T cell responses, rather than pathogens 
playing a causative role (Toussirot et al, 2000). It is well known that certain pathogens 
can lead to a reactive arthritis, but this usually remits spontaneously (Carter and 
Hudson, 2009). Hormonal factors are thought to play a role in the aetiology of RA; RA 
is 2-4 times more frequent in females than males (Kvien et al, 2006). RA also tends 
to improve during pregnancy and recur postpartum (Hazes et al, 2011).  RA is 
associated with the production of autoantibodies, notably rheumatoid factor and 
anti-citrullinated proteins (Song and Kang, 2010).   
 
1.3 The Normal Joint  
 
In order to understand the processes involved in RA, it is important to appreciate 
normal joint structure and environment and how these change in disease. There are 
three types of human joints: fibrous, synovial and cartilaginous. Joints affected in RA 
are predominately synovial. These are the most common joints in humans and 
include the metacarpophalangeal joints, hips, shoulders and knees. Synovial joints 
consist of the articular surfaces of two bones which are covered by hyaline cartilage. 
The cartilage functions in weight bearing, shock absorption and to reduce friction 
during movement. A fibrous capsule surrounds the joint and is comprised of two 
layers; an outer fibrous membrane and the inner synovial membrane. The joint 
capsule is filled with synovial fluid which provides lubrication and allows oxygen and 
nutrients to pass to the cartilage (Knedla et al, 2007). The synovial membrane is 
composed predominately of synovial fibroblasts and macrophages (Knedla et al, 
2007). The synovium is infiltrated by capillaries and venules and also has lymphatic 
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drainage. It is the central area of pathology in a number of inflammatory joint 
diseases, including RA (Smith, 2011). In the normal joint, bone turnover is carefully 
balanced. Osteoclasts resorb bone by attaching themselves to the periosteum and 
releasing proteolytic enzymes and acid, causing degradation of the bone and its 
membrane (Clarke, 2008). Osteoblasts synthesise bone; secreting bone extracellular 
matrix proteins which become mineralised to form bone (Clarke, 2008).   
1.4 Pathogenesis of RA 
 
The pathogenesis of RA is complex and not fully elucidated. However, several 
mechanisms underlying the development of the disease have been recognised. It is 
proposed that in genetically predisposed individuals the repeated activation of both 
the innate and adaptive immune system leads to the breakdown of self-tolerance, 
leading to autoantigen presentation and antigen-specific T and B cell activation 
(Picerno et al, 2015). Several cell types, most notably dendritic cells, express pattern-
recognition molecules, such as Toll-like receptors, which bind to various self and 
foreign structures and become activated. These then act on cells of the adaptive 
immune system. This culminates in synovial inflammation and hyperplasia, with 
leucocytes, predominately T-lymphocytes and macrophages, infiltrating the synovial 
compartment via activated endothelial cells expressing various adhesion molecules 
(Smolen et al, 2007). There is also angiogenesis and increased synovial fluid 
production, containing polymorphonuclear cells with some T cells and macrophages.  
The inflammatory exudate overlying synovial cells on the inside of the joint capsule, 
pannus, contains osteoclasts and this destroys bone, leading to bone erosion. Bone 
repair by osteoblasts usually does not occur in active RA (Smolen and Steiner, 2003). 
The growth of the synovial membrane is accompanied by neovascularisation. 
Cartilage is also degraded by enzymes secreted by chondrocytes, neutrophils and 
synoviocytes (Choy, 2012). 
Activated T and B cells produce cytokines and chemokines. Cytokines play key roles 
in the pathogenesis of RA, notably TNF-α and IL-6, both of which are used as 
therapeutic targets for treatment in RA. Other cytokines such as IL-1 and IL-17, 
although implicated in RA pathogenesis, have not been validated as successful 
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therapeutic targets in RA.. Chemokines, such as CXCL8 and CXCL9, also play 
important roles in RA, including cell-cell interactions, migration and chemoattraction 
(Koch, 2005).   These pathological changes are summarised in Figure 1.  
  
 
 
1.5 Cardiovascular risk in RA  
 
Mortality is increased in RA mainly due to CVD. Indeed, cardiovascular mortality in 
patients with RA is up to 50% higher than the general population (Meune et al, 2009; 
Avina-Zubieta et al, 2008; Peters et al, 2010; Solon et al, 2003; de Groot et al, 2010; 
Figure 1. Overview of a (A) Normal joint and (B) Joint affected by RA. In the RA joint inflammatory cells 
(macrophages, T and B cells, dendritic cells, plasma cells and mast cells) invade the synovium and surrounding 
areas. The synovial lining becomes hyperplastic, neovascularised and pannus erodes bone.  
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Gullick and Scott, 2011; Meune et al, 2010; Gabriel, 2008) and is of the magnitude 
seen in diabetes mellitus (Luqmani et al, 2006). Although it is well established that 
incidence of CVD is increased in RA, the precise cause is unclear. While traditional 
cardiovascular risk factors, such as smoking, diabetes and hypertension contribute to 
this increased mortality in RA patients, they do not fully explain the increase in risk 
(Dessein et al, 2005; del Rincon, 2001). The increased cardiovascular risk in RA is 
related to the severity and duration of inflammation (Kelt, 2009). Certain 
inflammatory cytokines, such as interleukin-6 (IL-6), have been implicated in the 
pathogenesis of both RA (Srirangan and Choy, 2010) and CVD (Hartman and 
Frishman, 2014).  
Cardiovascular events occur on average ten years earlier in RA patients than the 
general population (Bacon et al, 2002). Cardiovascular manifestations in RA include 
arrthymias, myocarditis, pericarditis, cardiac amyloidosis, coronary vasculitis, 
congestive heart failure, and atherosclerosis (Voskuyl, 2006). The focus of this thesis 
is atherosclerosis, which is the cause of the majority of cardiovascular deaths in RA. 
As well as having an increased incidence of CV events, RA patients also experience 
significantly lower survival rates after a myocardial infarction or stroke compared to 
those without RA (Solomon et al, 2006). Despite this, standardised admission rates 
for cardiovascular disease are not raised; suggesting either that CVD in RA goes 
unrecognised before the fatal event or has a higher case fatality than in the general 
population (Goodson et al 2005). In addition to an increase in actual cardiovascular 
events, RA patients have a higher prevalence of preclinical atherosclerosis than the 
general population, such as asymptomatic carotid artery atherosclerotic plaques 
(Roman et al, 2006). 
The term coronary microvascular dysfunction (CMD) has been introduced to describe 
abnormalities in the regulation of myocardial blood flow (MBF) which are not 
explained by disease of the epicardial coronary arteries. A study using PET to measure 
MBF found that patients with RA and SLE had reduced coronary flow reserve in the 
absence of significant coronary artery disease (Recio-Mayoral et al 2009).  There are 
also differences in the presentation and outcome of heart failure in those with and 
without RA. Despite RA patients having more subtle presentation of heart failure, 
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and having more preserved myocardial function, mortality from heart failure in RA 
patients is significantly higher (Davies et al 2008). 
 
The Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in 
Patients with Rheumatoid Arthritis (TRACE-RA) study was designed to assess whether 
atorvastatin 40mg daily was superior to placebo for the primary prevention of CVD 
events in patients with RA (Kitas et al, 2015). However, the study was terminated 
early, after more than 3,000 patients of the 4,000 target population had been 
recruited, due to a low incidence of the primary cardiovascular end point. This 
highlights the fact that using cardiovascular events as outcome for exploratory 
studies is not appropriate since sample size is prohibitively large. The following study 
therefore uses carotid ultrasound as a surrogate for determining subclinical 
atherosclerosis in RA.  
 
1.6 Hypotheses for increased CV risk in RA  
 
There are a number of theories put forward to explain the increased risk of CVD in 
RA patients. Firstly, RA patients have an increased prevalence of traditional 
cardiovascular risk factors. These include smoking and hypertension (Panoulas et al, 
2008). Secondly, due to the nature of the disease, some RA patients are less active 
than the general population, and inactivity in the general population has been linked 
to cardiovascular disease (Bijnen et al, 1994). Thirdly, some drugs used in the 
management of RA have been implicated, outlined in section 3 below. Lastly, there 
is increasing evidence that systemic inflammation plays an important role in the 
increased risk in RA patients. These theories are discussed in more detail below.  
1. Traditional CV risk factors are more prevalent in RA patients. Certain traditional 
cardiovascular risk factors, such as smoking (Wolfe, 2000; McEntegart et al, 
2001; Solomon et al, 2003), diabetes mellitus and reduced HDL cholesterol 
levels appear more prevalent in RA patients (Boyer et al, 2010). There is 
conflicting evidence in the literature regarding hypertension in RA patients; 
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some studies do not show a difference between RA patients and healthy 
subjects (Roman et al, 2006; Maradit-Kremers et al, 2005; Solomon et al, 
2003), while others have shown an increased prevalence in RA patients (Han 
et al, 2006). An important concept in RA patients is the ‘lipid paradox’. In the 
general population the risk of atherosclerosis development increases 
progressively with increasing LDL cholesterol levels and declines with 
increasing levels of HDL cholesterol, however, in RA, the presence of a 
proinflammatory state leads to a decrease of total cholesterol, HDL cholesterol 
and LDL cholesterol in patients (Robertson et al 2013). In contrast, reduction 
in inflammation coincides with increases in serum lipid values (Myasoedova et 
al 2011). These changes are complex and of importance are relative changes 
in the pro and anti-inflammatory lipoprotein components. Chronic 
inflammation leads to oxidative changes that alter HDL structure and reduce 
apolipoprotein-A-I in patients with active RA (Charles-Schoeman et al 2009). 
Several studies have shown an increased prevalence of diabetes mellitus in RA 
(Han et al, 2006; Dessein et al, 2002) but others have shown a similar 
prevalence to controls (Solomon et al, 2003). Several studies have found a 
higher prevalence of hyperlipidaemia in RA (Han et al, 2006). A recent large, 
retrospective cohort study of UK patients found that there were no differences 
in the frequency of testing and treatment of CV risk factors between RA 
patients and non-RA patients (Alemao et al, 2016). Thus, higher CV risk seen 
in RA patients is unlikely to be due to differences in traditional CV risk factor 
management.  
 
2. Inactivity of RA patients. Patients with RA have high levels of inactivity (Sokka 
et al, 2008) for various reasons, includuing physical pain, poor joint movement, 
fear of pain or joint damage, fatigue and mood disturbance. It is known that in 
the general population lack of exercise increases the risk of CV disease 
development and exercise reduces this risk (Gielen et al, 2009). However, this 
does not fully explain the increase in CV risk, which increases early in the 
disease course of RA, where inactivity may not be present, or may have only 
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been present for a short time period. Also, as treatments for RA improve, 
disease should become less disabling, such that levels of inactivity may reduce.   
 
3. Drugs used in RA management. Some drugs used in RA management have 
associated cardiovascular risk, such as NSAIDs and corticosteroids. Others 
seem to have a protective role.  
 
a. NSAIDS are commonly used for symptomatic treatment of RA, both 
before and after definitive diagnosis, to treat symptoms such as pain 
and swelling. Most NSAIDs act as nonselective inhibitors of the 
enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 
(COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyses the 
formation of prostaglandins and thromboxane from arachidonic acid. 
Selective cyclo-oxygenase-2 (COX-2) inhibitors are selective inhibitors 
of the COX-2 isozyme (FitzGerald and Patrono, 2001). A meta-analysis 
reports that selective COX-2 inhibitors are associated with a moderate 
increase in the risk of vascular events, as are high dose regimens of 
ibuprofen and diclofenac, but high dose naproxen is not (Kearney et 
al, 2006).  
 
b. Glucocorticoids are often used as a means of rapidly reducing 
inflammation in RA. Adverse effects of long-term glucocorticoid use, 
especially at high doses, are well recognised in the general population. 
These include effects on body weight and fat distribution (Macfarlane 
et al, 2008), blood pressure (Whitworth et al, 2000) and insulin 
resistance (Andrews and Walker, 1999). There are conflicting reports 
of their effects on lipid profile (Choi et al, 2005). In RA the effects of 
glucocorticoids on cardiovascular risk are not fully elucidated, in part 
because glucocorticoids reduce systemic inflammation which is 
thought to play a major role in CV risk in RA. In an inception cohort 
study of low-dose prednisolone use during the first 2 years of RA 
disease, the incidence of ischaemic coronary artery events was similar 
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in those taking prednisolone and those not (Ajeganova et al, 2014). 
However, those taking prednisolone had an increased long-term risk 
of ischaemic cerebrovascular event and there was a trend towards 
reduced survival in the prednisolone group.  
 
c. Several disease modifying anti-rheumatic drugs (DMARDS) are used to 
treat RA. The most commonly used are methotrexate (MTX), 
sulphasalazine (SSZ) and hydroxychloroquine (HCQ.) A case control 
study found that MTX and, to a lesser extent, SSZ were associated with 
significantly lower CVD risk compared to RA patients who had never 
used SSZ, HCQ or MTX (van Halm et al, 2006) While another study 
found a protective effect of MTX on cardiovascular risk (Choi et al, 
2002), others have not (Singh and Cameron, 2012). Interestingly, 
there is an ongoing trial assessing MTX efficacy as secondary 
prevention in non-RA patients with established CVD (Everett et al, 
2013). Hydroxychloroquine has been found to have a favourable 
effect on lipid profiles (Morris et al, 2011) and insulin sensitivity 
(Mercer et al, 2012). Leflunomide has been associated with 
hypertension (Rozman et al, 2002). 
 
d. Biological therapies  
 
i. TNF-α blocking agents. Most studies have found that TNF-α 
blocking agents are associated with a reduced cardiovascular 
risk in RA (Solomon et al, 2013; Jacobsson et al, 2005; 
Greenberg et al, 2011; Naranjo et al, 2008). Other studies have 
shown no difference in risk with anti TNF (Solomon et al, 2006; 
Dixon et al, 2007) and some have shown that there may be an 
increased cardiovascular risk (Suissa et al, 2006). TNF-α 
blocking agents are contraindicated in RA patients with heart 
failure on the basis that clinical trials which used these drugs 
in non-RA heart failure produced disappointing results in 
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patients with moderate to severe heart failure (Cacciapaglia et 
al, 2011). A more recent study found that patients with RA 
receiving a TNF inhibitor had a decreased risk of MI compared 
with patients with RA receiving non-biologcial DMARDs over 
the medium term (Low et al 2017). A mouse model of arthritis, 
the Tg197 arthritis model, develops TNF- driven and 
mesenchymalsynovial fibroblast (SF)-dependent polyarthritis 
(Ntari et al 2018). These mice also develop heart valve disease 
alongside chronic polyarthritis. Both pathologies were 
dependant on TNF in this model. 
 
ii. Anti-IL-6R antibody (Tocilizumab).  In a study of patients 
receiving Tocilizumab there was an association between the 
baseline total cholesterol:HDL ratio and an increased risk of 
major adverse cardiovascular events (Rao et al, 2015). The risk 
of cardiovascular events while receiving treatment, however, 
was associated with control of disease activity but not lipid 
changes. Studies have consistently shown that tocilizumab is 
associated with increased lipid levels in the context of 
decreased inflammatory marker levels (Nishimoto et al, 2010; 
Emery et al, 2008). Although lipid changes alongside reduction 
in inflammation are seen with all biological and non-biological 
DMARDs, theses are most well described and are more 
apparent with Tocilizumab. The ENTRACTE study compared 
rates of major cardiovascular outcomes in RA patients treated 
with Tocilizumab or Etanercept (Giles et al 2016). By week 4, 
total cholesterol, LDL, HDL, and triglycerides increased 
significantly in the Tocilizumab arm compared with the 
Etanercept arm, but there was no significant difference in 
major cardiovascular events over a mean follow up of 3.5 
years. Data from phase 3 studies and extension studies have 
shown rates of MI were lower with tocilizumab versus placebo 
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(Schiff et al, 2011) and analysis of the long-term safety (n = 
4171; median treatment duration 3.9 years) found a stable 
rate of cardiovascular events over time with tocilizumab 
exposure (Genovese et al, 2013; Schiff et al, 2011). Also, 
tocilizumab does not appear to increase CIMT in RA (Kume et 
al, 2011). 
 
 
iii. Rituximab, a monoclonal anti-CD20 antibody which causes B 
cell depletion, does not appear to increase risk of 
cardiovascular events at 6 months and in longer term follow 
up (van Vollenhoven et al, 2010) and appears to have 
beneficial effects on lipid profile (Raterman et al, 2013). Ait 
Oufella et al (2010) showed that mature B cell depletion using 
a CD20-specific monoclonal antibody caused a significant 
reduction of atherosclerosis in mouse models of 
atherosclerosis. 
 
4. Systemic inflammation in RA. The excess cardiovascular burden in RA persists 
after adjustment for traditional CV risk factors (del Rincon et al, 2001; Maradit-
Kremers, 2005). There is accumulating data implicating systemic inflammation 
as the major driver of this increased CV risk (Gabriel, 2008; del Rincon et al, 
2001; Arts et al, 2014). Inflammation contributes to the onset and 
pathogenesis of CVD in the general population. Epidemiological studies have 
shown that circulating CRP (Ridker and Cook, 2004) and IL-6 (Ridker et al, 2000) 
are associated with higher risk of CVD in the general population, independent 
of known CVD risk factors. It should be noted that evidence indicates that the 
CRP does not cause CVD, whereas IL-6 appears to play a causative role (Welsh 
et al 2017). High IL-6 levels are associated with increased mortality in patients 
with acute coronary syndromes (Biasucci et al, 1999). Levels of CRP and IL-6 
are much higher in RA patients than the general population, indeed there is a 
significant association between inflammation measured by erythrocyte 
12 
 
sedimentation rate (ESR) or CRP, and risk of CVD in RA (Chung et al, 2008; Book 
et al, 2005; Crilly et al, 2009; Graf et al, 2009; del Rincon et al, 2005; Gonzalez-
Gay et al, 2005). There is also evidence that reducing inflammation in RA 
lowers CV risk (van Halm et al, 2006; Dixon et al, 2007; Choy and Sattar, 2005).  
 
RA is associated with anti-citrullinated proteins (anti-CCP) antibodies. Within 
atherosclerotic plaque citrullinated proteins are prevalent in non-RA patients 
(Sokolove et al 2013). Certain anti-CCP antibodies were associated with 
atherosclerotic burden. These observations suggest that citrullinated 
epitopes within atherosclerotic plaque may be targeted by RA-associated 
anti-CCP antibodies which may form immune complexes, locally increasing 
plaque inflammation and progression. This may in part explain the 
accelerated atherosclerosis observed in patients with RA. Citrullination has 
also been found to be higher in the myocardium of RA patients compared to 
non-RA patients (Giles et al 2012). 
 
Advances in basic science have established the fundamental role of 
inflammation in all stages of atherosclerosis, from plaque formation, to 
instability and eventual rupture (Gonzalez Gay et al, 2005; Hansson and 
Hermansson, 2011; Libby et al, 2011). The pathophysiology of atherosclerosis 
is discussed in section 1.13.1.  
 
1.7 Assessing Cardiovascular Risk in RA 
 
National and International guidelines, including those of the British Society for 
Rheumatology (Luqmani et al, 2009), National Institute for Health and Clinical 
Excellence (2009) and European League Against Rheumatism (EULAR) (Peters et al, 
2010) recommend annual assessment of cardiovascular risk in RA patients. EULAR 
recommendations for cardiovascular management were based on a systematic 
literature review. Traditional cardiovascular risk factor assessment equations, such 
as the Framingham risk score (FRS) and Systematic Coronary Risk Evaluation Score 
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(SCORE) (Conroy et al, 2003) models, underestimate cardiovascular risk in RA. 
Therefore, EULAR recommends multiplying such traditional cardiovascular risk 
scores by 1.5 for RA patients who meet two of three criteria consisting of (1) disease 
duration >10 years, (2) positive rheumatoid factor or anti-cyclic citrullinated peptide 
(anti-CCP) serology, and (3) presence of severe extra-articular manifestation, to 
account for the unexplained increased cardiovascular risk in RA (Peters et al, 2010). 
However, recent studies have shown that even modified cardiovascular risk scores, 
such as recommended by EULAR still underestimate overall cardiovascular risk (Arts 
et al, 2014; Rosales-Alexander et al, 2014). Thus, there is a need for a better means 
of risk stratification. EULAR guidelines were updated in 2016 and recommend 
optimal control of RA disease activity, CV risk assessment at least once every 5 years, 
consideration of carotid ultrasound as screening for asymptomatic atherosclerotic 
plaques as part of the CVD risk evaluation (Agca et al 2016).  
 
1.8 Cardiovascular risk algorithms 
See Table 1 for comparison of different cardiovascular risk algorithms.  
a) SCORE  
 
The SCORE model is based on gender, age, smoking, systolic blood pressure 
and total cholesterol (Conroy et al, 2003). There are different charts for 
patients from a high or low CV risk region of Europe. It is derived from a large 
dataset of prospective European studies and predicts fatal atherosclerotic 
CVD events over a ten year period.  
 
b) The Framingham risk score  
 
The Framingham Risk Score (FRS) was first developed based on data obtained 
from the Framingham Heart Study in the USA and was first published in 1998 
(Wilson et al, 1998) and the current version in 2002 (Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults, 2002). It 
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performs well in North America (Eichler et al, 2007) but less so elsewhere 
(Brindle et al, 2003). The updated version includes age, gender, systolic BP, 
smoking status, total cholesterol and HDL cholesterol and whether the 
patient is on treatment for hypertension. The endpoint definition is angina 
pectoris and cardiovascular death.  
 
c) The QRISK2 score  
 
The QRISK2 is the only validated CV risk score to include RA as an independent 
CV risk factor. It includes age, systolic blood pressure, smoking status, total 
cholesterol:HDL ratio, body mass index, ethnicity, geographical measures of 
deprivation, family history of early CVD, chronic kidney disease, RA, atrial 
fibrillation, diabetes mellitus, and antihypertensive treatment. In the UK 
current National Institute for Health and Care Excellence (NICE) guidelines 
recommend using this to assess CV risk (NICE, 2014). The NICE guidelines 
state that if a patient has a greater than 10% risk of CVD event over the next 
ten years when calculated using the QRISK2 then primary prevention with 
lipid lowering therapy (such as statins) should be initiated (NICE, 2014). The 
algorithm is updated annually to reflect changes in populations, data quality 
and national guidelines. A prospective open cohort study found that the 
QRISK2 was better calibrated to the UK population than the FRS and has 
better discrimination (Hippisley-Cox et al, 2008).  
 
d) The Reynolds risk score (RRS) 
 
This score includes age, total cholesterol, HDL cholesterol, systolic blood 
pressure, diabetes mellitus assessed by haemoglobin A1c (for women only), 
current smoking, parental history of MI before age 60 years and serum high 
sensitivity CRP (hs-CRP) (Ridker et al, 2007). Endpoints assessed are 
cardiovascular death, nonfatal MI, non-fatal stroke and coronary 
revascularization.  
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e) The American College of Cardiology/American Heart Association (ACC/AHA) 
2013 guideline.  
This score includes age, gender, ethnicity, total cholesterol and HDL 
cholesterol, smoking status, diabetes, treatment for hypertension, systolic 
and diastolic blood pressure. Endpoints assessed are fatal and non-fatal MI 
and stroke.  
Risk algorithm   
 
SCORE 
 
Framingham Reynolds QRISK2 ACC/AHA 
Age 
 
     
Gender  
 
     
Systolic blood 
pressure 
     
Diastolic blood 
pressure  
     
Smoking 
 
     
Total Cholesterol 
 
     
HDL cholesterol 
 
     
Cholesterol:HDL ratio      
Rheumatoid arthritis        
Deprivation score 
 
 
    
On treatment for 
hypertension  
 
    
hsCRP 
 
 
    
Diabetes  
 
 
*    
Family history of early 
CVD 
 
    
CKD 
 
 
    
AF 
 
 
    
Ethnicity 
 
 
    
Endpoint definition Fatal 
atherosclerotic 
CVD events 
Angina 
pectoris, CV 
death 
MI, stroke, 
coronary 
revascularization, 
CV death 
MI AP, 
CAD, 
stroke, and 
TIA 
Fatal and 
non-fatal 
MI and 
stroke  
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Table 1. Summary of various cardiovascular risk algorithms. hsCRP (high sensitivity CRP), CKD 
(Chronic Kidney disease), AF( Atrial Fibrillation). *removed from updated version.   
 
Which risk score performs best in RA? 
The QRISK2 score is the only validated score to include RA as an independent risk 
factor for CVD. However, it does not factor in time since RA diagnosis as suggested 
by EULAR and may, therefore, over predict risk in patients recently diagnosed with 
RA. However, recent data suggests that patients with RA may have similar chances 
to develop CV events early and late in their disease course (Kerola et al, 2012a; Kerola 
et al, 2012b). 
One study used data collected prospectively from the Nijmegen early rheumatoid 
arthritis inception cohort in the Netherlands to assess the discriminatory ability of 
different cardiovascular risk algorithms in early RA (Arts et al, 2014). Algorithms 
assessed were SCORE, FRS, RRS and QRISK2. Discriminatory ability for CV risk 
prediction was estimated by the area under the receiver operating characteristic 
curve. Calibration was assessed by comparing the observed versus expected number 
of events. SCORE, FRS and RRS primarily underestimated CV risk at middle and low 
observed risk levels and mostly overestimated CV risk at higher observed risk levels. 
The QRISK2 primarily overestimated observed CV risk. Of note, depending on the 
model used, up to 32% of observed CV events occurred in RA patients who were 
classified as low risk for CV disease.  
It could be thought that the RRS may be good for assessing risk in patients with RA 
as it incorporates the inflammatory marker hs-CRP in addition to traditional risk 
factors. However, many patients with RA have high levels of CRP during the course 
of their disease (generally much higher than the general population) and thus it is 
unclear if adding hs-CRP to a CV risk algorithm improves the predictive performance 
in RA.  
In order to improve identification of patients at increased CV risk, different 
approaches have been suggested. The cut-off point for primary prevention could be 
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lowered. However, this could also lead to overtreatment, as most patients in low risk 
groups do not develop cardiovascular events (Arts et al, 2014). Alternatively, the CV 
risk score could be adjusted by a certain correction factor for patients with RA, such 
as suggested by the EULAR recommendations (Peters et al, 2010). This particular 
multiplicator was chosen as a meta-analysis showed a mean standardised mortality 
ratio (SMR) of 1.2 for inception cohorts (2 years’ disease duration) compared with a 
mean SMR of 1.9 for established disease (Ward, 2001). The EULAR guideline authors 
chose 1.5 as a multiplicator as available comparative studies did not adequately 
adjust for important confounders (including social class and physical activity), and 
few adjusted for all established CV risk factors using continuous data. Thus, it is 
possible that the excess CV risk in RA, over and above traditional risk factors, has 
been overestimated. Hence, a multiplication factor of 1.5 (rather than 2.0), was 
chosen on the basis of the evidence from observational SMR reporting studies as well 
as expert opinion (Peters et al, 2010). 
 
Drawback of current risk algorithms 
 
One problem with risk assessments are that they may be falsely reassuring for some 
patients who are defined as having low risk when they may actually have multiple 
marginal abnormalities. An important component of multivariate risk models for the 
estimation of CVD risk is that many of the risk factors (e.g. age, hypertension, serum 
LDL-cholesterol) are recognised as producing a graded increase in risk. In addition, 
the relative effects of traditional risk factors differ according to the particular vascular 
disease outcome being evaluated (Wilson, 2008). Some risk algorithms do not include 
patient important CVD outcomes such as stroke, heart failure or development of 
symptomatic peripheral artery disease. Therefore, there is a real need to better 
understand the aetiology of CVD in RA as current risk algorithms may lead to both 
over- and under-estimation of risk in different patients. Moreover, if a biomarker 
could be identified which could identify RA patients at high risk of CVD, they could be 
selected for more invasive investigation or management of risk.  
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1.9 Vascular function  
 
In order to understand vascular dysfunction it is important to understand the normal 
vascular structure and function.   
1.10 Normal structure of arteries  
 
To withstand regular pumping of the heart and thus high pressures, arteries have 
thick muscular walls. The artery wall consists of three layers, summarised in Figure 2.  
 
 
 Tunica Adventitia (or tunica externa) 
 
This is the outer layer rich in collagenous ECM molecules. It 
contains fibroblasts, blood vessels, and perivascular nerves. It 
also has a role in immune surveillance and inflammatory cell 
trafficking and contains the vasa vasorum, which maintains the 
Figure 2. A diagram of the normal arterial wall in cross section.  
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medial layer and provides access for macrophage and 
leukocyte migration into the intima (Majesky et al, 2011). 
 
 Tunica Media  
 
This consists of vascular smooth muscle cells (VSMCs) 
arranged concentrically with bands of elastin fibres between 
the layers. VSMCs enable blood vessels to constrict to allow 
vessel resistance (Rensen et al, 2007). When these cells 
contract they decrease the diameter of the blood vessel (i.e. 
vasoconstriction). When the VSMCs relax the blood vessel 
increases in diameter (i.e. vasodilation).  
 
 Tunica intima 
 
The innermost layer consists of a single layer of endothelial 
cells supported by an underlying internal elastic lamina. The 
endothelial cells are in direct contact with blood flow and form 
an interface between the circulating blood and the cells of the 
vessels (Rajendran et al, 2013). Intact endothelium 
mechanically separates platelets and their pro-coagulant 
products from intravascular, subendothelial and tissue 
coagulation factors, and also inhibits pro-coagulant proteins 
(Rajendran et al, 2013). It controls the passage of materials 
and white blood cells into and out of the circulation, reduces 
turbulence of blood flow and participates in fibrinolysis by the 
production of tissue plasminogen activator. The endothelium 
responds to numerous circulating factors, altering vascular 
tone and architecture. Several pathological conditions 
including hypercholesterolemia, diabetes mellitus and chronic 
inflammation disrupt the homeostatic mechanisms of the 
endothelial layer. This results in increased adhesiveness of the 
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endothelium to leucocytes and in altered permeability of the 
endothelium. This also leads to heightened reactivity of the 
adjacent vascular smooth muscle. Endothelial dysfunction is 
discussed in more detail in section 1.12.1.  
 
1.11 Vascular smooth muscle constriction  
 
Circulating endothelium-derived factors, hormones, neurotransmitters and shear 
stress all contribute to vascular smooth muscle tone, and thus lumen diameter 
(Wynne et al 2008). The final product is the control of blood pressure and organ blood 
flow. All VSMCs, regardless of the stimulus, produce contraction through cross-bridge 
cycling between actin and myosin filaments (Wynne et al 2008). In smooth muscle, 
this process is initiated by calcium-mediated change in the thick (myosin) filaments 
(Hilgers and Webb 2005). An increase in free intracellular calcium results from either 
increased flux of calcium into the cell through calcium channels or by release of 
calcium from internal stores, for example sarcoplasmic reticulum. The free calcium 
binds to calmodulin. Calcium-calmodulin activates myosin light-chain kinase, which 
phosphorylates myosin light chains (MLC) in the presence of ATP (Hilgers and Webb 
2005).  MLC phosphorylation leads to cross-bridge formation between the myosin 
heads and the actin filaments, and thus, smooth muscle contraction.  
 
1.12 Non-invasive assessment of vascular function and CVD in RA 
 
It is known that patients with RA have increased incidence of cardiovascular disease. 
There are various methods (invasive and non-invasive) used to measure both 
vascular function and structural abnormalities in RA and the general population.  
Coronary angiography is the gold standard test for identifying the presence and 
extent of atherosclerotic coronary artery disease. This invasive procedure is time 
consuming, costly and confers risk to the patient, such as bleeding, arrhythmia, 
infection, pain, blood vessel perforation and myocardial infarction. Non-invasive 
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techniques confer less risk. Each has its benefits and drawbacks, discussed in sections 
1.12.1 to 1.12.6. 
 
1.12.1 Endothelial dysfunction  
 
Endothelial dysfunction (ED) is one of the key early events in atherogenesis; it 
precedes structural atherosclerotic changes (Raitakari and Celermajer, 2000). 
However, it is also present in the late stages of atherosclerosis when it can lead to 
constriction or thrombosis of vessels (Raitakari and Celermajer, 2000). ED can be 
assessed invasively, by infusion of substances such as acetylcholine or substance P, 
which enhance the release of endothelial nitric oxide (Tousoulis et al, 2005). It can 
also be assessed noninvasively by measurement of endothelial-dependent ﬂow-
mediated vasodilatation (ED-FMD) of peripheral arteries, measured by 
ultrasonography (Corretti et al, 2002). Here, arterial diameter is measured in 
response to an increase in shear stress (induced by inflation and then deflation of a 
sphygmomanometer cuff around the limb, distal to the scanned part of the artery), 
which causes endothelium-dependent dilatation. In the general population ED-FMD 
is a predictor of cardiovascular events (Bonetti et al, 2003), and is associated with 
risk factors of CVD. Endothelial dysfunction is a reversible disorder; interventions 
such as cholesterol lowering and smoking cessation can improve it (Bonetti et al, 
2003).  
ED-FMD is routinely expressed as the percentage change in arterial diameter (FMD%) 
from a resting baseline. Several studies have shown impaired FMD% in RA patients 
compared to controls (Fan et al, 2012; Chatterjee et al, 2012; Temiz et al, 2015). In 
one study median FMD% was signiﬁcantly lower in RA patients compared to controls 
and according to the standard cut off value (FMD of 4.5%), 17 RA patients (48.57%) 
and 4 controls (11.43%) had abnormal FMD% (Chatterjee et al, 2012).  
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1.12.2 Arterial distensibility 
 
Arterial distensibility is a measure of vascular elastic behaviour, it measures arterial 
ability to contract and expand with cardiac relaxation and pulsation. Decreased 
arterial distensibility alters arterial flow dynamics and disturbs coronary perfusion. In 
animal models, a there is an alteration in arterial distensibility in the early stages of 
atherosclerosis of the aorta, before other vessel wall changes such as increased 
vessel wall thickness and plaque formation  (Hironaka et al, 1997). In humans, a 
decrease in distensibility (or increased artery wall stiffness) is related to risk factors 
for clinical vascular disease (Dart et al, 1991) and can predict those at increased risk 
of future coronary artery disease and stroke in apparently healthy individuals 
(Mattace-Raso et al, 2006). Of note, in the latter study, aortic pulse wave velocity 
was an independent predictor of coronary heart disease and stroke but carotid 
distensibility was not. However, this study used the brachial pulse pressure rather 
than the carotid pulse pressure, which may have led to an underestimation of the 
distensibility. In the atherosclerotic process, functional changes in the vascular wall 
may occur before anatomical changes such as intima media thickening or plaque 
formation. Previous studies have shown reduced carotid distensibility in women with 
RA compared to female controls and these changes correlated with disease severity 
(Turesson et al, 2005). There was no detected difference in men with RA compared 
to male controls.  
 
1.12.3 Echocardiography  
 
Transthoracic echocardiography (TTE) uses ultrasound to assess cardiac function and 
structure. It is safe, low cost and can also provide information on ischaemia when 
combined with pharmacological stress or exercise (Erhayiem et al, 2014). TTE is fairly 
easily available and well tolerated (Armstrong et al, 2012). However, adjacent 
structures can interfere with picture quality, obesity or acoustic shadowing from the 
lungs can be problematic, and reproducibility is limited by reporting variability 
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(Armstrong et al, 2012).  Studies using TTE have found that patients with RA have a 
higher incidence of valvular heart disease, pericarditis and aortic plaques than 
controls (Guedes et al, 2001), and also higher incidence of abnormal left ventricular 
remodelling than controls (Myasoedova et al, 2013). 
 
1.12.4 Cardiac MRI 
 
Cardiac magnetic resonance (CMR) imaging can assess both anatomy and function of 
the heart, as well as tissue characterisation. It can assess left ventricular mass, aortic 
distensibility, myocardial strain and myocardial ischemia (Erhayiem et al, 2014). 
There is no radiation exposure, it is a reproducible method and provides better 
accuracy than TTE for several measurements (Armstrong et al, 2012).  Unlike 
echocardiography, cardiac MRI can produce images without interference from 
adjacent bone or air. However, examination time is significantly longer than other 
non-invasive methods and requires more patient cooperation. Claustrophobic 
patients may have difficulty tolerating the procedure and installation and operation 
of the MRI equipment is expensive. Due to the magnets used in MRI, it is 
contraindicated in patients with ferromagnetic objects in situ, such as cardiac 
pacemakers and intracranial metal. In patients with RA mean left ventricular mass, 
left ventricular ejection fraction and cardiac output were both lower than in controls 
(Giles et al, 2010).  Other studies have shown myocardial abnormalities in RA patients 
without known cardiac disease and abnormal CMR findings were associated with a 
higher RA disease activity (Kobayashi et al, 2010). There are differences seen in the 
RA population compared to the general population in terms of LV mass; although 
there are conflicting results in the literature.  High LV mass in the general population 
is a poor prognostic indicator, but in RA patients, studies have shown reduced LV 
mass compared to pubished controls (Bissell et al 2014). 
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1.12.5 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed 
tomography (CT) 
 
Positron emission tomography (PET)/ computed tomography (CT) imaging of 
atherosclerosis using the metabolic marker fluorodeoxyglucose (FDG) allows 
quantification of arterial inflammation in vessels and plaques (Tawakol  et al, 2013). 
It was shown to improve prediction of future CVD events in the general population 
(Figueroa et al, 2013). However, resources are expensive and require advanced 
technical skill to perform and interpret, and not all centres will have the required 
equipment. RA patients were found to have significantly higher arterial FDG uptake 
compared with matched controls, after adjusting for atherosclerosis risk factors and 
statin use (Emami et al, 2014). In this study, arterial FDG uptake correlated with 
synovial activity. As well as arterial inflammation, a recent study has shown increased 
FDG uptake in the myocardium of RA patients compared to controls (Amigues et al, 
2016).  
 
1.12.6 Carotid Ultrasound Scan (USS) 
 
High-resolution B-mode ultrasound is a non-invasive method, used to assess the 
atherosclerotic process in various arteries. Atherosclerosis does not take place 
uniformly in the arterial tree, preferentially developing at arterial branches and 
opposite to flow dividers, as these sites are exposed to low or disturbed blood flow 
and low shear stress (Warboys et al, 2011). Regions exposed to unidirectional high 
flow are spared. These findings may be due to the fact that in areas of low blood flow, 
atherogenic cells or material have better access to the endothelium. Also, in areas of 
low shear stress, adhesion molecules are induced on endothelial cells (O’Keeffe et al, 
2009). Major sites for the atherosclerotic process are the coronary arteries, carotid 
and cerebral arteries, areas of the aorta and the large arteries to the lower 
extremities. The carotid arteries are easily accessible and atherosclerosis here 
reflects disease in other arteries such as the coronary arteries. Autopsy studies have 
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shown positive correlations between carotid and coronary plaque burden (Mitchell 
and Schwartz, 1962). However, the presence of carotid plaque alone has not been 
sufficient to identify patients with inflammatory joints diseases at risk for CAD, and a 
combination of ultrasonographic measurements has been suggested for risk 
stratification in these patients (Svanteson et al 2017). Skeoch et al (2017) used 
Dynamic Contrast Enhanced MRI (DCE-MRI) and FDG-PET in RA patients. A higher 
prevalence of plaque calcification was noted in RA compared to controls, despite 
similar plaque size. There was also plaque inflammation detected in 12/13 RA 
patients scanned. 
US allows assessment of plaque and measurement of intima-media thickness (IMT). 
IMT is the combined width of the intima and media layers of an artery, measured 
from the border between the vessel lumen and the intima and the border between 
the media and adventitia (Urbina et al, 2006). Far-wall carotid IMT (CIMT) accurately 
represents the intima-media thickness compared with direct histological 
examination, whereas near wall CIMT measurements may underestimate the intima–
media thickness (Wong et al, 1993). Prospective longitudinal studies have shown that 
detection of plaque or CIMT thickening on USS are associated with an increased risk 
of myocardial infarction (Salonen and Salonen, 1991; van der Meer et al, 2004) and 
stroke (Gupta et al, 2015) in the general population. In RA, CIMT predicts 
development of CV events (Gonzalez-Juanatey et al, 2009). In this study RA patients 
without traditional CV risk factors who had CIMT values >0.90 mm had an increased 
risk of CV events over a 5-year follow-up period. Another study found that RA 
patients with carotid plaque had a higher risk of acute coronary syndromes (ACS); 
those with unilateral plaques had a 2.5 times increased risk and those with bilateral 
plaques had a 4.3 times increased risk (Evans et al, 2011). Also, mean CIMT has been 
shown to be significantly higher in RA patients (s (0.50 + 0.16 mm) compared to 
controls (0.44 + 0.09 mm) (Chatterjee et al, 2012). 
In view of its merits of low cost, reproducibility, non-invasiveness, good correlation 
with coronary atherosclerosis and good predictive value in terms of CV risk, this 
thesis used carotid USS and measurement of CIMT and plaque as a surrogate marker 
for atherosclerosis, as well as measures of arterial distensibility.  
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1.13 Inflammation and CVD atherosclerosis in the general population  
 
 
Although great progress has been made in the prevention and treatment of 
cardiovascular disease, it is still the leading cause of death in the Western world 
(Braunwald, 1997). Advances in basic science have established the fundamental role 
of inflammation in all stages of atherosclerosis, from plaque formation to instability 
and eventual rupture (Gonzalez-Gay et al, 2005; Hansson and Hermansson, 2011; 
Libby et al, 2011). Both the innate and adaptive immune responses are involved in 
atherosclerosis, regulated by various cytokines. To appreciate the role of 
inflammation in the atherosclerosis process it is important to understand the 
pathogenesis of atherosclerosis.  
 
  
1.13.1 Pathogenesis of atherosclerosis  
 
Lesions of atherosclerosis occur mainly in medium and large muscular and elastic 
arteries (Ross, 1999). As mentioned in section 1.12.6, atherosclerosis does not take 
place uniformly in the arterial tree, developing at arterial branches and opposite flow 
dividers, where there is often disturbed blood flow. Although thought of as a disease 
of aging, early lesions can develop in childhood. ‘Fatty streaks’, the earliest type of 
lesion, are seen in infants and young children (Napoli et al, 1997). These are in fact 
inflammatory lesions, consisting of T lymphocytes and monocyte derived 
macrophages (Stary et al, 1994).  
 
Atherosclerotic lesions start to develop under a dysfunctional and leaky endothelium 
(Falk, 2006), augmented by factors such as high plasma LDL concentration (Ramji and 
Davies, 2015). As the process advances, endothelial cells may disappear, leaving 
denuded areas. Certain molecules and lipoprotein particles extravasate through this 
leaky endothelium into the subendothelial space (Falk, 2006). Here, lipoproteins 
become oxidized and therefore atherogenic. Once activated by various stimuli, the 
endothelium becomes activated and the expression of adhesion molecules such as 
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VCAM-1, ICAM-1, E selectin and P selectin are upregulated (Falk, 2006). 
Consequently, leucocytes, namely monocytes and T cells, are recruited to the 
endothelium, attracted to it by chemokines, such as CCL2 (Deshmane et al, 2009). 
These cells then migrate through the endothelium into the intima. Once here, 
monocytes differentiate into macrophages and these then ingest modified LDL to 
become foam cells (Libby et al, 2002). Sustained accumulation of modified LDL plus 
disturbed lipid homeostasis causes apoptosis and necrosis of foam cells (Ramji and 
Davies, 2015). This results in a necrotic core of the plaque and amplification of the 
inflammatory response (Moss and Ramji, 2016).  
 
T and B lymphocytes are also found in the intima during lesion development. These 
lymphocytes, as well as vascular wall cells, secrete growth factors and cytokines that 
promote the migration and proliferation of smooth muscle cells (SMCs). SMCs also 
undergo characteristic phenotypical changes, can up-regulate adhesion molecules 
(Ikeda et al, 1993) and secrete cytokines (Ikeda et al, 1991). SMCs also express 
enzymes that can degrade the collagen and elastin in response to inflammatory 
stimulation (Libby et al, 2002). This allows SMCs to invade through the elastic laminae 
and collagenous matrix of the plaque (Libby et al, 2002). SMCs also secrete 
extracellular matrix (ECM) proteins that stabilise plaque by forming a fibrous cap over 
it.  
 
 
1.13.2 Plaque rupture  
 
As the plaque evolves, inflammatory mediators induce the expression of 
collagenases by foam cells within the intimal lesion and also inhibit collagen synthesis 
(Libby et al, 2002). This leads to thinning of the plaque fibrous cap, rendering it weak 
and susceptible to rupture (Bentzon et al, 2014). When a plaque ruptures, a gap in 
the fibrous cap exposes the thrombogenic core of the plaque to blood (Bentzon et al, 
2014). This then leads to platelet aggregation, coagulation and thrombus, which 
causes most acute complications of atherosclerosis (Libby et al, 2002).  
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1.14 Biomarkers of inflammation in risk prediction in the general population  
 
As suggested above, inflammation is involved in all stages of atherosclerosis. Several 
studies have shown relationships between various biomarkers of inflammation and 
cardiovascular risk, in apparently healthy individuals as well as in patients with 
cardiovascular disease. There are several biomarkers that have been studied. 
Epidemiological studies have shown that circulating CRP (Ridker and Cook, 2004), IL-
6 (Ridker et al, 2000) and fibrinogen (Danesh et al, 2005) are associated with higher 
risk of CVD in the general population, independent of known CVD risk factors. In RA, 
levels of these pro-inflammatory molecules and cytokines are increased.  
1.14.1 C-reactive protein (CRP)  
 
For several reasons, CRP has been studied as a biomarker of CVD for clinical 
application. In healthy individuals without inflammatory diseases or infections, levels 
of hsCRP remain stable over long periods of time (Danesh et al, 2004). Most 
laboratories in developed countries used for routine clinical care also measure CRP 
and there is no diurnal variation (Meier-Ewert et al, 2001). CRP can be found within 
the atherosclerotic lesion, in the vascular intima, where it co-localizes with foam cells 
(Torzewski et al 1998). Most clinical studies report that CRP is an independent 
predictor of cardiovascular events (Paffen and DeMaat, 2006), even after adjusting 
for other cardiovascular risk factors such as age, smoking, obesity, 
hypercholesterolemia and hypertension. However, others have reported that 
although CRP predicts risk of MI, the increase in risk could be largely explained by the 
presence of other risk factors (Doggen et al, 2000). However, in RA, levels of CRP are 
generally much higher than the general population and are more subject to 
fluctuations (Aotsuka et al, 2005).  
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1.14.2 Interleukin-6 (IL-6) 
 
Various studies have examined the association of IL-6 and cardiovascular risk and 
disease. Elevated IL-6 levels in healthy men were associated with increased risk for 
future MI independently of hs-CRP (Ridker et al, 2000). Levels of IL-6 are higher in 
those with acute coronary syndromes compared to those with stable angina 
(Ozdemir et al, 2008). High IL-6 levels are associated with increased mortality in 
patients with acute coronary syndromes (Biasucci et al, 1999). Among women with 
prevalent CVD, those with high IL-6 levels had >4-fold risk of death compared to 
women with low IL-6 levels (Volpato et al, 2001). There is an increasing 
understanding of the complexity of IL-6 signalling and several studies have studied 
the IL-6 receptor (IL-6R).  
 
1.15 Reduction of inflammation can reduce risk of CVD in the general 
population  
 
Large studies in the general population have highlighted that inflammation is a key 
driver of atherosclerosis. The JUPITER study (Ridker et al 2008), found that in a trial 
of over 15,000 apparently healthy individuals without hyperlipidaemia but with 
elevated high sensitivity CRP, statin reduced the number of major cardiovascular 
events. The CANTOS study found that Canakinumab, a monoclonal antibody 
targeting interleukin-1, led to a significantly lower rate of recurrent CV events then 
placebo, independent of lipid lowering (Ridker et al 2017).  
Studies have shown that statin therapy lowers CRP levels independently of lipid 
levels, supporting the notion that statins have anti-inflammatory effects (Zakynthinos 
et al, 2008). One study has shown that statins limit both protein and RNA levels of IL-
6-induced CRP in human hepatocytes (Arnaud et al, 2005). In vivo animal and human 
studies show that statins can improve endothelial function. This improvement may 
be partly due to reduced LDL levels, however several studies have found that 
endothelial function is restored before significant changes in serum cholesterol levels 
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are seen (Anderson et al, 1995). Statins also inhibit the expression of VCAM-1 and 
ICAM-1, therefore reducing immune-cell recruitment within the vessel wall and 
reducing inflammation (Jain and Ridker, 2005). Statins also induce eNOS 
accumulation within endothelial cells, therefore reducing the effects of reduced NO 
availability in the inflammatory setting (Jain and Ridker, 2005).  
 
1.16 Animal models of RA and atherosclerosis  
 
Animal models for both RA and atherosclerosis are well established. They provide 
crucial tools to investigate the pathophysiology of these diseases and to test 
therapeutic strategies in vitro prior to use in humans. Assessments of disease and 
treatment outcomes can be made in well-controlled environments, without having 
to allow for individual variability between human patients. It is also possible to obtain 
tissue from animal studies that would be difficult or impossible to obtain from living 
humans. Animal models of RA and atherosclerosis provide the unique opportunities 
to unravel the pathophysiological features of vascular dysfunction and cardiovascular 
disease in these settings. 
 
 
1.16.1 Animal models of arthritis  
 
Animal models have been used extensively in studies of rheumatoid arthritis. The 
aetiology of RA is multifactorial, with both genetic and environmental components. 
Presentation and progression of RA in humans is very variable. In animal models, 
conditions can be tightly controlled and thus results can be compared and data can 
be reproduced. Animal models of RA have significantly advanced our understanding 
of the pathogenesis of RA and contributed to several major advances in its treatment, 
most notably the development of anti-TNF agents.   
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In terms of studying the pathogenesis of cardiovascular disease in RA, it is not feasible 
to sample human vascular tissue. Therefore using animal models of RA allows us to 
gain a greater understanding of the functional and histological abnormalities within 
vascular tissue that may contribute to cardiovascular disease in RA.  Studies have 
shown that even 10 years before disease onset in RA, patients have serum 
abnormalities such as presence of rheumatoid factors (Nielen et al, 2004) and 
antibodies against citrinullated self-proteins (Mandl et al, 2005). Also, patients who 
go on to develop RA have dyslipidaemia with a more atherogenic lipid profile than 
matched blood donors at least 10 years before onset of symptoms (van Halm et al, 
2007). Patients with RA have rapid progression of CVD soon after RA onset (Innala et 
al, 2011). Animal models allow us to study the early, and even pre-disease RA phase.  
Several animal models of inflammatory arthritis exist, each with their own 
advantages and limitations. Models can be induced, such as antigen induced arthritis 
or collagen-induced arthritis (CIA), or animals can be genetically manipulated to 
spontaneously develop arthritis, such as the TNF-alpha-transgenic mouse, K/BxN 
mouse, and the Skg mouse (Asquith et al, 2009). Table 2 summarises several rodent 
models of arthritis and their key features. In this thesis the CIA model was used for 
several reasons; its systemic nature, ease of induction, reproducibility of results, and 
previous experience of this model in the department. Moreover, there are previous 
reports of vascular dysfunction in the literature in this model.  
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Table 2. Summary of animal models of RA and effects on vascular function 
Model Animal 
Strain 
Examples of 
arthritogens 
Arthritogenic 
effector 
mechanism 
Mechanism of 
action  
Pattern of 
joint 
involvement  
Pathological 
features  
Vascular function 
Adjuvant –
induced 
arthritis  
Male 
Wistar or 
Lewis rat 
Heat-
killed.M. 
tuberculosis 
H37Ra or M. 
smegmatis 
- 
T cell and 
neutrophil 
mediated   
Polyarticular Marked bone 
resorption, and 
periosteal bone 
proliferation 
Reduced acetylcholine 
(ACh)-induced 
endothelium-dependent 
vasorelaxation (Prati et al, 
2011) 
Antigen 
Induced 
arthritis  
Mouse/rat  Methylated 
bovine.serum 
albumin 
(BSA) 
- 
T cell mediated  Monoarticular Cartilage and bone 
destruction  
Unknown (no systemic 
manifestations) 
Collagen 
Induced 
arthritis  
Male 
DBA/1 
mice  
Type II 
collagen (CII) 
- 
T and B cell 
mediated, 
complement-
dependent 
Polyarticular  Cartilage and bone 
destruction, 
synovitis, and 
periosteal 
proliferation 
Reduced ACh-induced 
endothelium-dependent 
vasorelaxation (He et al, 
2013) 
Reduced aortic 
constriction (Reynolds et 
al, 2012)  
Streptococcal 
cell wall 
induced 
arthritis 
Rat  Group A/B/C 
streptococci 
- 
T‐cell and 
monocyte‐mediated 
Polyarticular Cartilage and bone 
destruction 
Unknown  
K/BxN Mouse 
- 
Crossreactive 
autoantibodies 
against glucose-6-
phosphate 
isomerase  
Complement 
activation 
and mast cell 
degranulation 
Polyarticular Cartilage and bone 
destruction 
Mild aortic valve 
inflammation (Binstadt et 
al, 2009)  
Vascular function 
unknown 
SKG Mouse  
- 
A defective thymic 
selection of T cells 
due to a mutation in 
the SH2 domain of 
ZAP 70 
T cell mediated  Polyarticular Cartilage and bone 
destruction 
Unknown   
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1.16.1.1 Collagen Induced Arthritis  
 
CIA has proven to be an important model of human RA, helping to define the role of 
many of its cellular and molecular mediators (Myers et al, 1997), and is the most 
widely studied model of RA. Murine CIA (mCIA) has been very important in the testing 
and development of numerous agents, such as tumour necrosis factor inhibitors. 
Arthritis is induced by immunisation with an emulsion of type II collagen (CII) (usually 
heterologous, chicken or bovine) and complete Freund's adjuvant; subsequently 
auto-antibodies to collagen II are produced.  
CIA shares several pathological features with RA. Both are polyarticular, systemic 
diseases. The target tissue in RA is cartilage, and collagen II is a key protein here.  In 
terms of histological findings, several shared pathological features between RA and 
mCIA include synovial hyperplasia, mononuclear cell infiltration, and cartilage 
degradation (Brand et al, 2007). In RA it is well established that inherited 
susceptibility is associated with genes encoding the human MHC class II molecules 
(HLA-DR4 and HLA-DR1 alleles) (Todd et al, 1988).  Similarly, susceptibility to CIA is 
linked to expression of specific MHC class II genes (Brand et al, 2007).  
 
Differences between mCIA and RA 
There are differences between RA and mCIA. In mCIA rheumatoid factor is not 
present. There is no female preponderance as there is in RA, and CIA is generally 
monophasic, although some relapsing models have been described (Boissier et al, 
1987). In mCIA animals develop antibodies to collagen, while this is not the case in a 
large proportion of patients with RA (Bevaart et al, 2010). Of note, neutrophils are 
abundantly present in the synovial tissue of mice with CIA (Suzuki et al, 1997), which 
is in contrast to RA synovium, where there are relatively few neutrophils, and more 
T cells, plasma cells, macrophages, and B cells (Tak et al, 1997). Also, in RA there are 
marked variations in the synovial cell infiltrate in biopsy specimens from different 
patients, even in early disease (Tak et al, 1997), reflecting the heterogeneity of RA.  
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Mechanisms of CIA development  
The pathogenesis of CIA involves both T-cell and B-cell-specific responses to collagen 
II, a major protein constituent of joint cartilage. B cells are of critical importance as 
they produce antibodies to collagen II. Indeed, B cell-deficient mice are resistant to 
CIA (Svensson et al, 1998). The role of T cells in CIA are twofold; they provide help to 
B cells for the production of anti-CII antibodies (Corthay et al, 1999) and also play a 
role in joint inflammation through activation of other cells, e.g. synovial 
macrophages.  
Anti-collagen II antibodies bind to collagen II in the joint, resulting in complex 
formation and complement activation, C3 deposition and cleavage of C5 (Wang et al, 
1995). These events trigger a local inflammatory response during which T cells, 
monocytes and granulocytes are attracted to the joint, resulting in further immune 
activation and production of chemokines (Luross and Williams, 2001). At the time of 
the clinical onset of arthritis, IL-1, IL-10, TNFα, and IL-6 can be detected at the site of 
inflammation in the joint. More recently described cytokines such as IL-17, IL-21, IL-
23, IL-32, and IL-33 have all been reported to aggravate CIA (Moudgil et al, 2011).  
The symptoms of CIA begin around day 21 post immunisation. Within a few days after 
arthritis onset the affected joint shows an inflammatory reaction. The synovium, 
which is normally hypocellular, becomes infiltrated with macrophages, neutrophils 
and B and T cells. The histopathology is similar to that observed in RA, with formation 
of an erosive pannus tissue which invades cartilage and bone. Cartilage is damaged 
by matrix-degrading enzymes and osteoclasts induce bone erosion. This can lead to 
remodelling and ultimately destruction of the joint. The severity of arthritis and 
disease course varies depending on mouse strain, type and dose of collagen 
immunised. These factors are discussed in more detail in section 3.1.1. Most mouse 
strains are more resistant to development of arthritis after immunization with 
homologous (mouse) CII. However, some studies have shown that immunisation with 
homologous CII can produce a more chronic form of CIA, with periods of remission 
and exacerbations (Boissier et al, 1987; Holmdahl et al, 1985).   
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CVD and CIA  
The risk of CVD associated with RA appears to precede the ACR criteria–based 
diagnosis of RA (Maradit-Kremers et al, 2005). Therefore the CIA model offers an 
excellent opportunity to identify early changes within the vasculature that lead to 
CVD. 
Reynolds et al found a relationship between arthritic disease in DBA/1 mice and 
contractile dysfunction in rings of isolated aorta (Reynolds et al, 2012).  However, 
contractile dysfunction was not accompanied by overt endothelial dysfunction as 
endothelium-dependent relaxation responses to acetylcholine were similar to those 
seen in tissues from non-immunized control mice. Also, relaxation responses to 
exogenous nitric oxide (NO) were unaffected. These findings suggest that there is 
sufficient endothelium-derived NO bioavailability during mCIA, and that vascular 
smooth muscle responds both to endogenous and exogenous NO to produce 
vasodilation. This is unexpected given the fact that endothelial dysfunction is found 
early in RA. However, the mouse model of CIA occurs over days rather than weeks or 
months, and it may possible be that if experiments were left to run for longer, 
endothelial dysfunction may have occurred.  
Other studies have shown that CIA is associated with increased aortic expression of 
VCAM-1 (Denys et al, 2016). VCAM-1 mediates the adhesion of lymphocytes, 
monocytes, eosinophils, and basophils to vascular endothelium and has been shown 
to play a crucial role in early atherosclerosis (Cybulsky et al, 2001).  Interestingly in 
this study by Denys et al, at 15 weeks after the first CIA immunisation, atherosclerotic 
plaque formation in the aorta was detected with CIA mice fed a high fat diet, and 
non-immunised mice fed a high fat diet, but not in CIA alone. Previous work in our 
department by Williams et al showed that CIA drives an increase in systemic 
inflammation, represented by increased macrophages in the aorta and perivascular 
adipose tissue (PVAT) of mice with CIA (Williams et al, 2016). This is relevant to RA 
patients, as they are known to have more inflammation in both their aorta 
(Greenburg et al, 2012) and in atherosclerotic plaques (Aubry et al, 2007) compared 
with non-RA controls. Also, we know that systemic inflammation in RA is associated 
with increased cardiovascular risk. Other work from our department has shown that 
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vascular calcification is not responsible for the vascular dysfunction seen in CIA.  This 
work also showed that aortic collagen and elastin become dysregulated during CIA 
and show a fibrosis like phenotype (unpublished yet).  
 
1.16.2 Animal models of atherosclerosis  
 
Mouse models of atherosclerosis have proved useful to study the development and 
progression of atherosclerotic lesions. Knockout and transgenic mouse models of 
atherosclerosis have been valuable in understanding the molecular and cellular 
mechanisms involved and in evaluating the effectiveness of treatment (Zadelaar et 
al, 2007). The predominant lipoprotein in wild type mice is HDL, making them 
relatively resistant to atherosclerosis (Getz et al, 2012). Therefore mice have been 
genetically modified to produce changes in lipid metabolism, making them prone to 
atherosclerosis. The extent to which these models serve as accurate models of 
human diseases is debateable.  Unlike humans, mice rarely develop atherosclerosis 
in the coronary arteries but more so in the aortic root (Getz and Reardon, 2012). Also, 
atherosclerotic lesions tend to be less complex than human lesions (Getz and 
Reardon, 2012). Despite these drawbacks, mouse models of atherosclerosis provide 
valuable insights into lesion pathogenesis and the effect of various drugs on the 
disease.  
There are several animal models of atherosclerosis. Large animal models include 
rabbits, pigs and nonhuman primates. Due to the relative ease of genetic 
manipulation and the relatively quick time frame for atherosclerosis development, 
mouse models are currently the most extensively used (Getz and Reardon, 2012). 
The most widely used knock out mouse models are the LDL receptor deficient mouse 
(LDLR-/-) and the ApoE-/- mouse.  The LDLR-/- mouse has delayed clearance of VLDL 
and LDL from plasma. They have a moderate increase of plasma cholesterol level and 
develop atherosclerosis slowly on normal chow diet (Zaragoza et al, 2011). Unlike the 
ApoE−/− mice, no systematic pathological analysis of lesion development in the 
LDLR−/− mice has been reported (Getz and Reardon, 2012), and they also do not 
develop a fibrous cap (Breslow, 1996). ApoE-/- mice have been created by 
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homologous recombination in embryonic stem cells (Nakashima et al, 1994). These 
mice develop a range of atherosclerotic lesions from fatty streaks to fibrous plaques, 
distributed throughout the arterial tree. Atherosclerotic lesions show several 
features of the inflammatory-fibroproliferative response characteristic of 
atherosclerosis in humans (Nakashima et al, 1994).  ApoE−/− mice do have some 
disadvantages; plasma cholesterol in this model is largely carried on lipoprotein 
remnants rather than the LDL, which is generally the most frequent carrier of 
cholesterol in human atherosclerosis (Getz and Reardon, 2012). Due to the complex 
lesions that develop rapidly and their comparability with human lesions, the ApoE−/− 
mouse was used in this thesis.  
 
 
Relevance to RA patients  
Although there are obvious differences in the ApoE-/- model and RA patients, RA 
patients are known to have dyslipidaemia more than ten years before the onset of 
arthritis, with higher total cholesterol, triglyceride and Apo B levels and lower HDLc 
levels than matched controls (van Halm et al, 2006). Interestingly, CRP had only a 
marginal influence on the differences in lipid levels between patients and controls in 
this study. Therefore, utilising the ApoE-/- model and enhancing systemic 
inflammation (for example by using tools to enhance IL-6 trans-signaling), presents a 
way to study the effect of dyslipidaemia and inflammation, processes that occur in 
early or even pre-RA. In addition, RA patients have increased inflammation in plaques 
and increased proportion of unstable plaques compared to non-RA patients at 
autopsy (Aubry et al, 2007). Using this mouse model also allows examination of other 
defined outcomes such as plaque size, expression of SCCPs in plaque and fibrous cap 
thickness.  
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1.17 IL-6 in RA and CVD 
 
1.17.1 IL-6  
 
IL-6 is a pleiotropic cytokine, a 26-kDa glycopeptide. It is produced by various cell 
types such as B cells, T cells, fibroblasts, osteoblasts, monocytes, and endothelial cells 
(Srirangan and Choy, 2010). It is involved in a wide range of biological activities 
including immune regulation, haematopoiesis and inflammation (Hunter and Jones, 
2015). IL-6 has hormone like characteristics that affect many systems and processes 
such as lipid metabolism (Glund and Krook, 2008), neuropsychological behaviour 
(Rohleder et al, 2012) and the neuroendocrine and vascular systems (Hou et al, 
2008).  IL-6 deficiency can lead to compromised innate and adaptive immunity in 
mice (Kopf et al, 1994) and in humans (Puel et al, 2008).   
Serum levels of IL-6 in a normal physiological state are low (2.6-6.5 pg/mL (Kim et al, 
2011) but can increase rapidly in inflammatory states, such as infection. In severe 
inflammatory states, such as septic shock, levels can reach the ng/ml range (Calandra 
et al, 1991). In RA, serum levels range from around 1.5–234.0 pg/ml (Robak et al, 
1998). In RA, IL-6 is seen at high levels in synovial fluid and IL-6 in the joint has been 
shown to induce pannus formation, osteoclast activation and mediate chronic 
synovitis (Srirangan and Choy, 2010). IL-6 can activate cells via two signaling 
pathways, IL-6 classical signaling and IL-6 trans-signaling, discussed in more detail 
below and outlined in Figure 3.  
 
1.17.2 IL-6 signaling  
 
In classical signaling, IL-6 binds to membrane bound IL-6R (mIL-6R). The complex of 
IL-6/mIL-6R then associates with another protein, gp130, which then dimerizes and 
instigates intracellular signalling (Jones et al, 2001).  IL-6R is only present on certain 
cells, these are hepatocytes, and some leukocyte subpopulations, including 
monocytes, neutrophils, and some T cells and B cells (Rose-John, 2012). Thus, 
classical signaling only affects certain cells. In addition to signal transduction through 
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mIL-6R, there is also ‘trans-signaling’. Here, soluble IL-6R (sIL-6R), which is generated 
by either alternative splicing or ectodomain shedding (Dayer and Choy, 2010), 
triggers gp130 signaling by first binding to IL-6 (Rose-John, 2012). As gp130 is 
ubiquitously expressed, trans-signaling enables IL-6/sIL-6R to activate cells that lack 
the IL-6R. SIL-6R is released by monoctyes and activated T cells (Briso et al, 2008). 
Importantly, unlike other soluble cytokine receptors such as soluble TNF-αR, sIL-6R 
does not act antagonistically, thus limiting the IL-6 cytokine activity, but rather acts 
as an agonist.  
 
 
 
 
Figure 3. Two modes of IL-6 signaling. IL-6 classic-signaling requires membrane bound IL-6R and is 
therefore restricted to cells that express this: hepatocytes, some epithelial cells and some leukocytes. 
IL-6 trans-signaling requires sIL-6R and can affect any cell of the body since gp130 is ubiquitously 
expressed. (Adapted from Rose-John, 2012) 
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A soluble from of gp130, (sgp130) is found in the circulation. This is formed from 
translation from alternatively spliced mRNA (Rose-John, 2012). Sgp130 blocks trans-
signaling by binding to the complex of IL-6/sIL-6R so that this cannot bind to gp130 
(Figure 4). IL-6 alone does not interact with sgp130, therefore signaling via 
membrane-bound IL-6R is not inhibited by sgp130 (Jostock et al, 2001). Serum levels 
of sgp130 are around 400 ng/mL (Narazaki et al, 1993). sIL-6R levels are around 
75ng/ml. As mentioned previously, serum IL-6 levels in a normal physiological state 
are 2.6-6.5 pg/mL.  Thus, sgp130 is the most abundant protein, followed by sIL-6R 
and then IL-6 at much lower levels. This implies that under physiological conditions, 
IL-6 will be bound to sIL-6R, which is in turn bound to sgp130, and is, therefore 
neutralised. In extreme conditions such as sepsis, levels of IL-6 will increase 
profoundly and levels of sIL-6R increase. These will exceed levels of sgp130 which 
change little during inflammation (Rose-John, 2012), and IL-6 can therefore act 
systemically, by classical signaling if levels exceed sIL-6R, or by trans-signaling if sIL-
6R levels are higher. What is not clear however, are specific levels of these cytokines 
and receptors at the sites of inflammation.  
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Figure 4. Blockade of IL-6 trans-signaling by sgp130. Sgp130 only binds to the complex of IL-6/sIL-6R 
and therefore only blocks IL-6 trans-signaling. Excess IL-6 will continue to bind to mIL-6R and 
classical trans-signaling will continue. Adapted from Rose-John, 2012.  
 
  
JAK/STAT pathway  
Once the complex of IL-6/IL-6R (either IL-6/mIL-6R or IL-6/sIL-6R) has bound to 
gp130, gp130 dimerises, leading to the activation of Janus Kinases and the activation 
of transcription factors of the STAT (signal transducers and activators of 
transcription) family. STATs are latent transcription factors that reside in the 
cytoplasm until activated. Gp130-associated kinases Jak1, Jak2, and Tyk2 become 
activated upon stimulation, and the cytoplasmic tail of gp130 is phosphorylated. This 
mediates the recruitment of STAT1, STAT3 and STAT5 proteins (Hunter and Jones, 
2015). Subsequently, STAT3 also becomes phosphorylated, forms dimers and 
translocates to the nucleus, where it regulates transcription of target genes (Heinrich 
et al, 1998). These genes include those that encode acute-phase proteins. STAT3 also 
upregulates the transcription of genes encoding the SOCS3 proteins, which inhibit 
STAT3 activation (Nishimoto and Kishimoto, 2006).  
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1.17.3 Pro and anti-inflammatory activities of IL-6  
 
There is increasing evidence that trans-signaling is pro-inflammatory whereas 
classical signaling has important regenerative or anti-inflammatory effects, such as 
regeneration of damaged intestinal epithelium and wound healing, discussed in more 
detail below. Two research tools have been developed to differentiate the activities 
of classical and trans-signaling. Hyper-IL-6 is a complex of IL-6/sIL-6R bound by a 
flexible peptide linker (Fischer et al, 1997).  This specifically induces trans-signaling. 
Sgp130Fc is an engineered fusion protein which consists of the extracellular portion 
of gp130 linked to the Fc domain of a human IgG1 antibody. Sgp130Fc blocks IL-6 
trans-signaling without affecting IL-6 classic signaling.  
Evidence that trans-signaling is pro-inflammatory  
In a mouse sepsis model using caecal puncture and ligation (CLP) classical versus 
trans-signaling was examined (Barkhausen et al, 2011). This model has a 60% 
mortality untreated. Mice given neutralising IL-6 antibody did not have a significant 
increase in survival but 100% of mice given sgp130Fc survived. CLP led to an 
upregulation of the acute phase protein serum amyloid A (SSA). This SAA induction 
was inhibited by global IL-6 blockade but was unaffected by treatment of the mice 
with sgp130Fc. Also, sgp130Fc inhibited epithelial apoptosis whereas anti IL-6 
antibody did not.  
In another experiment, mice were infected with Mycobacterium tuberculosis (Mtb) 
and administered either sgp130Fc or anti-TNF (Sodenkamp et al, 2012). With anti-
TNF antibody treatment there was a 10-100 fold increase in mycobacterial colony 
forming units in the lung, liver and spleen. In contrast, administration of sgp130Fc 
did not interfere with protective immune responses after infection with Mtb and 
there was no increase of bacterial burden. Sgp130Fc-overexpressing transgenic 
(sgp130Fctg) mice were also infected with Mtb. These mice were capable of 
controlling mycobacterial growth. This is of importance in RA as other biological 
agents, especially anti-TNF agents are associated with an increased rate of 
reactivation of tuberculosis (Stallmach et al, 2010).  
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Table 3 summarises the effect of sgp130Fc on animal models of human diseases  
 
Human disease Mouse model Effect of sgp130fc 
Rheumatoid arthritis  Antigen induced arthritis (Nowell 
et al, 2003) 
Collagen induced arthritis (Nowell 
et al, 2009) 
 
Reduced disease severity 
Reduced disease severity  
Sepsis  Caecal puncture and ligation 
(Barkhausen et al, 2011) 
 
Increased survival  
Tuberculosis  Pulmonary infection with 
mycobacterium tuberculosis 
(Sodenkamp et al, 2012)  
 
No interference with protective 
immune responses  
Acute inflammation  Air pouch model (Rabe et al, 2008)  Reduction in infiltrating 
inflammatory cells  
Atherosclerosis  LDLr-/- mice (Schuett et al, 2012)  
 
Reduction in atherosclerosis  
Ovarian cancer  Human ovarian tumour xenograft 
model in NOD/SCID mice (Lo et al, 
2010) 
Reduced ascites formation and 
enhanced tumour sensitivity to 
paclitaxel 
 
Table 3 Effect of sgp130Fc on animal models of human diseases 
 
Evidence that IL-6 has anti-inflammatory or regenerative effects  
IL-6-/- mice exhibited less tumours but more inflammation than wild type mice in an 
inflammatory colon cancer model (Grivennikov et al, 2009). The IL-6-/- mice had 
impaired regeneration of the irritated intestinal epithelium. Another mouse model 
found that IL-6-/- mice failed to control bacterial numbers 2-3 weeks after infection 
with Citrobacter rodentium and exhibited increased mortality (Dann et al, 2008).  
From these studies it was concluded that the regenerative activities of IL-6 are 
needed for wound healing in the intestine.  
IL-6-/- mice have impaired wound healing with reduced expression of IL-1, 
chemokines, adhesion molecules, transforming growth factor-β1, and vascular 
endothelial growth factor at the wound sites compared to wild type mice (Lin et al, 
2003). In IL-6-/- mice there was reduced leukocyte infiltration, re-epithelialization, 
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angiogenesis, and collagen accumulation. Wild type mice were also given neutralizing 
anti-IL-6 monoclonal antibody which significantly delayed wound closure. These 
findings suggest that IL-6 plays an important role in wound healing.  
 
 
1.17.4 IL-6 and sIL-6R in RA  
 
Serum IL-6 is higher in patients with RA than controls, correlates with CRP and 
duration of morning stiffness (Madhok et al, 1993). In RA, IL-6 is found at high levels 
in synovial fluid and IL-6 in the joint has been shown to induce pannus formation, 
osteoclast activation and mediate chronic synovitis (Srirangan and Choy, 2010). 
Several cell types within the joint can produce IL-6, but the main source is from 
fibroblast-like synoviocytes (Bartok and Firestein, 2010). Serum sIL-6R levels in RA 
patients have been found to be significantly higher than those of control subjects 
(Kohno et al, 1998). In this study, sIL-6R was detectable in synovial fluid, but at a 
lower level than in the serum, in contrast to IL-6 which was much higher in the 
synovial fluid than serum. One important source of sIL-6R is circulating neutrophils. 
Previous work by Jones et al (1999) found CRP causes a 3-fold increase in sIL-6R 
release by neutrophils. CRP levels are substantially elevated in patients with active 
RA. CRP-stimulated release of sIL-6R by circulating neutrophils could lead to an 
increase in circulating sIL-6R levels. 
Tocilizumab, a humanised monoclonal antibody against the IL-6R is a licensed 
treatment for RA. This is an effective treatment; reducing disease severity, 
inflammatory markers and slowing progression in terms of radiologic damage 
(Smolen et al, 2011). Tocilizumab blocks both classical and trans-signaling (Rose-
John, 2012). Although a very effective treatment for RA, several side effects have 
been reported. These include abnormalities in liver function tests (LFTs), increases in 
serum cholesterol levels, increase in infection rates, and a risk of gastrointestinal 
perforation if the patient has pre-existing diverticulitis (Navarro-Millán et al, 2012). 
These potential side effects are thought to be due to the blockade of classical 
signaling rather than trans-signaling.  
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1.17.5 IL-6 and sIL-6R in CVD 
 
Inflammation contributes to the onset and pathogenesis of CVD in the general 
population. Epidemiological studies have shown that circulating CRP (Ridker and 
Cook, 2004) and IL-6 (Ridker et al, 2000) are associated with higher risk of CVD in the 
general population, independent of known CVD risk factors. High IL-6 levels are 
associated with increased mortality in patients with acute coronary syndromes 
(Biasucci et al, 1999). Both IL-6 and sIL-6R levels are increased in patients presenting 
with acute myocardial infarction compared to controls and those with stable 
coronary artery disease (CAD) (Anderson et al, 2013), but sgp130 showed no 
significant change between AMI, CAD, and control patients. 
A non-synonymous allelic variant in the IL-6R gene (rs2228145):358Ala increases 
serum sIL-6R by 35% but reduces surface IL-6R expression (Ferreira et al, 2013). Two 
large-scale genetic and biomarker studies found a causal link between IL-6R gene 
polymorphism and development of CVD in the normal population (IL6R Genetics 
Consortium Emerging Risk Factors Collaboration, 2012; Interleukin-6 Receptor 
Mendelian Randomisation Analysis (IL6R MR) Consortium, 2012). However, in RA, IL-
6R polymorphism is not associated with CVD   (López-Mejías et al, 2011). This is not 
unexpected since sIL-6R level is 2-3 fold higher in RA patients than the general 
population (Usón et al, 1997), hence the impact of RA on circulating sIL-6R level is 
greater than IL-6R genotype. 
Although IL-6R is associated with atherosclerosis, human endothelial cells express 
gp130 but not IL-6R. sIL-6R mediated trans-signaling is known to activate endothelial 
cells to express vascular adhesion molecules and bind neutrophils (Modur et al, 
1997), inducing vascular inflammation. sIL-6R correlates with markers of endothelial 
function and inversely correlates with pulse wave propagation time (Weiss et al, 
2013). A study by Klouche et al (1999) describes an autocrine stimulation loop of IL-
6/sIL-6R. Human vascular SMC constitutively express only scant amounts of IL-6R and 
so do not respond to stimulation with IL-6. The study showed that SMC also do not 
constitutively express significant levels of gp130, so that they would not be 
appreciably sensitive to trans-signaling by the IL-6/sIL-6R complex. However, it was 
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found that treatment of SMC with IL-6/sIL-6R induced up-regulation of gp130 mRNA 
and surface protein expression. This was accompanied by secretion of IL-6 by the 
SMC. Alongside this, there was induction and secretion of CCL2, up-regulation of 
ICAM-1, and marked cell proliferation. Thus, presence of the IL-6/sIL-6R seems to 
drives an amplification loop that causes a proinflammatory state of SMCs. 
In animal models of atherosclerosis, there is evidence that IL-6 plays an important 
role, although specific pathways are not completely understood. Administration of 
exogenous IL-6 to ApoE-/- mice enhances atherosclerotic lesion formation, suggesting 
a pivotal role for IL-6 in plaque progression (Huber et al, 1999). In contrast, Schieffer 
et al showed that ApoE-/--IL-6-/- double knockout mice had higher serum cholesterol 
and increased atherosclerotic lesion formation compared to ApoE-/- mice (Schieffer 
et al, 2004). These experiments show that IL-6 plays a pivotal role in the 
atherosclerosis process but do not examine the role of classical versus trans-
signaling. Another study found that administration of sgp130Fc reduced 
atherosclerosis in LDLR-/- mice (Schuett et al, 2012).  
 
1.17.6 IL-6 effects of lipids  
 
IL-6 has various and complex effects on lipid metabolism. IL-6 increases VLDLR 
expression in several tissues and this decreases triglyceride levels (Hashizume et al, 
2009). In healthy volunteers administration of IL-6 caused an increase in total 
cholesterol (Lyngso et al, 2002). IL-6 was infused intravenously for 2.5 hours giving 
rise to circulating concentrations of approximately 35ngl-1. During infusion of IL-6 the 
heart rate, oxygen uptake and energy expenditure increased significantly and the 
respiratory quotient decreased significantly. The calculated lipid oxidation rate 
increased significantly while the carbohydrate oxidation rate decreased significantly. 
In the control study all parameters remained constant. IL-6 infusion gave rise to 
increased net glycerol release in subcutaneous adipose tissue while the net release 
of fatty acids did not change significantly. Conversely, administration of IL-6 to 
middle-aged and old rhesus monkeys (Ettinger et al, 1995), and cancer patients 
(Veldhuis et al, 1995) resulted in a decrease of total cholesterol levels.  
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In patients with myocardial infarction circulating IL-6 levels are correlated negatively 
with total cholesterol levels (Brugadas et al, 1996). The same is true of patients after 
major surgery (Akgun et al, 1998) and those on haemodialysis (Bologa et al, 1998). 
Interestingly, low serum cholesterol levels are among the most consistent predictors 
of mortality in patients with end-stage renal disease undergoing haemodialysis, 
thought to be due to cytokine-mediated acute-phase reaction to acute or chronic 
inflammation and in the latter study, IL-6 level was the strongest predictor of 
mortality.  
 
1.18 SIL6R-regulated CVD Candidate Proteins (SCCPs) 
 
As indicated in section 1.17.2, human endothelial and vascular smooth muscle cells 
do not express the IL-6R but can respond to the complex of IL-6/sIL-6R. Increasing 
data suggests that trans-signaling, which is regulated by sIL-6R, plays important roles 
both in RA and CVD. Previous work, using the human primary cell based BioMAP® 
system has examined biological pathways driven by sIL-6R (Tan et al, 2013).  The 
BioMAP® system uses human primary cell based cultures and puts them under 
various stimulation conditions. Biomarker responses are measured and stored in a 
database. They can be used to predict outcomes, for example of a drug or cytokine. 
The results are quantitative and reproducible. The effects of sIL-6R on cells implicated 
in the pathogenesis of atherosclerosis have been examined. These cells examined 
were endothelial, peripheral blood mononuclear and coronary artery smooth muscle 
cells. sIL-6R was found to regulate the release of several proteins, including VCAM-1, 
Interleukin-8 (CXCL-8), Monocyte Colony Stimulating Factor (M-CSF), CXCL9, CCL2, 
Thrombomodulin, Tissue Factor and Matrix Metalloproteinase-1 (MMP-1). I have 
collectively called these proteins sIL-6R-regulated CVD Candidate Proteins (SCCPs). 
While there are various other proteins that are regulated by sIL-6R, I have selected 
those that have been implicated in cardiovascular disease. Many of these SCCPs have 
also been linked to rheumatoid arthritis. Table 4 summarises what is known about 
their role in CVD and RA. This thesis uses this data to investigate the association of 
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these proteins in animal models of RA and atherosclerosis, and also in patients with 
RA, investigating their potential predictive role of CVD in RA.  
 
 
Protein regulated by 
sIL-6R  
Levels in RA Levels in CVD  
Matrix 
Metalloproteinase-1 
Increased, correlates with 
disease activity (Green et al, 
2003) 
Elevated MMP-1 predicts presence 
of advanced CVD  in normal 
population (Hwang et al, 2009) 
CCL2 Increased in serum and 
synovial fluid (Koch et al 
1992) 
Correlates with CIMT 
(Södergren et al, 2010) 
CCL2 gene inactivation decreases 
progression of atherosclerotic 
lesions (Linic et al, 2013) 
Increased expression in 
atherosclerotic lesions (Egashira, 
2003) 
M-CSF Increased in RA patients 
(Kawaji et al, 1995) 
Correlates with disease 
activity (Rioja et al, 2008) 
Found in atherosclerotic plaques 
(Ait-Oufella et al, 2011) 
Risk factor adverse outcomes in 
angina & elevated in acute coronary 
syndromes (Saitoh et al, 2000) 
Strong predictors of cardiac events 
in those with angina (Rallidis et al 
2004) 
CXCL9 Increased in synovium 
(Iwamoto et al, 2008), 
unknown in serum 
Increased expression in plaques 
(Mach et al, 1999) 
VCAM-1 Correlates with disease 
activity (Navarro-Hernández 
et al, 2009) 
Rapidly induced by 
proatherosclerotic conditions, 
including early lesions (O’Brien et al, 
1993)  
CXCL-8 Correlates with disease 
activity (Slavić et al, 2005) 
Correlates with carotid intimal 
thickness in RA patients (Benucci et 
al, 2013)  
Thrombomodulin  Conflicting data (Ichikawa et 
al 1993, Abdul-Monieum et 
al, 2001; Hanyu et al, 1999) 
Decreased (Wei et al, 2011) 
Expression reduced in 
atherosclerotic lesions (Lasik et al, 
2001) 
Tissue factor  Unknown (involved in pannus 
formation (Chen et al, 2013))  
Increased in plaques in unstable 
angina or myocardial infarction 
compared to stable angina (Annex 
et al, 1995). Serum levels higher in 
unstable than stable angina 
(Soejima et al, 1999) 
 
Table 4. SCCPs in RA and CVD 
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1.19 Project summary  
 
Patients with RA are at increased risk of cardiovascular disease compared to the 
general population. Atherosclerosis and RA are both diseases in which inflammation 
plays a pivotal role in pathogenesis and progression. IL-6 has been implicated in 
pathogenesis of both RA and CVD, in particular there is increasing evidence that IL-6 
trans-signalling is pro-inflammatory. Although several studies have examined 
relationships between IL-6 and cardiovascular disease and/or rheumatoid arthritis, 
none have examined the role of IL-6 trans-signaling in CVD in RA. In this thesis animal 
models of RA were used to examine the role of IL-6 trans-signalling in vascular 
dysfunction in RA.  
 
Patients with RA have increased markers of inflammation within atherosclerotic 
plaques compared to the general population. To examine the direct effect of IL-6 
trans-signalling on atherosclerosis, an animal model was used, the ApoE-/- mouse. 
Here, for the first time, the effect of trans-signalling versus classical signalling was 
examined on plaque size.  
 
Cardiovascular risk scores, even with modification as recommended by EULAR, 
underestimate CVD risk in RA patients. Previous work using the BioMAP® system has 
identified several proteins that are regulated by sIL-6R. Most of these SCCPs have 
been implicated in both CVD and RA. As CVD is increased in early RA, I have 
investigated the association of SCCPs with progression of subclinical atherosclerosis 
in this patient group. Potential candidate proteins may serve as predictors of 
progression of subclinical atherosclerosis or even as novel therapeutic targets for 
reducing CVD in RA. 
 
1.20 Hypothesis and Aims  
 
The overall aim of the thesis was to examine the role of IL-6 trans-signalling in 
cardiovascular disease in rheumatoid arthritis using both human and animal studies. 
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I hypothesise that sIL-6R-mediated trans-signaling is a major driver of CVD in RA. This 
hypothesis was addressed through the following aims: 
 
1. 
A. To investigate whether IL-6R KO mice are protected against vascular 
dysfunction in collagen-induced arthritis (CIA).   
B. To investigate whether blocking IL-6 trans-signalling using sgp130Fc restores 
vascular function in CIA 
 
2. To determine whether IL-6 trans-signaling accelerates atherosclerosis in Apo-E-/- 
mice.  
3. To determine whether SCCPs are associated with progression of CVD using carotid 
intimal thickness (CIMT) as a surrogate marker for subclinical atherosclerosis. 
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2 Chapter 2 - Materials and general methods  
 
2.1 Chemicals and buffers:  
 
Citrate buffer (0.2M): 8.4 g citric acid, was dissolved in 200 ml dH20 then pH adjusted 
to 3.95 by the addition of a potassium hydroxide solution. 
 
Tetramethylbenzadine (TMB): 240 mg of TMB was dissolved at a concentration of 
(0.1 M) in 5 ml of dimethyl sulphoxide (DMSO) and 5 ml of ethanol, and stored at 4°C. 
ELISA Developing Buffer: was freshly prepared on each occasion by the addition of 
10 µl Hydrogen Peroxide and 100 µl TMB to 10 ml of Citrate Buffer per 96 well plate. 
Miller’s elastin (Fisher Scientific catalogue number LAMB-1080-D): 1:1 dilution with 
distilled water. 
Oxalic acid (Fisher Scientific, catalogue number 75688): 1% oxalic acid (1 g in 100 mL 
distilled water).  
Potassium permanganate (Fisher Scientific catalogue number P/6520/53):  2 g of 
potassium permanganate was dissolved in 400 mL of distilled water.  
Van Gieson stain solution: (Fisher Scientific 88011)  
 
Ethylenediaminetetraacetic acid (EDTA) decalcification solution: 70g of (EDTA) in 
900ml of PBS (pH 7) 
S-nitrosothiol (SNO):  SNO was made by adding 500ul of n-acetlycyteine to 500ul 
nitrite. This was kept on ice in the dark. A spectrometer was used to calculate to the 
molar concentration. Serial dilutions were performed to get concentrations of 1nM 
to 10mM.  
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Krebs Buffer 
  
Reagent mM 
NaCl 
 
109.17 
 
KCl 
 
2.68 
 
KH2PO4 
 
1.18 
 
MgSO4.7H2O 
 
1.22 
 
NaHCO3 
 
25.00 
 
Glucose 
 
10.99 
 
CaCl2.H2O 
 
1.71 
Table 5. Composition of Krebs buffer 
 
High potassium Krebs buffer  
 
Reagent mM 
NaCl 
 
39.36 
 
KCl 
 
59.99 
 
KH2PO4 
 
1..18 
 
MgSO4.7H2O 
 
1.22 
 
NaHCO3 
 
25.00 
 
Glucose 
 
10.99 
 
CaCl2.H2O 
 
1.71 
Table 6. Composition of high potassium Krebs buffer 
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2.2 General methods  
 
Specific methods are detailed in methods sections in each chapter 
2.2.1 ELISA 
 
Levels of SCCPS were measured using duoset ELISA development kits from R&D 
systems in accordance with manufacturer’s instructions. Standards and samples 
were assayed in duplicate. Concentrations used in each ELISA are detailed in the 
relevant methods section in each chapter.   
 
Protocol for ELISA on murine serum  
 
Step 
 
Process Time 
1 96-well ELISA plate coated with 50µl of capture 
antibody  
Overnight  
2 Excess liquid was removed from the wells by 
inverting and blotting against paper towels. Plate 
washed three times with 150µl per well of 0.1% 
(v/v) Tween in PBS  
- 
3 300µl blocking buffer to each well 1 hour minimum  
4 Repeat step 2 - 
5 Add 50µl of standard and samples. Cover and 
incubate for 2 hours at room temperature 
2 hours  
6 Repeat step 2 - 
7 50µl detection antibody per well. Cover and 
incubate for 2 hours at room temperature 
2 hours  
8 Repeat step 2 - 
9 50µl of streptavidin-HRP, cover and place in the 
dark  
20 minutes  
10 50µl of substrate solution to each well, cover and 
place in dark  
Up to 10 
minutes-observe 
colour  
11 50µl stop solution to each well   
12 Immediately determine optical density of each 
well at 450nm. 
 
 
Table 7. Protocol for ELISA on murine serum 
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Protocol for ELISA on human serum  
 
Step 
 
Process Time 
1 96-well ELISA plate coated with 100µl of capture 
antibody  
Overnight  
2 Excess liquid was removed from the wells by 
inverting and blotting against paper towels. Plate 
washed three times with 150µl per well of 0.1% 
(v/v) Tween in PBS  
- 
3 300µl blocking buffer to each well 1 hour minimum  
4 Repeat step 2 - 
5 Add 100µl of standard and samples. Cover and 
incubate at room temperature 
2 hours  
6 Repeat step 2 - 
7 100µl detection antibody per well. Cover and 
incubate at room temperature 
2 hours  
8 Repeat step 2 - 
9 100µl of streptavidin-HRP, cover and place in the 
dark  
20 minutes  
10 100µl of substrate solution to each well, cover and 
place in dark  
Up to 10 
minutes-observe 
colour  
11 50ul stop solution to each well   
12 Immediately determine optical density of each 
well at 450nm. 
 
 
Table 8. Protocol for ELISA on human serum 
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3 Chapter 3 - Effect of IL-6R mediated trans-signalling on 
Vascular Function in CIA  
 
3.1 Introduction  
 
As discussed in the general introduction, CIA offers an excellent model to examine 
the systemic effects of RA.   
3.1.1 CIA in DBA-1 versus C57BL/6 mouse strains   
 
For this thesis both the DBA-1 and the C57BL/6 mouse strain were used. It was shown 
previously that susceptibility to CIA is linked to the H-2q haplotype (DBA-1 mice) and 
that H-2b (C57BL/6) mice were less sensitive to CIA development (Stevenson et al, 
2006). Several studies have since shown that it is possible to induce CIA in C57BL/6 
but there is both reduced incidence and reduced severity of arthritis, compared with 
DBA/1 mice (Bevaart et al, 2010). Generally, in DBA-1 mice arthritis starts at around 
day 25-28 and arthritis incidence reaches 80-100% (Brand et al, 2007). In C57BL/6 
mice arthritis can start at around day 30, but incidence is variable. Several groups 
have induced CIA in C57BL/6 mice (Campbell et al, 2000; Campbell et al, 1998; Kai et 
al, 2006), although there have been difficulties with reproducibility in this strain (Pan 
et al, 2004). Table 9 summarises the literature on mCIA in C57BL/6, in terms of 
reagents used to induce arthritis, time course and arthritis incidence. Some groups 
have also used lipopolysaccharide (LPS) to boost arthritis incidence and severity in 
C57BL/6 mice. 
The main advantage of using the C57BL/6 strain is that most transgenic and knockout 
strains of mice are on his background.  Indeed, the in-house colony of IL-6R knockout 
mice was on this background. However, CIA in DBA-1 mice is more reproducible and 
onset of arthritis is quicker than in C57BL/6. An ideal scenario would be to back-cross 
the genetically modified strain onto the DBA/1 background but this is time 
consuming and costly. C57BL/6 mice with CIA can develop a chronic form of CIA 
which resembles human RA in terms of disease course, histological findings, and 
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response to drugs commonly used in RA (Inglis et al, 2007). In DBA-1 mice the T-cell 
proliferative response to type II collagen in immunised mice peaks before the onset 
of arthritis and is in decline by the time of disease onset; in C57BL/6 however the T 
cell response is strong and sustained (Inglis et al, 2007). Hence, the C57BL/6 strain 
may be more useful to assess T-cell activity and to evaluate T-cell-targeted therapies 
(Inglis et al, 2007). 
For this chapter, we used both C57BL/6 and DBA-1 mice; IL-6 and IL-6KO mice are 
only available on the C57BL/6 background and DBA-1 mice were used as CIA in this 
model is better characterised than in C57Bl/6, and arthritis in C56BL/6 mice takes 
approximately 60 days to appear. 
 
3.1.2 Vascular function in CIA  
 
Investigating the effect of RA on vascular function is challenging to conduct on human 
vascular tissue. The CIA model offers a useful tool to assess early changes within the 
vasculature that lead to CVD. Previous work by Reynolds et al (2012) found a 
relationship between arthritic disease in DBA/1 mice and contractile dysfunction in 
rings of isolated aorta.  Here, we were able to assess the effect of absence of IL-6 and 
IL-6R, and also the effect of selective blockade of IL-6 trans-signalling, on contractile 
dysfunction in CIA.
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Paper Age CIA induced, sex 
& source of mice 
Reagents used and route given Dose TB per 
mouse 
Type collagen Dose collagen per mouse Incidence of arthritis Time stopped Used 
LPS? 
Inglis et al, 
2007 
10-12wks male Harlan ID Bovine, chicken, or mouse T2 
collagen in CFA with M. 
tuberculosis. 
150ug on day 0 Type II 
bovine, 
mouse or 
Chicken 
 200ug  on day 0 Only chicken collagen induced 
arthritis - incidence 61.7%  
2wks after 
onset (early 
arthritis) or 6-
8wks after 
onset (late 
arthritis) 
No 
Campbell et 
al, 2000 
>8wks, male & female, 
in house (B6, B6/N11, 
B6:129c, 
B6:C3HeB/FeJd) 
ID T2 Chicken collagen and CFA 
with M. tuberculosis.  
250ug on day 0 
and 21 
Type II 
Chicken  
100ug on day 0 and 21 
 
incidence of 60–70% by day 
60 
100 days No  
Asquith et al, 
2010 
12 wks, male, Harlan 
(Indianapolis) 
T2 chicken collagen/ CFA  ID day 
0. T2 chicken collagen/PBS day 
21 IP.  
150ug on day 0 Type II 
chicken  
200ug of collagen on d0 and 
200ug in PBS on day 21 
75% of mice receiving a 
normal diet and 54% of mice 
on high-fat diet developed 
diseaseby day 42. 
Day 42  Yes (20-
40ug on 
D26 if no 
arthritis 
Bäcklund et 
al, 2012 
7-12 wks male, in 
house  
ID chicken or rat in CFA with 
Mycobacterium butyricum, or in 
IFA with M. tuberculosis.  
166.5ug ( M. 
butyricum or  M. 
tuberculosis) 
chicken or rat 
Type II  
100 or 200ug on day 0. Some 
mice were boosted 5 weeks 
later with 50ug of CII in IFA  
all three CII preparations 
induced arthritis in with a 
comparable phenotype (28% 
incidence) 
50 days  No 
Chu et al, 
2003  
 
8-10wks  female,  
Jackson 
ID Bovine CII and CFA with M 
tuberculosis.  
125ug on day 0 Bovine type II 100ug bovine cII on day 0  3/30 (10%) 65  No  
Pan et al, 
2004 
8-10  weeks  male, 
Jackson 
(Bar Harbor, pathogen 
free 
ID Bovine CII and CFA 
containing M. Tuberculosis. 
200ug on day 0 Bovine type II 100ug on day 0 and then 
100ug in IFA on day 21  
 
5/35 Bl6 mice had arthritis by 
day 35 (14%) 
Day 35 all 
stopped  
No  
Mould et al, 
2008 
Female 8-12 weeks. 
C57bl6/J 
ID Chicken T2 collagen and CFA 
with M. tuberculosis.  
125ug on day 0 
only   
Chicken type 
II  
100ug . Then on day 8 OR 
day 21, 100ug collagen with 
IFA only (100ul).  
First arthritis evident on day 
25. 89% incidence in  control 
c57bl6 mice . 
Day 69  No  
Geboes et al 
2009 
Female, Ludwig 
institute cancer 
research. Age unclear  
Followed Campbell et al 
protocol  
250ug on day 0 
and 21 
Chicken type 
II  
100ug on day 0 and 21  
mouse 
60% incidence (5/9 wild type 
c57bl6), mean day of onset 27 
Day 37  No  
Table 9 Summary of CIA induced in C57BL/6 mice in the literature 
58 
 
3.1.3 Tools to investigate the role of IL-6 signalling on vascular function in CIA  
 
Using IL-6-/- and IL-6R-/- mice allows us to investigate the complete absence of IL-6 
and IL-6R on vascular function in CIA. As functions mediated by IL-6R require binding 
to its receptor, it may be expected that IL-6-/- and IL-6R-/- mice would have the same 
phenotype. Although they do share similarities, there have also been differences 
observed phenotypically. For example, whereas IL-6-/- mice have impaired wound 
healing, IL-6R-/- mice heal almost as well as WT mice (McFarland-Mancini et al, 2010). 
Here in Cardiff there are in-house colonies of IL-6-/- and IL-6R-/- mice. It has been 
shown that IL-6-/- mice have delayed CIA onset and reduced CIA severity (Saiai et al, 
1999), others have shown that IL-6-/- mice are completely protected from CIA (Alonzi 
et al, 1998). Vascular function in CIA in these mice has not been previously assessed. 
In this chapter, for the first time, we assess the induction of CIA in IL-6R-/- mice and 
compare with IL-6-/- mice. We also assess, for the first time, the effect of CIA induction 
in these mice on vascular function. The advantage of using knock-out mice is the 
knowledge that there is a complete absence of IL-6 or IL-6R. However, in these mice, 
both IL-6 signalling pathways are redundant and thus we cannot gather information 
about the role of classical versus trans-signalling in vascular function in CIA in this 
setting. Also, using knock-out mice has reduced clinical relevance as these mice have 
a total lack of cytokine activity, compared to a reduction in cytokine activity; the 
latter seen generally with anti-cytokine therapies.  Also, the complete absence of IL-
6 or IL-6R from conception may result in other cytokines being overexpressed. As 
mentioned in section 1.17.3, using sgp130Fc allows us to investigate the effect of 
selective blockade of IL-6 trans-signalling. However, using antibody blockade has 
several possible disadvantages in terms of practicalities: how well the antibody works 
depends on multiple factors including binding affinity of the antibody, dosing, tissue 
penetrance and technical ability of the investigator e.g. performing intraperitoneal 
injections.  
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3.2 Hypothesis and Aims 
 
As can be seen from Table 9, there is variable penetrance and incidence of CIA in 
C57BL/6 mice. Therefore it was necessary to characterise CIA in these mice in our 
facility before inducing CIA in knockout strains and assessing vascular function. The 
vascular constriction response was also determined in these animals to assess the 
impact of CIA on vascular function. IL-6-/- and IL-6R-/- mice were also used alongside 
sgp130Fc treatment to characterise the role of IL-6 and IL-6 trans-signaling in both 
CIA progression and associated vascular dysfunction. This chapter details 
methodology, results and discussion under the following hypothesis and objectives: 
Hypothesis: IL-6R mediated trans-signalling is a major driver of vascular dysfunction 
in CIA.  
  
In order to address this hypothesis the following five aims were identified: 
 
1. To establish a protocol for the induction of CIA in C57BL/6 WT mice.  
a. Further, to characterise CIA in C57BL/6 mice in terms of incidence, 
time course, and severity of arthritis. 
 
2. To assess vascular constriction and relaxation responses in aortic tissue from 
age and sex matched C57BL/6 mice with CIA and without CIA.  
 
3. To assess the effect of complete absence of IL-6 signalling on CIA induction, 
using IL-6R-/- and IL-6-/- mice, and compare arthritis time course, severity and 
penetrance with CIA induction in wild-type age-and sex matched C57BL/6 
mice.  
 
4. To assess the effect of complete absence of IL-6 signalling on vascular 
constriction and relaxation responses in aortic tissue, using IL-6R-/- and IL-6-/- 
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mice immunised with CIA compared with wild type immunised/arthritic 
C57BL/6 mice and non-immunised controls.  
 
5. To assess the effect of blocking IL-6 trans-signalling using sgp130Fc on 
vascular function in DBA-1 mice with CIA.   
 
 
3.3 Materials and methods  
 
3.3.1  Sgp130Fc  
 Spgp130Fc was obtained from two sources, both of which had been used 
previously in the department. The first was from a gift from Professor Rose Jose in 
Kiel University. The second was from R&D systems (Q6PDI9). 
  
 
3.3.2 Etanercept  
 
The TNF receptor fusion protein, etanercept, was used as a positive control 
in experiments. This is an established treatment for rheumatoid arthritis and its 
efficacy has been proven in both mouse and human studies. It is a combination 
protein consisting of the extra-cellular portion of two of the 75 kd-TNF receptors 
(TNF-R2) for TNF combined with a human Fc portion of human lgG1 (Horiuchi et al, 
2010). Etanercept (Enbrel®, Amgen) was sourced from the clinical rheumatology 
department in the University Hospital of Wales.  
 
3.3.3   Mice  
All work with mice was performed in accordance with the United Kingdom 
Animals (Scientific Procedures) Act 1986 and under the authority of the Home Office 
Personal (I56CC73C0) and Project (30/2928) Licences. Wild type C57BL/6 mice 
(specific strain C57Bl/6JOlaHsd) were sourced from Harlan, UK. DBA-1 mice were 
sourced from Charles River, UK. Mice had free access to normal chow diet and water 
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and had a light dark cycle of 12 hours. The temperature range in the animal house 
was 19-23°C and humidity 55 + 10%. Mice were purchased at 7 weeks of age and 
allowed a 1 week settling in period before arthritis was induced at 8 weeks, unless 
otherwise stated. Mice were euthanised under schedule 1 of the United Kingdom 
Animals (Scientific Procedures) Act 1986 by inhalation of carbon dioxide and death 
confirmed by palpation. 
 
3.3.4 Knockout mice  
 
Specific knock out strains used (IL-6-/- and IL-6R-/-) were sourced from in-house 
colonies. Due to breeding difficulties within these colonies, and in keeping with the 
ethical principles of replacement, reduction and refinement, both female and male 
mice were used to utilise available mice. Age and sex matched wild type C57BL/6 
mice were used as controls. Knock out mice were 18 weeks old at day 0. Control wild 
type C57BL/6 mice (specific strain C57Bl/6JOlaHsd) were sourced from Harlan, UK at 
17 weeks and were 18 weeks old at day 0.  
Numbers, gender and strain immunised, along with age and sex-matched control are 
shown in Table 10.  
 
Strain Gender Age at day 0 Number immunised 
with CIA 
Number not 
immunised with CIA 
C57BL/6 
WT 
Male 18 weeks 2 2 
IL-6R-/- Male 18 weeks 2 0 
C57BL6 
WT 
Female 18 weeks 5 5 
IL6-/- Female 18 weeks 3 0 
IL-6R-/- Female 18 weeks 3 0 
 
Table 10. Characteristics of knockout mice and matched wild-type mice undergoing CIA protocol 
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3.3.5 Establishing a protocol for induction of CIA in C57BL/6 mice  
 
Two strengths of type II collagen (CII)/complete Freund’s adjuvant (CFA) were used 
in this chapter. See Table 11 for a summary of the concentration/doses used in each 
protocol.   
3.3.5.1 Preparation of CII/CFA (low dose) 
 
Type II collagen (CII) from chicken sternal cartilage (Sigma Aldrich Ltd) (5mg) was 
dissolved overnight in 2.5ml of 10mM acetic acid and kept on a cold plate overnight 
at 4°C with continuous stirring. CFA was prepared by grinding 100mg heat-killed 
Mycobacterium tuberculosis H37Ra to a fine powder using a pestle and mortar, in a 
fume hood. To this, 20ml Freund’s incomplete adjuvant was added, providing a final 
concentration of 5mg/ml. This was stored at -20°C.  
 
3.3.5.2 Preparation of CII/CFA emulsion  
 
At the time of immunisation an equal volume of CII solution and CFA were mixed and 
passed through a glass syringe 20 times to ensure thorough mixing. To check that an 
emulsion had formed a drop was placed on in water; if it floated it was of the correct 
consistency.  
 
 
 Low dose CII High dose CII 
Dose per mouse 
on day 0 and 21 
Concentration 
per injection 
per mouse 
Dose per 
mouse on day 
0 and 21 
Concentration 
per  injection 
per mouse  
Type II collagen  100ug 1mg/ml 250ug 2.5mg/ml 
Mycobacterium 
tuberculosis 
250ug 2.5mg/ml 500ug 5mg/ml 
Table 11. Doses of collagen and mycobacterium tuberculosis in low and high dose CII/CFA 
preparations. 
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3.3.6 Injection of mice with emulsion 
 
Mice were anesthetised with isoflurane (4L/min) and oxygen (2-4L/min) and 
immunised with the collagen and CFA emulsion. Mice were injected on day 0 via the 
intradermal route. 50 µl was injected twice at adjacent sites, on the right lateral side 
of the tail base. From day 0 to day 21 mice were inspected at least 3 times per week 
to check general health status and injection sites. Two booster injections of 50 µL 
were given on day 21, on the left lateral side of the tail base. From day 20, as an 
analgesic, Temgesic (400 mcg/L) was crushed and suspended in the drinking water of 
the mice and changed daily.  
3.3.7  Assessment of arthritis severity 
 
 Animals were observed daily from day 21 for the development of arthritis except 
where specified.  
 Clinical gradation of arthritis severity  
Arthritis severity was scored in each paw using a scale from 0 to 5, see Table 12. The 
sum of the four paw scores was calculated for each mouse, this was the total paw 
score. Paw swelling was also measured in hind paws daily for each mouse using a 
spring calliper gauge. Mice were also weighed and inspected daily. 
 
Severity limits  
If any mouse reached any one of the following at any point in the experiment it would 
have been removed from the experiment and killed. These humane end points were 
defined by the procedure project licence:  
 A paw score of 5 in one paw or a combined score above 14 
 A greater than 20% weight loss in two consecutive weigh-ins  
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Scoring arthritis severity  
Individual paw score Clinical features 
0 
No evidence of erythema or swelling  
1 
Erythema and mild swelling confined to the 
tarsals or ankle joint  
2 
Erythema and mild swelling extending from 
the ankle to the tarsals 
3 
Erythema and moderate swelling extending 
from the ankle to metatarsal joints  
4 
Erythema and severe swelling encompasses 
the ankle, foot and digits 
5 
Deformed paw/ankylosis  
 
Table 12. Individual Paw Scoring System in mCIA 
 
 
3.3.8 Isolating blood serum 
 
Once palpation had confirmed death of the mouse a cardiac puncture was performed 
to remove blood. Using a 25 gauge needle, approximately 1ml of whole blood was 
taken. This was placed into vacutainers coated with clot activator and stored on ice. 
Samples were then centrifuged at 1600g for 10 minutes at 4°C. The serum was then 
aliquoted in 50ul aliquots and stored at -80°C.  
 
3.3.9 Dissection technique  
 
The dorsal skin, peritoneum, ribs and lungs were removed to expose the heart. The 
abdominal aorta was observed and snipped distally. The left ventricle of the heart 
was perfused slowly with 1ml of Krebs solution to gently flush the aorta. The thoracic 
aorta was exposed and carefully dissected so that any force on it was kept to a 
minimum. This was placed in fresh Krebs buffer for use in myography. Under a 
dissecting microscope, fat was removed from half of the aorta and two 2mm rings of 
thoracic aorta were cut for use in myography. The rest of the aorta was placed in 70% 
(v/v) methanol for 1 week for use in histology.  
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Hind paws were removed, and then fixed in neutral buffered formal saline for 1 week 
prior to processing for immunohistological evaluation. 
 
 
3.3.10 Assessment of Vascular Function- Myography 
 
Isometric tension studies using a myograph were used to assess vascular function ex 
vivo in isolated aortae. The thoracic aorta was cut into rings of 2 mm length, using a 
ruler for scale. Each ring was mounted in separate wells of a Mulvany myograph 
(Danish Myo-Technology, Aarhus, Denmark) and bathed in Krebs buffer for 20 
minutes. Each ring was held between two prongs, one connected to a force 
transducer to allow ring tension measurement and the other connected to a 
micrometer to allow manual increase in tension. Each well was continually gassed 
with 95% oxygen/5% carbon dioxide. The temperature was maintained at 37°C by 
the steel block that the myography well was placed on. Myograph output was 
recorded and analysed using Myodaq and Myodata (Aarhus, Denmark) software 
respectively.  
 
After mounting, the rings were subjected to equilibration for 20 minutes and it was 
ensured there was no tension on the rings. Each ring was then zeroed (the tension 
set at 0 mN). Then, over a period of 10 minutes, the tension on each ring was 
increased by 0.5mN per minute to reach a baseline tension of 5mN. This baseline 
tension had been used previously in DBA-1 mice by Reynolds et al (2012). Tissues 
were then rested for 20 minutes and the tension adjusted so that it was maintained 
at 5 mN. Tissues were then exposed to 60 mM K+ for 5 minutes to condition the 
vessels to contraction. Baths were then emptied and refilled with fresh Krebs buffer 
8 times to wash them, and then left to re-equilibrate for a further 20 minutes in 5 ml 
fresh Krebs. If the baseline tension had altered during this time then the tension was 
manually adjusted to reach 5 mN. Tissues were then sequentially exposed to 
increasing concentrations of 5-hydroxytryptamine (5-HT) (10-9 to 10-5M) in half log 
increments.  
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For experiments also examining relaxation responses tissues were then washed 8 
times, left to re-equilibrate for 20 minutes and then re-constricted to using 5-HT to 
reach 80% of their maximal constriction established previously. This was usually 
achieved with a final 5-HT well concentration of 10-7. Once the vessel constriction 
had reached a plateau at 80% of their maximal constriction, increasing 
concentrations were added of Acetylcholine (ACh) (10-9 to 10-5M), in half log 
increments. ACh causes relaxation of the vessel via endothelium-derived nitric oxide 
generation. Tissues were then washed and reconstricted to 80% maximal with 5-HT. 
Increasing concentrations of S-nitrosothiol (SNO) (see Section 2.1 in general 
methods) were then added (10-9 to 10-5M ), in half log increments. SNO causes 
relaxation of the vessel via exogenously donated nitric oxide.  
 
 
 
3.3.11 Myography analysis  
 
The myodata programme was used to record constriction and relaxation responses. 
5-HT-induced contraction responses were calculated as the increase in tension above 
the resting tension. Relaxation responses to ACh and SNO were measured and 
expressed as a percentage of the 5-HT-induced tone.  
 
3.3.12 Histological assessment of arthritis severity  
 
 Sample preparation  
Hind paws were cut so that the knee and ankle were separated at the mid tibia. 
Excess fat and connective tissue was removed and then joints were placed into 
histocassettes.  
 Decalcification  
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In order to section the joints for histology they were decalcified with EDTA for 2 
weeks at 4°C. The EDTA solution was changed every 2-3 days. In order to ensure 
bones were decalcified, radiographs were taken of the joints using a Kodak FX-Pro 
after 2 weeks.   
 Shandon tissue processor cycles  
Joints were dehydrated using a Thermoshandon Tissue Processing Path Centre 
machine. The paws were immersed in increasing concentrations of ethanol; 70% 
(v/v) for 30 minutes, 90% (v/v) for 90 minutes, 100% ethanol for 60 minutes 
(repeated 3 times). Paws were then immersed in xylene for three incubation of an 
hour each. Joints were then immersed in four changes of wax and then removed from 
the tissue processor.  
Tissue embedding  
After removal from the tissue processor joints were set in paraffin wax using the 
Thermoshandon Histocentre.  
 Sectioning of embedded joints 
Serial 7µm thick sections of wax-embedded joints were cut using a microtome and 
mounted on Superfrost Plus glass slides. Slides were then placed for 3 hours in the 
oven at 56°C to ensure adherence of the tissue to the slide and also remove paraffin 
from tissue sections. 
 
3.3.13 Haematoxylin and Eosin Staining  
 
This staining method allows grading of severity of arthritis histologically. 
Haematoxylin stains nuclei purple and eosin stains cytoplasm and connective tissue 
pink. This allows distinction between different parts of the joint and identification of 
changes in the normal structure.  
After sectioning and baking of the slides were treated as follows:  
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3.3.14 Grading of arthritis severity histologically  
  
Sections were scored for synovial hyperplasia, cellular infiltration, cellular exudate, 
and cartilage and bone degradation, with 0 representing a normal joint, outlined in 
Table 14. The maximal score for each joint was 14. 
 
 
 
 
 
 
 
 
Process Rationale Time 
3 X xylene washes  Slide rehydration and wax 
clearing  
3 X 5 minutes  
 
2 X 100% IMS washes  Slide rehydration  2 X 3 minutes  
90% IMS wash  Slide rehydration  3 minutes 
Distilled water Equilibrate  5 minutes  
Haematoxylin  Nuclear stain  1 minute  
Running tap water  Removal of excess 
haematoxylin 
Until water runs clear 
Distilled water  Equilibrate  1 minute  
Eosin  Eosinophilic structure stain  30 seconds  
Running tap water  Removal of excess eosin  Until water runs clear  
Distilled water  Equilibrate 1 minute  
90% ethanol  Slide dehydration and wax 
clearing 
3 minutes  
2 X 100% ethanol  Slide dehydration and wax 
clearing 
2 X 3 minutes  
3 X xylene  Slide dehydration and wax 
clearing 
3 X 5 minutes  
Mount with DPX and 
coverslip  
Preservation of staining   
Table 13. Haematoxylin and Eosin Staining protocol 
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Component  Subcomponent  Grade  
Subsynovial 
inflammation  
 
 Normal  
 Focal inflammatory infiltrates, adiposity hardly 
affected (10% inflammatory cells, 90% adipose 
tissue)  
 Focal inflammatory infiltrate equals adiposity 
(50% inflammatory cells, 50% adipose tissue)  
 Random inflammatory infiltrates dominating 
cellular histology (70% inflammatory cells, 30% 
adipose tissue)  
 Substantial inflammatory infiltrate with severe 
loss of adiposity (90% inflammatory cells, 10% 
adipose tissue)  
 Ablation of adiposity due to inflammatory 
infiltrate (100% inflammatory cells, 0% adipose 
tissue) 
0 
1 
 
2 
 
3 
 
4 
 
5 
Synovial exudate  
 
 Normal  
 Evidence of inflammatory cells in space  
 Moderate numbers of inflammatory cells in 
space, possibly with evince of fibrin deposits.  
 Substantial number of inflammatory cells with 
large fibrin deposits 
0 
1 
2 
 
3 
Synovial hyperplasia 
and pannus 
formation  
 
 Normal (1-3 layers thick)  
 Over three–layer thick synovial lining, showing 
evidence of thickening and/or invasion of joint 
space  
 Over three–layer thick synovial lining ‘creeping’ 
over cartilage surfaces and/or finger-like 
processes into joint pace  
 Over three layer thick synovial lining showing 
substantial covering of cartilage surfaces with 
evident cartilage loss 
0 
1 
 
2 
 
 
3 
Cartilage/bone 
erosion  
 
 Normal  
 Detectable loss of cartilage  
 Detectable erosion of underlying bone by 
pannus activity  
 Pannus has destroyed a significant part of the 
bone 
0 
1 
2 
3 
 
Table 14. Histological grading system for arthritis severity in mCIA 
 
 
3.3.15 Immunohistochemistry  
 
The following protocol was used for immunohistochemistry to determine expression 
of pSTAT3 (Table 15). Antibody concentrations are outlined in Table 16. Identification 
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of pSTAT-3 (phosphorylated STAT3) was carried out. pSTAT3 was measured to allow 
identification of tissues activated by IL-6; in response to IL-6 (either classical signaling 
or trans-signaling), STAT3 is phosphorylated.  
 
Process Rationale Time 
Xylene  Rehydration and wax clearing  2 X 5 minutes  
100 % ethanol  Slide rehydration  2 x 5 minutes  
90% ethanol Slide rehydration  5 minutes  
70% ethanol  Slide rehydration  5 minutes  
Distilled water  Equilibrate 5 minutes  
Citrate buffer in water bath 
at 95°C 
Antigen retrieval 60 minutes 
Allow to cool on bench   30 minutes  
Distilled water  Wash  2 x 5 minutes  
3% H2O2 Peroxidase block  10 minutes  
Distilled water Wash  5 minutes 
Distilled water Wash  5 minutes 
10% normal goat serum  in 
TBS/T 
Decrease non-specific binding of antibody  
 
60 minutes  
Avidin block Decrease non-specific binding of antibody  
 
10 minutes  
TBS-T  Wash  5 minutes  
Biotin block  Decrease non-specific binding of antibody  
 
10 minutes  
TBS/ T  Wash  5 minutes  
Primary antibody or isotype 
control antibody  
Identification of target protein and control 
IgG staining  
 
Overnight  
TBS/T  Remove excess antibody  3 x 5 minutes  
Detection antibody  Identification of bound primary antibody 1 hour  
TBS/T Remove excess antibody 3 x 5 minutes 
Streptavidin-HRP  Identify bound Antibody in sections  20 minutes  
TBS/T Wash  3 x 5 minutes  
DAB substrate  Allow identification of positive staining  1-20 minutes  
Distilled water Rinse  1 minute 
Harris Haematoxylin Nuclear stain  1-15 seconds  
Running tap water Remove excess stain Until water runs 
clear  
70% ethanol Dehydration of slides and clearing 5 minutes 
90 % ethanol  Dehydration of slides and clearing  5 minutes  
2 x 100 % ethanol  Dehydration of slides and clearing 2 x 5 minutes  
2 x Xylene  Dehydration of slides and clearing 2 x 5 minutes  
Mount with DPX and 
coverslip  
Preservation of staining   
 
Table 15. Immunohistochemistry protocol for pSTAT3 
 
 
 
 
71 
 
Reagent pSTAT3 
Primary antibody  Rabbit anti mouse pSTAT3 (cell 
signalling technologies) 40ug/ml 
Primary antibody 
concentration 
1:50 
Isotype Rabbit IgG 1.622mg/ml 
Isotype concentration  1:50 
Secondary antibody  Biotinylated Goat Anti-Rabbit IgG 
Antibody (vector laboratories) 
 
Table 16. pSTAT3 immunohistochemistry reagents and concentrations for ELISA 
 
 
 
 
3.3.16 Assessing the effect of blockade of IL-6 trans-signaling on CIA  
 
3.3.16.1 Establishing a concentration, dosing schedule, source and 
route of administration of sgp130Fc to inhibit CIA  
  
 
For all CIA experiments in DBA-1 mice, low dose CII/CFA emulsion was used and mice 
were immunised on day 0 and day 21, in the same method as in C57BL/6 mice.  
 
Figures 5, 6 and 7 are schematic representations of the experimental approach and 
Table 17 summarises the experimental approach.  
 
 
3.3.16.2 Dose and dosing schedule of sgp130Fc  
 
Sgp130Fc has been previously used in the department to inhibit CIA. Previous studies 
by Nowell et al 2009 were used to calculate the dose of sgp130Fc. The half-life of 
sgp130fc is 72 hours (Sommer et al, 2014). In experiment 1 Sgp130Fc at 2.5mg/kg 
was given from day 21, on alternate days, for 7 doses (see Figure 5 for schematic 
representation). An age and sex-matched group were immunised with CIA and 
administered sterile PBS 100ul IP on alternate days from day 21 for 7 doses. Mice 
were sacrificed on day 34 and myography was performed. As these myography 
experiments were time consuming and required great accuracy, 3 mice were killed 
per day. Therefore to ensure mice were all sacrificed on day 34, day 0 and day 21 
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were staggered so that 2 mice were immunised with low-dose type II collagen and 
CFA on each day 0 and 21. 
 
As previous work in DBA-1 mice in the department found that arthritis severity can 
increase rapidly from day 21, another dosing schedule of sgp130Fc was used, with 
increased frequency of administration. Here (Experiment 2, Figure 6), sgp130Fc 
2.5mg/kg was administered daily from day 21 to day 27. An age and sex-matched 
group were immunised with CIA and administered sterile PBS 100ul IP daily from day 
21 to day 27. All mice were sacrificed on day 28. As myography was performed on all 
mice, to ensure accuracy whilst performing experiments, 3 mice were killed per day. 
Therefore day 0 and day 21 were staggered so that 2 mice were immunised with low 
dose type II collagen and CFA on each day 0 and 21.  
 
  
3.3.16.3 Route of sgp130Fc administration  
 
Previous work in the department has administered sgp130Fc intraperitoneally. 
Sgp130Fc is a large protein, its molecular weight is 186kDa. Previously studies have 
also administered sgp130Fc intravenously with good effects in monkeys with CIA 
(unpublished). Therefore, in Experiments 1 and 2, sgp130Fc was administered 
intraperitoneally. Following this, as IP sgp130Fc did not work as was previously 
found, in experiment 3, spg130Fc was administered intravenously.  
 
In experiment 3 (Figure 7), sgp130Fc was administered at 2.5mg/kg on day 21 and 
again on day 28. In this experiment, etanercept served as a positive control and mice 
were immunised with CIA and administered 2.5mg/kg etanercept on day 21 and day 
28. Mice were sacrificed on day 30. So that myography could be performed 
accurately, the experiment was run in two batches and the immunisation days for 
each batch were staggered. 
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3.3.16.4 Control mice  
 
For all experiments, a group of mice served as age and sex-matched non –immunised 
controls.  
 
 
 
 
 
 
Figure 5. Representation of experimental procedure for treatment of mice with sgp130Fc IP, 
Experiment 1 
Figure 6. Representation of experimental procedure for treatment of mice with sgp130Fc IP, 
Experiment 2. 
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Figure 7. Representation of experimental procedure for treatment of mice with either IV sgp130Fc, 
PBS or etanercept, experiment 3.  
 
 
 
 
 
Experiment 1 Experiment 2 Experiment3 
Concentration of 
sgp130Fc  
2.5mg/kg 2.5mg/kg 2.5mg/kg 
Source of 
sgp130Fc  
Kiel University R&D systems Kiel University 
Day of first 
sgp130Fc 
administration    
 
21 21 21 
Frequency of 
administration  
Alternate days Daily Weekly  
Route of sgp130Fc 
administration  
IP IP IV 
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Number of doses 
of sgp130Fc 
7 7 2 
Day experiment 
ended  
34 28 30 
Number mice 
immunised with 
CIA and 
administered 
sgp130Fc 
4 4 10 
Number mice 
immunised with 
CIA and 
administered PBS 
4 4 10 
Number of non-
immunised 
controls  
4 4 10 
 
Table 17. Summary of experimental approach of blocking IL-6 trans-signaling using sgp130Fc in CIA 
in DBA-1 mice. 
 
 
3.3.17 ELISA measurements of CCL2, VCAM-1 and sgp130 
 
It has been shown in human studies that CCL2 and VCAM-1 are associated with both 
rheumatoid arthritis and cardiovascular disease. Both are SCCPs and have been 
found, using the Biomap system, to be regulated by IL-6 trans-signaling. To determine 
whether sgp130Fc was detectable in the circulation of mice to whom it was 
administered, human sgp130 was measured in mouse serum.   
 
Approximately 1ml of whole blood was obtained from mice after sacrifice, from 
which 200 µl of serum was aliquoted after centrifuging at 4°C at 10,000 rpm for 10 
minutes. Serum CCL2, VCAM-1 and sgp130 were measured using duoset ELISA 
development kits from R&D systems in accordance with manufacturer’s instructions, 
at concentrations in Table 18. See Table 7 in general methods for ELISA protolol for 
murine serum.   
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The optical density was then immediately measured at 450nm. A standard curve was 
plotted, and protein concentrations were calculated from this. 
 
 
Protein 
measured  
Capture antibody 
working 
concentration 
Detection antibody 
working 
concentration 
High standard 
concentration 
Mouse 
CCL2 
200 ng/ml 50 ng/ml 250 pg/ml 
Mouse 
VCAM-1 
1 µg/ml 100 ng/ml 8000 pg/ml 
Human 
Sgp130 
4 µg/ml 400 ng/ml 10000 pg/ml 
 
Table 18. Antibody and standard concentrations used in ELISA in CIA experiments 
 
 
 
3.3.18 Statistics  
 
Statistics used were dependant on the experiments performed. Where two groups 
were compared the paired means student’s t-test was used. Where multiple groups 
are compared, a one way ANOVA and post hoc Bonferroni test were performed. All 
results were expressed as the mean + SEM.  Differences that were considered 
significant were p < 0.05.   
 
Sample size estimation  
 
This was based on a previous study in CIA in C57BL/6 mice showing 75% of animals 
developed an inflammatory arthritis (Asquith et al, 2010). A reduced incidence of 
arthritis in 30% of animals is considered biologically relevant. A group size of 12 
animals is necessary to achieve 90% statistical power p<0.05 in a primary ANOVA 
screen followed by post-hoc Bonferroni corrected T-test. However, taking into 
consideration the principles of reduction in animal studies, less animals were used in 
the first instance.  
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3.4 Results  
 
All results including text, tables and error bars in figures are mean + SEM.  
 
Establishing a protocol for CIA induction in C57BL/6 mice  
 
3.4.1 No clinical or subclinical arthritis in C57BL/6 mice using low dose collagen and 
CFA 
 
 
There was no clinical sign of arthritis 66 days after the initiation of the CIA protocol 
using low dose CII/CFA regimen. Non-immunised control mice had a trend towards 
greater weight gain than immunised mice from day 0 to 66 (7.1 + 0.65 g versus 5.7 + 
0.5 g) but this was not significant (Figure 8). Although there was no arthritis clinically, 
four hind paws were taken from four immunised mice and four control mice to check 
for subclinical inflammation. There was no difference in histology between 
immunised mice and controls, all paws were scored as 0. Figure 9 shows examples of 
knee and ankle joint from C57BL/6 non-immunised control mice and immunised, 
non-arthritic mice.  
 
 
 
 
 
 
 
 
 
Figure 8. Mean weight gain for control mice versus C57BL/6 mice immunised with CIA. No significant 
difference between mean weight gain in C57BL/6 non-immunised control mice (7.1 + 0.65 g), n=4 and 
immunised, non-arthritic mice (5.7 + 0.5 g), n=8.  
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3.4.2 No significant difference in constriction or relaxation responses in immunised 
C57BL/6 non-arthritic mice and control mice    
 
 
In C57BL/6 mice immunised with low dose collagen and CFA there was no significant 
difference in maximal developed tension to 5-HT in control (9.8 + 1.1 mN), and 
immunised, non-arthritic mice (7.11 + 1.1) (Figure 10A). Similarly, there was no 
statistically significant difference in percentage relaxation to ACh in control (123 + 
 
Figure 9. H&E staining of knee and ankle from C57BL/6 non-immunised control mice and immunised, 
non-arthritic mice. (A1) non-immunised control mouse knee. (B1) immunised, non-arthritic mouse knee. 
(A2) non-immunised control mouse ankle. (B20 immunised, non-arthritic mouse ankle. All given score of 
0, representing a normal joint. Scale bar represents 0.5 mm. M = meniscus, S = synovium  
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22%) and immunised non-arthritic mice (95 + 8%) (Figure 10B).  There was also no 
statistically significant difference in percentage relaxation to SNO in control (100 + 
1.7%) and immunised non-arthritic mice (97 + 1.4 %) (Figure 10C).  
 
 
 
 
 
 
 
Figure 10. Vascular responses of aorta of C57BL/6 mice.  (A) Constriction responses to 5-HT in C57BL/6 control 
mice compared to immunised, non-arthritic mice. No significant difference in maximal developed tension to 5-
HT in vessels from control (9.8 + 1.1 mN), n = 4 and immunised, non-arthritic mice (7.11 + 1.1 mN), n = 8. (B) 
Relaxation responses to ACh in C57BL/6 control mice compared to immunised, non-arthritic mice. Vessels were 
constricted to 70-80% of their previously induced maximal contraction using 5-HT and then relaxed using ACh. 
No significant difference in percentage relaxation to ACh in control (123 + 22%) and immunised non-arthritic 
mice (95 + 8%). (C) Relaxation responses to SNO in C57BL/6 control mice compared to immunised, non-arthritic 
mice. Vessels were constricted to 70-80% of their previously induced maximal contraction using 5-HT and then 
relaxed using SNO. No significant difference in percentage relaxation to SNO in control (100 + 1.7%) and 
immunised non-arthritic mice (97 + 1.4 %) 
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3.4.3 Arthritis induction in C57BL/6 mice using high dose collagen and CFA  
 
In total 10 of 16 C57BL/6 mice developed an arthritis (62.5%). This experiment was 
run in two batches so that myography could be performed at the same time points, 
as only a certain number of myography experiments could be run on the same day. 
In the first experiment 7 of 8 mice developed arthritis (87.5%), and in the second 
experiment 3 out of 8 mice developed arthritis (38%) (Figure 11). One mouse 
developed arthritis (maximal paw score 1) which then spontaneously resolved, thus 
at the time of sacrifice, 9 out of 16 mice had an arthritis. Arthritis onset in those mice 
that developed arthritis was between day 26 and 43. Mice with CIA had significantly 
lower weight gain (2.0 + 0.7g) than control mice (4.9 + 2.5g), p = 0.015 (Figure 12A). 
There was a significant negative correlation between total paw score and weight gain 
at the time of sacrifice for C57BL/6 mice, R = -0.86, p < 0.0001 (Figure 12B).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Incidence of arthritis in C57BL/6 mice immunised with high dose collagen and CFA. 10 out of 
16 mice (62.5%) developed an arthritis. Results are presented from two experiments combined  
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3.4.4 Induction of arthritis confirmed histologically in C57BL/6 mice immunised with 
high dose collagen and CFA 
 
Five knees from control mice and five knees from immunised mice scored as having 
arthritis clinically were stained with H&E to check for histological signs of arthritis 
(Figure13). This confirmed findings in keeping with CIA, with subsynovial 
inflammation, synovial exudate, synovial hyperplasia, pannus formation and 
cartilage and bone erosions.  
 
Figure 12. (A) Mean weight gain significantly higher in C57BL/6 non-immunised control mice (4.9 + 2.5 g)  
compared to arthritic mice (2.0 + 0.7g), p < 0.05 (B) Significant negative correlation between total paw score 
and weight gain at the time of sacrifice for C57BL/6 mice immunised with CIA using high dose collagen and 
CFA protocol. (R -0.87, p <0.0001).  
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Figure 13. Arthritis confirmed histologically by H&E staining in C57BL/6 mice immunised with high 
dose collagen and CFA. A) Control mouse knee, score 0. B) Arthritic mouse knee, score 4. * 
represents erosion of underlying bone by pannus activity, ∆ focal inflammatory infiltrates in 
synovium. Scale bar represents 0.5mm. M = meniscus, S = synovium.  
 
 
3.4.5 Arthritis significantly reduces the vascular constriction response in aortic tissue 
but does not alter relaxation responses  
 
Mice with clinical arthritis had significantly lower mean maximal aortic contraction 
(7.8 + 3.1 mN), compared to non-immunised control mice (11.4 + 2.7 mN), p < 0.05 
(Figure 14). There was no significant difference between maximal relaxation in 
control (93 + 6.9 %), arthritic (77 + 13 %) and immunised non-arthritic mice (91 + 18 
%). There was no significant difference in maximal relaxation to SNO between control 
(99.5 + 7.0 %), arthritic (98.0 + 4.8 %) and immunised non-arthritic mice (101.7 + 5.5 
%). Of the nine mice that had a clinical arthritis at the time of termination, there was 
no significant correlation between maximal developed tension and total paw score 
(Figure 15).  
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R= -0.58 p= 0.10 
Figure 14. Vascular responses in the aorta of control, immunised and arthritic C57BL/6 mice to 5-HT, ACh and 
SNO. (A) Mean maximal contraction for control (11.4 + 2.7 mN), n =8 was significantly higher than arthritic 
mice, n= 9 (7.8 + 3.1 mN) p < 0.05, but not immunised non-arthritic mice (9.1 + 2.5 mN), n=7. (B) No significant 
difference between maximal relaxation in control (93 + 6.9 %), arthritic (77 + 13 %) and immunised non 
arthritic mice (91 + 18 %). (C) No significant difference in maximal relaxation to SNO between control (99.5 + 
7.0 %), arthritic (98.0 + 4.8 %) and immunised non arthritic mice (101.7 + 5.5 %). 
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3.4.6 Complete absence of IL-6 signalling using IL-6-/- and IL-6R-/- mice confers 
resistance to CIA  
 
 No IL-6-/- or IL-6R-/- mice developed arthritis when immunised with CIA using high 
dose CII/CFA (Figure 16). One of five (20%) immunised WT females developed 
arthritis on day 23, developed a moderate arthritis by day 33 but then regressed to 
mild at day 49. The plan was to allow the arthritis to progress to severe but in view 
of an improvement clinically the mouse was sacrificed on day 49. One of two (50%) 
immunised WT male mice developed CIA.   
 
Figure 15. No significant correlation between maximal developed tension and total paw score 
in C57BL/6 arthritic mice, n= 9.  
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3.4.7 Female immunised IL-6-/- and IL-6R-/- mice have reduced aortic constriction 
compared to wild type mice.   
 
Mean maximal developed aortic tension for female control wild-type mice (13.5 + 0.6 
mN) and wild type immunised-non arthritic mice (12.3 + 0.6 6 mN) was significantly 
higher than IL-6-/- (8.5 + 0.5 mN) and IL-6R-/- (6.4 + 0.7 mN) mice, p < 0.01 (Figure 17). 
Maximal developed tension for the single wild type arthritic mouse was 12.2 mN. 
There was no significant difference in percentage relaxation to ACh between the 
groups (Figure 18). The mean percentage relaxation to ACh for control mice was (89.3 
+ 2.3 %), immunised non arthritic mice (75.7 + 9.1 %), IL-6-/- mice (90.8 + 6.1 %), IL-
6R-/- mice (85.4 + 1.3 %) and for the wild type arthritic mouse was 83.2 %. There was 
also no significant difference in percentage relaxation to SNO between the groups 
Figure 16. Incidence of arthritis for C57BL/6 WT and IL-6 KO and IL-6R KO mice in (A) female and (C) male 
mice. No IL-6-/- or IL-6R-/- mice developed arthritis. Mean total paw score for (B) females, n = 3 per group 
in IL-6-/- and IL-6R-/- and n = 5 WT and (D) males, n = 2 per group. 
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(Figure 19). Mean percentage relaxation to SNO for control mice (101.9 + 1.1 %), 
immunised non-arthritic mice (103.0 + 1.5%), IL-6-/- mice (97.0 + 7.0 %), IL-6R-/- mice 
(101.0 + 2.8 %) and the wild type arthritic mouse 106.1%.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. (A) Vasoconstriction concentration–response curves to 5-HT in aortic rings from female non-
immunised control and female wild type arthritic mice. Maximal developed tension for the single wild type 
arthritic mouse was 12.2 mN and for control mice (13.5 + 0.6 mN). (B)  Vasoconstriction concentration–
response curves to 5-HT in aortic rings from female immunised non arthritic wild type IL-6-/-and IL-6R-/- mice. 
Mean maximal developed tension for female wild type immunised-non arthritic mice (12.3 + 0.6  mN) was 
significantly higher than IL-6-/- (8.5 + 0.5 mN) and IL-6R-/- (6.4 + 0.7 mN) mice **p < 0.01.  
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Figure 18. (A) Relaxation–response curves to ACh following pre-constriction to 70–80% of their appropriate 
Rmax response to 5-HT in aortic rings from female non-immunised control and wild type arthritic mice. No 
significant difference in mean percentage relaxation to ACh for control mice (89.3 + 2.3 %) and the wild type 
arthritic mouse (83.2 %). (B) Relaxation–response curves to ACh following pre-constriction to 70–80% of 
their appropriate Rmax response to 5-HT in aortic rings from female immunised, non-arthritic wild type,  IL-
6-/-and IL-6R-/- mice. No significant difference in mean percentage relaxation to ACh for immunised WT non 
arthritic mice (75.7 + 9.1 %) immunised IL-6-/- mice (90.8 + 6.1 %) and immunised IL-6R-/- mice (85.4 + 1.3 %)  
 
Figure 19. (A) Relaxation–response curves to SNO following pre-constriction to 70–80% of their 
appropriate Rmax response to 5-HT in aortic rings from female wild type non-immunised control, and 
arthritic mice. No significant difference in percentage relaxation between control mice (101.9 + 1.1 %) and 
the wild type arthritic mouse (106.1%). (B) Relaxation–response curves to SNO following pre-constriction 
to 70–80% of their appropriate Rmax response to 5-HT in aortic rings from female immunised, non-arthritic 
wild type, IL-6-/-and IL-6R-/- mice. No significant difference in percentage relaxation between percentage 
relaxation to SNO for WT immunised non-arthritic mice (103.0 + 1.5%), immunised IL-6-/- mice (97.0 + 7.0 
%) and immunised IL-6R-/- mice (101.0 + 2.8 %)  
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3.4.8 Trend for reduced aortic constriction in male IL-6R-/- mice compared to non-
immunised control wild type 
 
Mean maximal constriction to 5-HT in the male control WT mouse was 12.4 mN and 
male WT arthritic mouse 3.1 mN (Figure 20A). Although numbers in each group were 
only 1 or 2, there appears to be a trend for higher mean maximal constriction to 5-
HT in the immunised non-arthritic mouse (11.0 mN) compared to the IL-6R-/-  mice 
(3.0 + 2.1 mN) (Figure 20B).  There was no significant difference in percentage 
relaxation to ACh between the groups; percentage relaxation to ACh in the control 
mouse was 92.7%, immunised non arthritic mouse 77.3%, arthritic mouse 82.4% and 
mean for IL-6R-/- mice was 75.9 + 1.9 % (Figure 21). There was also no difference in 
percentage relaxation to SNO; percentage relaxation to SNO in the control mouse 
was 115.4%, immunised non arthritic mouse 110.4%, arthritic mouse 104.7% and 
mean for IL-6R-/- mice was 105.2 + 0.2 % (Figure 22). The male mouse experiment did 
not have an IL-6-/- mouse included as there were none available.  
 
 
Figure 20. (A) Vasoconstriction concentration–response curves to 5-HT in aortic rings from male 
wild type non-inmmunised control, and wild type arthritic mice. Mean maximal developed tension 
in the control mouse (12.4 mN) and wild type arthritic mouse (3.1 mN). (B) Vasoconstriction 
concentration–response curves to 5-HT in aortic rings from male immunised non-arthritic wild 
type and IL-6R-/- mice. Mean maximal developed tension to 5HT was significantly higher in the 
wild type immunised non arthritic mouse (11.0 mN) compared to the IL-6R-/- mice (3.0 + 2.1 mN) * 
p < 0.05.  
 
* 
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Figure 21. Relaxation–response curves to ACh following pre-constriction to 70–80% of their 
appropriate Rmax response to 5-HT in aortic rings from (A) Male non-immunised control wild type 
mice and male wild type arthrititc mice and (B) Male immunised non arthritic wild type mince and IL-
6R-/- mice. No significant difference in percentage relaxation between the groups. Mean percentage 
relaxation to ACh in WT control mouse 92.7 %, WT arthritic mouse 82.4 %, immunised non-arthritic 
mouse 77.3 %, and IL-6R-/- immunised mouse (75.9 + 1.9 %) 
Figure 22. Relaxation–response curves to SNO following pre-constriction to 70–80% of their appropriate 
Rmax response to 5-HT) in aortic rings from (A) Male non-immunised control wild type mice and male 
wild type arthritic mice and (B) Male immunised non arthritic wild type mince and IL-6R-/- mice. No 
significant difference in percentage relaxation between the groups. Percentage relaxation to SNO in the 
WT control mouse was 115.4 %, WT arthritic mouse 104.7 %, WT immunised non arthritic mouse 110.4%, 
and mean for IL-6R-/- mice was 105.2 + 0.2 %.  
 
 
 
 
* 
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3.4.9 The effect of blockade of IL-6 trans-signaling on CIA using sgp130Fc  
 
3.4.9.1 No effect of sgp130Fc on arthritis incidence or severity in DBA-1 mice when 
administered intraperitoneally  
 
In experiment 1 and 2, where mice were administered sgp130Fc intraperitoneally, 
there was no effect on arthritis onset, incidence or severity (Figure 23). Of those mice 
immunised with CIA and administered PBS, in experiment 1 arthritis incidence was 
100% and in experiment 2 was 75%. There was no effect whether sgp130Fc was 
administered on alternate days (Experiment 1) or daily (Experiment 2); there was no 
significant difference in mean total paw score on day 34 for mice administered IP 
sgp130Fc in Experiment 1 (8.5 + 1.7) and those administered PBS (8.3 + 1.5) (Figure 
24). Mean total paw score on day 28 for IP sgp130Fc in Experiment 2 was 3.8 + 1.5, 
PBS (2.0 + 1.4), not significant.  
 
 
Figure 23. Arthritis Incidence in DBA-1 mice treated with IP sgp130Fc. (A) Experiment 1: 100% 
arthritis incidence in DBA-1 mice immunised with CIA and administered either PBS or sgp130Fc on 
alternate days from day 21, n =4 in each group. (B) Experiment 2: 100 % incidence in DBA-1 mice 
immunised with CIA and administered sgp130Fc daily from day 21 and 75% arthritis incidence in 
those administered PBS, n = 4 in each group.  
91 
 
 
 
Figure 24. Mean total paw score over time for mice immunised with CIA and administered sgp130Fc 
IP. (A) Experiment 1: IP sgp130Fc or PBS IP from day 21 on alternate days for 7 doses, no significant 
difference, n = 4 in each group. (B) Experiment 2: IP sgp130Fc or PBS from day 21 daily for 7 doses, 
no significant difference, n = 4 in each group 
 
 
3.4.9.2 No effect on aortic constriction responses in mice with CIA administered IP sgp130Fc  
 
There was no statistically significant difference in maximal developed tension in mice 
with CIA administered sgp130Fc compared to PBS. In Experiment 1 there was no 
difference in maximal developed tension in those administered sgp130Fc (mean 
maximal developed tension 7.88 + 1.0 mN) compared to those administered PBS 
(6.55 + 1.0 mN), but mean maximal developed tension was statistically significantly 
higher in non-immunised control mice (11.3 + 0.7 mN), p < 0.05 (Figure 25A). There 
was no difference in maximal developed tension in those treated with sgp130Fc in 
Experiment 1 (mean maximal developed tension 6.0 + 0.9 mN), compared to those 
administered PBS (5.2 + 1.0 mN), or non-immunised control mice (7.89 + 0.7 mN) 
(Figure 25B). 
92 
 
 
 
3.4.9.3 Detection of sgp130Fc in serum in DBA-1 mice administered IP or IV sgp130Fc  
 
ELISA was performed to measure human sgp130 in mouse serum from those mice 
administered both sgp130Fc from Kiel and from R&D systems. In all mouse serum 
samples where  sgp130Fc was administered intraperitoneally, all absorbance values 
for sgp130 were below the lower limit of detection (0.23 OD), indicating absence in 
serum. In the same ELISA, human samples were also tested, and all samples tested 
contained sgp130. In mice administered intravenous sgp130Fc, human sgp130 was 
detectable in the serum (mean concentration 205 + 36 pg/ml, taken 48 hours after 
administration), but not in mice administered PBS or etanercept), n = 4 per group 
(Figure 26).  
 
* 
Figure 25. Vasoconstriction concentration–response curves to 5-HT in aortic rings from DBA-1 mice 
immunised with high dose collagen and CFA and administered IP sgp130Fc or PBS. (A) Sgp130Fc sourced from 
Kiel, Germany. No difference in mean maximal developed tension in those administered sgp130Fc (7.88 + 1.0 
mN) compared to those administered PBS (6.55 + 1.0 mN), but mean maximal developed tension was 
significantly higher in non-immunised control mice (11.3 + 0.7 mN), *p < 0.05. n = 4 in each group (B) sgp130Fc 
sourced from R&D systems. No significant difference in maximal developed tension in mice administered 
agp130Fc or PBS. n = 4 in each group.  
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3.4.9.4 Intravenous sgp130Fc reduced arthritis incidence and severity in immunised DBA-1 
mice   
 
Intravenous sgp130Fc reduced arthritis incidence in DBA-1 mice immunised with low 
dose collagen and CFA compared to those administered PBS. Arthritis incidence on 
day 29 was 90% for PBS-administered mice, 50% for sgp130fc-administered mice and 
50% for etanercept-administered mice (Figure 27A). Mean total paw score for PBS–
administered mice (4.3 + 3.4) was significantly higher than sgp130Fc–administered 
mice (1.5 + 1.8), and etanercept-administered mice (1.2 + 1.7), p < 0.05 (Figure 27B) 
  
 
 
 
 
Figure 26. Measurement of human sgp130 in serum in mice administered human sgp130Fc IV. Human 
sgp130 was detected in serum from mice administered sgp130Fc (mean concentration 205 + 36 pg/ml), 
but not in etanercept or PBS administered groups (n=4 in each group). Blood was collected 48 hours 
after the second intravenous dose of sgp130Fc. 
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3.4.9.5 Intravenous sgp130Fc restored vascular function in CIA  
 
There was a significant reduction in maximal developed tension in mice with CIA 
administered PBS (5.8 + 2.4 mN) compared to non-immunised control mice (8.5 + 1.8 
mN), p < 0.05. There was no significant difference in mean maximal developed 
tension between sgp130Fc (8.1 + 2.0 mN), etanercept treated mice (7.7 + 1.9 mN) 
and non-immunised controls (Figure 28).  
 
 
 
 
Figure 27. (A) Arthritis incidence and (B) Paw score over time for mice immunised with CIA and 
administered intravenous sgp130Fc, etanercept or PBS. Significant reduction in mean total paw score at 
day 30 in mice administered sgp130Fc (1.5 + 1.8),  or etanercept (1.2 + 1.7), compared to those 
administered PBS (4.3 + 3.4), *p <0.05. n = 10 in each group 
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3.4.9.6 IV sgp130Fc reduced serum CCL2 and VCAM-1 levels in immunised mice compared 
to those administered PBS 
 
Serum CCL2 was significantly higher in mice with CIA treated with PBS (117.3 + 14.5 
pg/ml) compared to those treated with IV sgp130Fc (41.87 + 12.1 pg/ml), p < 0.001 
and non-immunised controls (16.9 + 4.8 pg/ml) p < 0.001 (Figure29A). CCL2 was 
significantly higher in CIA mice administered etanercept (116.7 + 36.7 pg/ml) 
compared to those treated with IV sgp130fc (p < 0.01) and non-immunised controls 
(p < 0.001).  
Serum VCAM-1 was significantly higher in PBS-administered mice (3144 + 366 ng/ml) 
compared to controls (1861 + 160 ng/ml), mice administered etanercept (2077 + 173 
ng/ml) and mice administered IV sgp130Fc (1979 + 136 ng/ml), p < 0.01 (Figure29B). 
There was no significant difference in serum VCAM-1 between etanercept or 
Figure 28. Effect of IV sgp130Fc on aortic constriction in DBA-1 mice immunised with CIA and administered 
either sgp130FC, PBS or etanercept, compared with non-immunised controls. Graphs show vasoconstriction 
concentration–response curves to 5-HT (following pre-constriction to 80% of their appropriate Rmax response 
to 5-HT) in aortic rings N = 10 in each group. Significant reduction in maximal developed tension in mice with 
CIA administered PBS (5.8 + 2.4 mN) compared to non-immunised control mice (8.5 + 1.8 mN), p < 0.05. No 
significant difference in mean maximal developed tension between sgp130Fc (8.1 + 2.0 mN), etanercept 
treated mice (7.7 + 1.9 mN) and non-immunised controls. 
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sgp130fc treated groups compared to non-immunised controls. In immunised DBA-1 
mice there was a significant positive correlation between paw score and both serum 
VCAM-1 and serum CCL2 level (Figure30). 
 
 
 
 
 
 
Figure 29. Serum levels of (A) CCL2 and (B) VCAM-1 in DBA-1 mice. (A) Significantly higher CCL2 in mice with CIA 
administered PBS (117.3 + 14.5 pg/ml) compared to sgp130Fc (41.87 + 12.1 pg/ml), and non-immunised controls 
(16.9 + 4.8 pg/ml). Significantly higher CCL2 in mice immunised with CIA and administered etanercept (116.7 + 36.7 
pg/ml) compared to sgp130Fc and controls, n = 9 in each group. (B) Serum VCAM-1 was significantly higher in PBS 
treated mice (3144 + 366 ng/ml) compared to controls (1861 + 160 ng/ml), mice administered etanercept (2077 + 
173) and mice administered sgp130Fc (1979 + 136). There was no significant difference in serum VCAM-1 between 
etanercept or sgp130fc treated groups compared to controls, n = 10 in each group. *p <0.05, ** p <0.01, *** p < 
0.001 
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Figure 30. Correlations between serum CCL2 or VCAM-1 and total paw score in DBA-1 mice 
immunised with low dose collagen and CFA. Significant positive correlation between serum CCL2 
and total paw score, R = 0.54, p = 0.004. Significant positive correlation between serum VCAM-1 and 
total paw score, R = 0.3749, p = 0.00187 
 
 
3.4.9.7 PSTAT3 not detected in the aorta of arthritic mice  
 
PSTAT3 was present in the synovium of arthritic joints of mice with CIA (Figure 31).  pSTAT3 
was not present in the aorta of control mice or in the aorta of mice with CIA (Figure 32).  
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Figure 31. pSTAT3 staining in synovium from arthritic joints in DBA-1 mice with CIA. (A) Positive 
staining for pSTAT3 in synovium at X 20 magnification (B) Isotype control at X 20 magnification. (C) 
Positive staining for pSTAT3 in synovium at X 40 magnification (D) Isotype control at X 40 
magnification 
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Figure 32. No pSTAT3 staining in the aorta of control DBA-1 mice and arthritic DBA-1 mice. (A) 
Negative staining for pSTAT3 in arthritic mouse aorta, X 20 magnification. (B) Isotype control aorta 
from arthritic mouse, X 40 magnification. (C) Negative staining for pSTAT3 in control mouse aorta, 
X 20 magnification (D) Negative staining for pSTAT3 in control mouse aorta, X 40 magnification (E)  
Isotype control aorta from arthrtitic mouse, X 20 magnification (F) Isotype control aorta from 
arthrtitic mouse, X 40 magnification.  
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3.5 Discussion  
 
3.5.1 Arthritis induction in wild type C57BL/6 and DBA-1 mice  
 
When using the same doses of collagen and CFA that are used to induce CIA in DBA-
1 mice (low dose collagen and TB) no C57BL/6 mice developed arthritis.  When using 
high dose collagen and CFA, CIA was successfully induced in C57BL/6 mice but with a 
variable severity and time course. This is in keeping with the literature, in which there 
are differing reports of arthritis incidence and severity of CIA in C57BL/6 mice. It is 
known that this reduced susceptibility to CIA is linked to the H-2b haplotype in 
C57BL/6 mice, and that the H-2q haplotype in DBA-1 mice confers greater 
susceptibility to CIA, with greater clinical scores and more paw swelling  than C57BL/6 
mice (Bevaart et al, 2010). Of note, in the two experiments using high dose collagen 
and CFA, the first incidence of arthritis was 87.5% and the second 38%. These mice 
were sourced from the same company, were the same age, were housed in the same 
environment and the same methods were used to induce arthritis. Possible factors 
in this variability in incidence could involve the quality of collagen preparation, 
quality of immunisation injections and slight changes in environment, such as noise 
level. It has previously been observed that fighting amongst male mice reduces the 
incidence of arthritis (Inglis et al, 2007). Although no fighting was reported and no 
wounds were observed, we cannot rule out the possibility of fighting amongst mice. 
In DBA-1 mice, arthritis was induced successfully with low dose collagen and CFA, 
with an incidence of 100% in the first experiment and 75% in the second. This is in 
line with the literature on arthritis incidence in DBA-1 mice (Brand et al, 2007).  
 
3.5.2 Effect of CIA on weight gain  
 
Mice with CIA had significantly lower weight gain than control mice; this is in line with 
previous literature (Yongfeng et al, 2016; Filippin et al, 2013). There was a significant 
negative correlation between weight gain and arthritis severity for immunised mice. 
From day 21 onwards food pellets were left in the bottom of the cage, as well as in 
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the food hopper of the cage lid, to ensure that arthritic mice could reach these easily 
and were not disadvantaged by having to reach up to get food on their hind paws. 
Therefore ability of the mice to reach food should not have impacted on their weight 
gain. The cause of reduced weight gain in arthritic mice may be anorexia or systemic 
inflammatory response causing inflammatory cachexia. Studies have found that daily 
food intake did not differ between controls and CIA animals (Filippin et al, 2013). 
Another study found that in adjuvant arthritis induced in rats, pair fed animals (mice 
with arthritis and controls fed the same amount), those with adjuvant arthritis lost 
20% of their body weight at the end of experimentation, and pair-fed animals lost 
only 5% body weight, indicating that anorexia alone does not explain inflammatory 
cachexia (Roubenoff et al, 1997). In these mice, weight loss correlated with TNF-α 
production by spleen mononuclear cells.  
What is unknown in this chapter is the components of the mass weighed, and 
whether the reduction in weight gain is due to less fat or less muscle gain. Previous 
studies in CIA have shown that there is a correlation between arthritis score and 
locomotion; mice with more severe arthritis scores had reduced locomotion (Hartog 
et al, 2009). Those with higher levels of locomotion had higher muscle weight. 
Studies in patients with RA have shown that energy and protein intake were similar 
to control patients but body cell mass (the mass of all the metabolically active tissue 
of the body) was lower in RA patients (Roubenoff et al, 1994). 
 
3.5.3 Effect of CIA on vascular responses in WT C57BL/6 mice 
 
In line with previous work in DBA-1 mice (Reynolds et al, 2012), arthritic C57BL/6 
mice had impaired vasoconstriction to 5-HT compared to non-immunised control 
mice. Contractile dysfunction was not accompanied by overt endothelial dysfunction; 
endothelium-dependent relaxation responses to Acetylcholine were similar between 
groups. Moreover, relaxation responses to exogenously donated nitric oxide (using 
SNO) were unaffected. This again is in line with previous work by Reynolds et al 
(2012).  There was no significant relationship between maximal developed tension 
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and arthritis severity at the time of sacrifice, although there was a trend towards 
higher maximal developed tension with lower total paw score. However, the number 
of mice that developed an arthritis was relatively small (nine) and so this may have 
become significant with a greater group numbers. Previous work by Reynolds et al 
found there was a significant reduction in maximal developed tension in mild and 
moderate graded mice compared to the severe grade. See Reynolds et al (2012) for 
information about arthritis severity grading. Due to the variable day of onset of 
arthritis and variable progression of arthritis severity for each mouse, at the time of 
sacrifice mice had variable total paw scores (although all were in the mild category 
except for one). Mice also had had arthritis for a variable number of days at the time 
of sacrifice. In view of this, constriction responses may have differed between 
arthritic mice.  
The reason for the observed reduction in aortic constriction in CIA has been 
examined previously in our department. Aortic and plasma levels of MMP-9 were 
increased with increasing contractile dysfunction (Williams et al, 2016). MMP-9 is 
type IV collagenase enzyme, and thus can degrade the extracellular matrix in the 
aorta. A previous study found that inhibition of cytokine-induced NO expression in 
rat aortic smooth muscle cells was associated with a selective, dose-dependent 
increase in MMP-9 expression and synthesis (Upchurch et al 2001). Other work in our 
department has found that aortic collagen and elastin become dysregulated during 
CIA and show a fibrosis like phenotype (unpublished yet).  
 
3.5.4 CIA and vascular responses in IL-6-/- and IL-6R-/- mice  
 
No IL-6-/- mice developed arthritis, in line with previous work in IL-6-/- mice (Alonzi et 
al, 1998). Here, for the first time, we show that IL-6R-/- mice are resistant to CIA. This 
is in line with the evidence that the action of IL-6 is necessary for the development 
of CIA. 
Although small numbers, there appears to be impaired vasoconstriction in 
immunised IL-6-/- and IL-6R-/- mice. This is interesting, as there is much evidence that 
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IL-6 is implicated in the pathogenesis of CVD and correlates with CV risk in humans 
(Hartman and Frishman, 2014). Previous work found no significant difference in 
phenylephrine induced constriction between WT and IL-6-/- mice (Coles et al, 2007), 
but constriction responses have not been assessed in IL-6R-/- mice previously. 
Another previous study has found that IL-6-/- mice were protected against 
angiotensin II induced endothelial dysfunction and hypertrophy in carotid arteries 
(Schrader et al, 2007). Unfortunately, breeding of the in-house IL-6-/- and IL-6R-/- 
colonies was poor and no further mice were available to increase numbers to assess 
constriction responses. It would be of interest to assess constriction responses in 
non-immunised IL-6-/- and IL-6R-/- mice and compare with immunised IL-6-/- and IL-6R-
/- mice; perhaps baseline constriction responses would be unaffected, but the 
addition of an inflammatory insult, such as immunisation with CFA, could promote 
the vascular dysfunction seen in this experiment. We know from several previous 
studies that IL-6 plays homeostatic roles in lipid metabolism and atherosclerosis 
(Schieffer et al, 2004). What has not been fully elucidated is the role of IL-6 in 
homeostatic vascular function. It is known that IL-6 is needed for epithelial cell repair, 
for example in the gastrointestinal tract. Perhaps IL-6 is also needed for vascular 
endothelial cell repair and to protect against early insult to the vasculature. IL-6 is 
known to play a role in lipid metabolism and ApoE-/--IL-6-/- double knockout mice have 
greater atherosclerosis than ApoE-/- mice. If complete absence of IL-6 promotes 
atherosclerosis then perhaps IL-6-/- and IL-6R-/- mice have early atherosclerotic 
changes such as fatty streaks which may be contributing to reduced aortic 
constriction. One way to assess this would be to histologically examine the aortas of 
both immunised and non-immunised IL-6-/- and IL-6R-/- mice for early atherosclerosis.  
As mentioned, although IL-6-/- and IL-6R-/- mice share similarities, some differences 
have been seen phenotypically. Whereas IL-6-/- mice have impaired wound healing, 
IL-6R-/- mice heal almost as well as WT mice (McFarland-Mancini et al, 2010). In this 
study, 100% of IL-6-/- mice developed ulcers at the wound boundary, compared to 
just 18% of IL-6R-/- mice and 8% of WT mice. It is unclear whether these ulcers were 
provoked by persistent irritation from an open wound, phenotypic defects in wound 
contraction or psychological/stress-induced from defects in IL-6. Surprisingly, mice 
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deficient in both IL-6 and IL-6R, or IL-6-/- mice treated with an IL-6R blocking antibody, 
showed better wound healing than IL-6-/- mice. This suggests that absence of IL-6R is 
beneficial to wound healing. The reasons for this is unclear but there are other 
members of the IL-6 family; ciliary neurotrophic factor (CNTF) ( Schuster et al, 2003) 
and IL-27 (Crabe et al, 2009), which can bind to IL-6R in vitro but with lower affinity 
than IL-6. The relevance of these findings remains unclear in vivo. 
 A disadvantage of using IL-6-/- or IL-6R-/- mice in this model is that these mice are 
resistant to arthritis. Therefore, we cannot be sure if any change in vascular response 
is just due to the absence of arthritis and its associated systemic inflammation. IL-6-
/- mice do produce antibodies to collagen II in response to CIA, but levels peak later 
and are reduced compared to IL-6+/+ mice (Sasai et al, 1999). In addition, IL-6-/- mice 
have a complete lack of IL-6 and so any effect on the vasculature could be due to 
absence of either IL-6 classical or trans-signaling, or both. Similarly with IL-6R-/- mice 
there is neither classical IL-6 signaling, nor IL-6 trans-signaling, as there is no IL-6 or 
sIL-6R available.  Therefore, it was decided that to further understand the role of 
trans-signaling on vascular function in mCIA, sgp130Fc would be used to specifically 
block IL-6 trans-signaling, whilst allowing classical signaling to continue.  
 
 
3.5.5 Effect of sgp130fc on arthritis severity and vascular function 
 
When administered intraperitoneally, there was no effect of sgp130Fc on arthritis 
incidence or severity compared to PBS controls. This is in contrast to previous work 
(Nowell et al, 2006).  Sgp130Fc consists of the extracellular portion of gp130 linked 
to the Fc domain of a human IgG1 antibody. Its molecular weight is 186kDa. Since 
these previous experiments were performed, the production process of sgp130Fc 
has changed. Human sgp130 was undetectable, when checked by ELISA, in mice 
administered given sgp130Fc IP, suggesting it did not reach the vasculature. One 
reason for this may be that the change in sgp130Fc production process may have 
changed its structure, perhaps conferring a greater propensity to aggregate and 
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making it unable to cross the peritoneal membrane. There was also no difference in 
maximal aortic developed tension in those given IP sgp130Fc, probably as this did not 
affect arthritis severity. When administered intravenously, human sgp130 was 
detectable in the serum. Therefore the reason for IP sgp130Fc having no effect is 
likely to be due to its route of administration. Other possible reasons for sgp130Fc 
being ineffective when administered IP are poor administration skill, although this 
seems less likely as previous experiments with the same investigator using IP 
injections have been successful. 
When administered intravenously, both sgp130Fc and etanercept reduced arthritis 
severity in CIA compared with mice administered PBS. Paw scores were more than 
double in the PBS group compared to sgp130Fc and etanercept groups. Sgp130Fc and 
etanercept each reduced arthritis incidence by 55%. This is similar to the literature; 
Wooley et al (1993) found a 61% reduction in CIA incidence in anti-TNF treated mice 
on day 55. Carty et al found a 50% reduction in incidence of mCIA when mice were 
administered sgp130Fc compared to PBS (from thesis but not published). Rose et al 
(2013) developed a mouse model called K/BxAg7 which develop an erosive 
inflammatory arthritis, followed by atherosclerosis after 12 weeks. These mice have 
dyslipidaemia and increased IL-6 levels. The study found that etanercept reduced 
arthritis and atherosclerotic burden in these mice. 
For the first time this chapter demonstrates that both sgp130Fc and etanercept 
prevented the reduction in constriction responses seen in PBS treated mice. As both 
of these drugs also improved the arthritis severity, it is difficult to know whether this 
effect on the vasculature is related to reduced arthritis severity, or whether the drugs 
are having a direct effect on the blood vessels. Interestingly, although the arthritis 
incidence in sgp130Fc and etanercept groups was 50%, constriction responses in 
these mice were not significantly different from non-arthritic control mice, perhaps 
suggesting a greater effect of both drugs on the vasculature than on the joints. Within 
individual groups: sgp130Fc, etanercept and PBS there was no significant correlation 
between paw score and maximal developed aortic contraction. There was a trend 
within each group for a negative correlation, and this was most pronounced in the 
PBS group. Therefore, we cannot say that there is a direct relationship between 
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improvement in arthritis severity and improvement in vascular function with 
sgp130Fc and etanercept.  
Serum CCL2 was significantly higher in mice with CIA administered PBS than those 
administered sgp130Fc. CCL2 recruits monocytes, memory T cells and dendritic cells 
to sites of inflammation and is known to be increased in serum and synovial fluid of 
RA patients (Koch et al, 1992). CCL2 levels also correlate with CIMT in RA patients 
(Södergren et al, 2010). CCL2 gene inactivation significantly decreases progression of 
atherosclerotic lesions (Linic et al, 2013) and CCL2 expression is increased in 
atherosclerotic lesions and injured arteries (Egashira et al, 2003). CCL2 is produced 
by many cell types, including endothelial, fibroblasts, epithelial, smooth muscle, 
mesangial, astrocytic, and microglial cells. However, monocytes and macrophages 
are the major source of CCL2 (Deshmane et al, 2009). Macrophage numbers in the 
aorta have been shown to be increased in CIA (Williams et al, 2016). The reduction 
in CCL2 in mice administered sgp130Fc seen in this work is in line with the literature; 
work by Nowell et al (2003) has shown that IL-6 trans-signaling (via Hyper-IL-6) 
increased arthritis severity and controlled intrasynovial mononuclear leukocyte 
recruitment through CCL2. In the same study, treatment of IL-6+/+ mice with sgp130Fc 
significantly reduced the intensity of CCL2 staining to levels comparable with that 
seen in IL-6−/− mice. Treatment with etanercept did not reduce CCL2 levels compared 
to PBS. Previous studies have found that TNF-α enhances the expression of CCL2 in 
astroctyes (Barna et al, 1994) and human proximal tubular epithelial cells (Ho et al, 
2008) but to my knowledge, there are no studies reporting the effect of TNF-α on 
expression of CCL-2 on the vascular endothelium. As both sgp130Fc and etanercept 
restored vascular function but etanercept did not reduce serum CCL2, we cannot 
conclude that the improvement in vascular responses with these drugs is solely due 
to reduced CCL2.  
 
Serum VCAM-1 levels were significantly higher in mice with CIA administered PBS 
than those administered IV sgp130Fc, etanercept or non-immunised control mice.  
Previous work using the Biomap® system has shown that IL-6 trans-signaling 
regulated the release of VCAM-1 from endothelial cells, PBMCs and coronary artery 
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smooth muscle cells. Thus, the reduction seen in serum VCAM-1 levels in those 
administered sgp130Fc compared to PBS would fit with this. Mice administered 
etanercept also had lower VCAM-1 than those administered PBS. TNF-α is known to 
increase the expression of VCAM-1 in human endothelial cells (Kim et al, 2001; 
Haraldsen et al, 1996) and a study in patients with RA found that serum VCAM-1 
levels were significantly lower after treatment with infliximab, an anti-TNF antibody 
(Klimiuk et al, 2004). Previous work in CIA has shown that qRT-PCR VCAM-1 
expression in the aorta was higher in CIA versus non immunised mice (Denys et al, 
2013). Interestingly, the expression of IL-6 in the aorta was similar in all groups. 
VCAM-1 induces immune-cell recruitment within the vessel wall and therefore 
inflammation. Thus, the improved vascular constriction response seen with both 
sgp130Fc and etanercept could be due to the reduction in VCAM-1 and therefore 
reduction in recruitment of inflammatory cells into the aorta. 
 
pSTAT3 was not detected in the aorta of either control or arthritic mice in this study, 
but was present in the arthritic joints. This positive staining in the joint is in keeping 
with previous work in AIA which has reported rapid activation of STAT-3 following 
arthritis induction, with pSTAT3 staining in arthritic joints (Nowell et al, 2009). In this 
study, activation of STAT-3 was significantly impaired in IL-6-/- mice. A previous study 
in human aortic tissue has shown that pSTAT3 staining only occurred in aneurysmal 
tissue, and not in non-aneurysmal tissue (Liao et al, 2010). Studies in ApoE-/- mice 
have shown positive staining for pSTAT3 in the aorta (Madrigal-Matute et al, 2010). 
As blockade of trans-signalling restored vascular function in CIA, it could be proposed 
that in the aorta of arthritic mice, IL-6 trans-signaling pathways should be at play, and 
thus pSTAT3 should be detectable in the aorta of arthritic mice. However, this maybe 
time dependant and perhaps if mice were culled earlier, this may have been 
detectable. Another reason for the lack of pSTAT3 staining in the aortic tissue could 
be tissue dependant; the pSTAT3 stain has been used previously in the laboratory 
with good results in joints, but has not been used previously in aortic tissue.  
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3.6 Conclusion  
 
This work confirms the variable penetrance and severity of CIA in C57BL/6 mice. The 
work in this chapter also shows validation of previous findings of vascular dysfunction 
in CIA, in that arthritic wild type mice have reduced aortic constriction to 5-HT. In line 
with previous work, IL-6-/- were resistant to CIA. For the first time, we show that IL-
6R-/- are also resistant to CIA. Interesting trends for reduced vascular constriction in 
immunised IL-6-/- and IL-6R-/- have been presented. We have shown that selective 
blockade of IL-6 trans-signalling using intravenous sgp130Fc reduces arthritis severity 
and restores the vascular dysfunction associated with CIA. We have also shown that 
blockade of TNF-α also restores vascular dysfunction in CIA. Blockade of IL-6 trans-
signaling was associated with a reduction in serum CCL2 and VCAM-1. This work 
demonstrates the importance of IL-6 trans-signaling in vascular dysfunction in an 
animal model of CIA. However, the relevance of this in human RA remains to be 
established. Also, the role of IL-6 trans-signaling in the ‘end points’ of vascular 
dysfunction, namely atherosclerosis, remains to be elucidated. Therefore the 
following chapters will explore the role of IL-6 trans-signaling in atherosclerosis in an 
animal model and the association of IL-6 trans-signaling-regulated proteins with 
progression of atherosclerosis in patients with RA.  
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4 Chapter 4 – The Effect of IL-6R mediated trans-signalling on 
Atherosclerosis in the ApoE-/- Mouse   
 
4.1 Introduction  
 
Cardiovascular risk is increased in RA and strongly associated with inflammation. This 
increase in cardiovascular risk and cardiovascular events is present soon after RA 
diagnosis. This suggests that inflammation in RA could accelerate pre-existing 
subclinical atherosclerosis. By using an animal model of atherosclerosis we can 
examine the effect of inflammation, specifically the effect of IL-6 trans-signaling, on 
atherosclerosis development in susceptible animals. As mentioned in section 1.16.2 
of the general introduction, there are several animal models of atherosclerosis. 
However, the ApoE-/- mouse model detailed in this chapter was chosen because of 
its lesion comparability with humans and the timescale of lesion development in this 
model (Asquith et al, 2010).   
 
4.1.1 The ApoE-/- mouse 
 
Apolipoprotein E (ApoE) is a class of apolipoprotein found in chylomicrons and 
intermediate density lipoproteins and functions primarily as a lipid transporter. It 
plays a protective role in atherosclerosis. ApoE has three major isoforms; ApoE2, 
ApoE3 and ApoE4. It functions as a ligand for receptors that clear very low–density 
lipoprotein (VLDL) remnants and chylomicrons. ApoE is predominantly synthesized in 
the liver but is also found in the brain, spleen, lung, kidney, ovary, testis, peripheral 
nerves and muscle (Zhang et al, 2011). It is also synthesized by macrophages and 
monocytes in vessels, and has local effects on inflammatory reactions in 
atherosclerotic vessels (Curtiss, 2000), such as inhibiting SMC proliferation and 
migration induced by oxidised LDL and platelet-derived growth factor (Ishigami et al, 
2000). ApoE exerts its biological functions by binding to the low-density lipoprotein 
receptor (LDLR) family, effectively mediating the uptake of lipoproteins by cells 
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(Mahley, 1988). Therefore, ApoE-/- mice have delayed clearance of lipoprotein 
particles and even on a normal chow diet have increased cholesterol and triglyceride 
levels compared to their normal litter-matched controls (Jawieri et al, 2004).  
The initial stages of atherosclerosis in the ApoE-/- mouse develop after 5-6 weeks on 
a normal chow diet. This involves the attachment of monocytes to the endothelial 
wall, then subsequent passage into the endothelial space. After 10 weeks, fatty 
streaks appear and at around 20 weeks fibrous plaques develop. Lesions in ApoE-/- 
mice on Western-type diet occur earlier and contain more lipid than those on chow 
diet (Nakashima et al, 1994). On a western diet fatty streaks occur at around 8 weeks 
and by 15 weeks early fibrous plaques are seen (Nakashima et al, 1994).  
 
 
4.1.2 The effect of IL-6 on atherosclerosis on the ApoE-/- mouse  
 
In humans, long term IL-6 levels are associated with CVD risk as strongly as some key 
established CV risk factors (Danesh et al 2008). There are conflicting results of the 
effect of IL-6 on atherosclerosis in ApoE-/- mice. A study by Huber et al showed that 
IL-6 increased atherosclerotic lesion size in both C57BL/6 and ApoE-/- mice 1.9- to 5.1-
fold compared to saline-treated animals (Huber et al, 1999). Mice were administered 
recombinant IL-6 (5000u) weekly whilst fed either high fat or normal chow diet for 6 
to 21 weeks. In contrast to this, ApoE-/--IL-6-/- double knockout mice had higher serum 
cholesterol and increased atherosclerotic lesion formation compared to ApoE-/- mice 
(Schieffer et al, 2004). Therefore these studies have shown an increase in 
atherosclerosis when IL-6 is administered above physiological levels, but also in the 
complete absence of IL-6. However, the studies do not specifically examine the role 
of IL-6 trans-signaling versus classical IL-6 signalling in atherosclerosis.  
One study has examined the role of IL-6 trans-signaling in atherosclerosis 
development in LDLR-/- mice (Schuett et al, 2012). Here, blockade of IL-6 trans-
signaling, by administration of sgp130Fc, reduced atherosclerosis in LDLR-/- mice 
without affecting serum lipid levels. This study addressed the effect of blocking IL-6 
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trans-signaling on atherosclerosis in a non-inflammatory setting. These mice do not 
have inflammatory disease so their IL-6 and IL-6R levels will be similar to normal 
individuals and patients with ischaemic heart disease. However, in RA patients levels 
of IL-6 and IL-6R are 10 fold higher. This chapter uses Hyper-IL-6 to reflect these 
increased IL-6/IL-6R levels and examines their effect on atherosclerosis in the ApoE-
/- mouse model.  
 
4.1.3 Assessment of atherosclerosis in mice 
 
Assessment of atherosclerosis has mostly been made by quantifying the area of 
plaques, usually in the aorta, aortic root or brachiocephalic artery. Two main 
methods have been used, the en face method and cross sectional analysis. The en 
face method involves spitting the aorta down its entire length and pinning it to 
expose the luminal endothelium. The aorta can then be stained for lipids, e.g. with 
Oil red O.  In cross sectional analysis, the brachiocephalic artery or aortic root are 
most often used. This allows serial quantification of cross sections, and also staining 
for other uses, such as immunohistochemistry. Imaging software can be used for 
both methods to accurately measure plaque size.  
As well as plaque size, other measures are necessary to assess plaque stability. 
Plaque stability is a key factor in atherosclerosis assessment as this is directly linked 
to risk of a rupture, which in turn can lead to occlusive thrombosis and death. 
Markers of plaque stability include thickness of fibrous cap, and presence and extent 
of intraplaque hemorrhage, inflammation and necrotic core (van der Wal and Becker, 
1999) (Figure 33). There is increasing data that the brachiocephalic artery is a useful 
site to examine plaque size and stability in mice (Jackson et al, 2007; Teupser et al, 
2003). The brachiocephalic artery is a short vessel which arises from the arch of the 
aorta (Figure 34). It branches into the right subclavian and right common carotid 
arteries. In this chapter, we also examine the effect of Hyper-IL-6 and IL-6 on fibrous 
cap thickness in the brachiocephalic artery in the ApoE-/- mouse.  
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Figure 34. A schematic diagram of the brachiocephalic artery. This branches 
off the arch of the aorta and then divides into the right subclavian artery and 
the right common carotid artery. 
Figure 33. A schematic diagram of an artery showing a ruptured unstable plaque versus a stable 
plaque. Unstable plaques are characterised by increased numbers of inflammatory cells and 
mediators, large necrotic cores and thin fibrous caps. When the fibrous cap is eroded, 
prothrombotic material leaks out, resulting in thrombus formation. In contrast, stable plaques 
have less inflamamtion, smaller necrotic core and thicker fibrous cap. (MACE = major adverse 
cardiac events)  Taken from Charo et al, 2011.   
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4.2 Hypothesis and aims  
 
The aim of this chapter was to determine the effect of IL-6 trans-signaling on 
atherosclerosis development in the ApoE-/- mouse. Using this model allows 
examination of other defined outcomes such as plaque size, expression of SCCPs in 
plaque and fibrous cap thickness.  
This chapter details methodology, results and discussion under the following 
hypothesis and aims:  
Hypothesis: IL-6 trans-signaling accelerates atherosclerosis in ApoE-/- mice.  
In order to address this hypothesis the following four aims were identified:  
1. To determine the effect of IL-6 trans-signaling, using Hyper-IL-6, on aortic 
plaque size and to compare any effect with that caused by IL-6 and PBS using 
ApoE-/- mice 
2. To determine the effect of IL-6 trans-signaling, using Hyper-IL-6, on 
brachiocephalic plaque size and to compare any effect with that caused by IL-
6 and PBS using ApoE-/- mice 
3. To analyse the effect of IL-6 trans-signaling  on fibrous cap thickness by 
treating ApoE-/- mice with Hyper-IL-6 and comparing against results obtained 
by IL-6 and PBS administration. 
4. To measure levels of VCAM-1 in serum and the brachiocephalic artery from 
ApoE-/- mice treated with Hyper-IL-6, IL-6 and PBS.  
 
 
4.3 Specific methods  
 
4.3.1 Mice 
 
All ApoE−/− mice were purchased from Charles River, UK at 7 weeks of age. A previous 
study demonstrated no significant difference in lesion size formation between 
114 
 
C57BL/6 mice housed under two conditions that inferred a range of infective states 
(Mallat et al, 1999). There are many variables that could potentially affect 
atherosclerosis development other than pathogen status, for example sterilisation 
status of food, water source, and bedding composition. As RA patients are exposed 
to multiple environmental agents, including infectious agents, it was felt that 
conventional housing was more likely to mirror this environment than pathogen-free 
housing.  
 
At 8 weeks of age mice were fed high-fat diet containing 21% (wt/wt) pork lard and 
supplemented with 0.15% (wt/wt) cholesterol for 8 weeks. Experiments were 
performed in accordance with the home office approved project licence (PL 302822). 
Mice had free access to water and had a light dark cycle of 12 hours. The temperature 
range in the animal house was 19-23°C and humidity 55 + 10%. 
To ensure atherosclerosis development in our facility over this time period, under 
the above conditions, 6 mice were initially sourced and fed as above. This test batch 
was then sacrificed and atherosclerosis was quantified. Once it was shown that these 
conditions produced atherosclerosis the following experimental approach was taken. 
Mice were divided into three groups and drugs were administered intraperitoneally 
as follows:  
 
 
Group  
N 
number 
Drug Dose 
per 
mouse 
Volume per 
administration  
Frequency of 
administration  
Duration  
1A 
 
6 
Hyper-IL-
6 
0.5µg 100µl Twice weekly 8 weeks 
1B 
 
6 IL-6 0.16µg 100µl Twice weekly 8 weeks 
1C 
 
6 PBS N/A 100µl Twice weekly 8 weeks 
 
Table 19. Drugs and doses administered to ApoE-/- mice in Experiment 1. See section 4.3.2 for 
rationale for drug doses 
 
115 
 
In order to check the reproducibility of the initial result a second experiment was 
undertaken (Experiment 2). An additional experimental group was introduced in this 
experiment; 1 µg Hyper-IL-6 was tested in order to assess whether the effect upon 
IL-6 trans-signalling was concentration dependent. 
 
 
Group 
N 
number 
Drug 
Dose  
per 
mouse 
Volume per 
administration 
Frequency of 
administration  
Duration 
2A 
 
6 
Hyper-IL-
6 
0.5µg 100µl Twice weekly 8 weeks 
2B 
 
6 IL-6 0.16µg 100µl Twice weekly 8 weeks 
2C 
 
6 PBS       N/A 100µl Twice weekly 8 weeks 
2D 
 
6 
Hyper-IL-
6 
1µg 100µl  Twice weekly 8 weeks 
 
Table 20. Drugs and doses administered to ApoE-/- mice in Experiment 2. 
 
4.3.2 Rationale for drug doses  
 
No previous studies in the literature could be found which had administered Hyper-
IL-6 to mice over a period of 8 weeks; most studies administered Hyper-IL-6 only as 
one dose (Nechemia-Arbely et al, 2008; Rakemann et al, 1999). Therefore an 
approximate equivalent dose was chosen to that of levels of circulating IL-6/sIL-6R 
complex in human inflammatory arthritis. In a study by De Benedetti et al (1994), 
levels of circulating IL-6/sIL-6R complex in systemic JIA were 6.8-8.9 ng/ml. From my 
own work in patients with RA, serum levels of IL-6/sIL-6R complex were between 0-
16.5 ng/ml (n= 83).  Peters et al (1998) administered 0.4 µg IP of Hyper-IL-6 to mice 
and sacrificed them 4 hours after administration. Serum levels of Hyper-IL-6 were 
approximately 10 ng/ml, thus for this experiment 0.5 µg of Hyper-IL-6 was thought 
to be an appropriate dose. An equivalent molar concentration of IL-6 was used; the 
molecular weight of IL-6 is 20kDa and Hyper-IL-6 60kDa therefore 0.16 µg of IL-6 was 
chosen.  
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Hyper-IL-6 was a gift from Professor Rose John in Kiel University and IL-6 was sourced 
from R&D systems (206-IL).  
 
4.3.3 Monitoring of mice  
 
Mice were weighed twice weekly and monitored at least 3 times per week for general 
health status. A side effect that can occur with high fat feeding in ApoE−/− mice is skin 
irritation, manifest as scratching and scaly skin which can lead to ulceration. This 
tends to occur after several months of high fat feeding. If mice in this experiment had 
developed ulcers from these effects then they would have been euthanised using a 
humane method. 
 
 
4.3.4 Collection of Experimental Samples  
 
Mice were culled using a schedule 1 approach and blood collected by cardiac 
puncture for serum analysis. The chest cavity was opened and the heart continuously 
perfused with PBS. The right atrium was snipped to allow blood to flow out. The chest 
and neck were dissected to allow observation of the brachiocephalic and carotid 
arteries. The brachiocephalic artery was carefully dissected and removed with a piece 
of the aortic arch. This was immediately embedded in OCT and snap frozen in liquid 
nitrogen (Figure 35). The heart was removed, cut and placed in OCT and immediately 
frozen.  
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4.3.5 Sectioning of cardiac tissue and brachiocephalic artery 
 
The OCT-embedded heart was mounted in a cryostat set at -22°C. Serial aortic root 
cross-sections of 7μm thickness were taken at the level of all three leaflets of the 
aortic valve and mounted on glass slides (Superfrost Pink). Slides were then stored at 
-80°C.  
 
The OCT-embedded brachiocephalic artery was mounted in a cryostat set at -22°C. 
The section was orientated so that the aortic arch was cut first. Sections were cut 
through the aorta until the brachiocephalic artery was reached. Serial section of 7um 
thickness were cut and mounted on glass slides (Superfrost pink).  
 
 
 
Figure 35. Diagram of mounting procedure of the brachiocephalic artery. After dissection the 
brachiocephalic artery, along with a piece of the aortic arch was suspending into OCT which is 
mounted on a frozen stand. This was then immersed in liquid nitrogen to snap freeze it.   
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4.3.6 Staining tissue with Oil-red O for lipid content 
 
 
Oil red O stock was prepared by dissolving Oil red O (2mg/ml) (Sigma UK) in Isopropyl 
Alcohol (Fischer scientific). Then an equal concentration of Oil red O stock was mixed 
with 30% Isopropyl Alcohol and filtered through a 0.22 micron filter. This was allowed 
to stand for 15 minutes before use.  
Slides were air dried for 20 minutes. Then the protocol was performed as below.  
 
Procedure  Duration  Purpose  
Distilled water  Dip in   Remove residue 
30% Isopropyl Alcohol 5 minutes  Rinse 
Working Oil Red O 20 minutes Stains lipids  
30% Isopropyl Alcohol Dip in  Differentiate  
Distilled water Dip in  Rinse  
Harris Haematoxylin 1 minute  Stains nuclei  
Distilled water Until Haematoxylin stops 
leaching out 
Remove excess stain 
Mounted in glycerol and 
coverslip  
 Keep moist and preserve 
stain 
 
Table 21. Protocol for Oil Red O staining of frozen sections 
 
 
4.3.7 Determination of plaque size  
 
Lesion size was determined by computer-assisted morphometry on stained sections. 
Morphometry was performed using Image ProPlus™ software version 4.0 (Media 
Cybernetics). 
 
4.3.8 Immunohistochemistry 
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Immunohistochemistry of the brachiocephalic lesions was performed to examine 
staining for VCAM-1. VCAM- was stained for as in human RA patients this correlated 
with disease activity and CV risk and in CIA models CIA is associated with increased 
aortic expression of VCAM-1 (Denys et al, 2016). Slides were taken out of the freezer 
and left at room temperature before the following protocol was performed.   
 
Process Rationale Time 
Acetone at -20°  To fix slide  5 minutes  
PBS  Wash  5 minutes  
10% H202   Block endogenous peroxide 15 minutes  
PBS Wash 5 minutes  
10% normal goat serum  in 
TBS/T  
Decrease non-specific binding of antibody  
 
15 minutes  
Remove serum    
Avidin block Decrease non-specific binding of antibody  
 
10 minutes  
TBS/T Wash  5 minutes 
Biotin block  Decrease non-specific binding of antibody  
 
10 minutes  
Remove biotin   60 minutes  
TBS/T Wash  5 minutes 
Primary antibody or isotype 
control antibody  
Identification of target protein and control 
IgG staining  
 
Overnight (at 4°C) 
Allow to stand at room 
temperature  
 1 hour  
PBS Remove excess antibody 3 X 5 minutes  
Detection antibody : 
biotinylated anti-rabbit IgG, 
affinity purified from goat, 
Vector labs #BA-10000) at 
1:200 dilution in TBS/T 
Identification of bound primary antibody 60 minutes   
TBS/T Remove excess antibody 3 x 5 minutes 
ABC reagent from kit 30 mins  
 
Identify bound Antibody in sections  30 minutes  
TBS/T Wash  3 x 5 minutes  
DAB substrate  Allow identification of positive staining  1- 20 minutes  
Distilled water Rinse  1 minute 
Harris Haematoxylin Nuclear stain  10 seconds  
Distilled water Remove excess stain Until water runs clear  
Cover with glycerol and 
coverslip  
Prevent drying   
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Table 22. Protocol for immunohistochemistry for staining for VCAM-1 on frozen brachiocephalic 
sections. 
4.3.9 Analysis of VCAM-1 staining  
 
Firstly the brachiocephalic artery and plaque was examined to determine the location 
of the most intense VCAM-1 staining. In order to do this, specific areas of the same 
artery were examined, for example the arterial wall underlying plaque, the plaque 
itself and the arterial wall opposite the plaque. Photoshop was used to determine 
the total number of pixels in the selected area of the picture (Figure 36A). The 
number of brown pixels, representative of positive staining, was then calculated. 
To compare the percentage staining of VCAM-1 in brachiocephalic arteries and 
plaque in the different experimental groups the entire brachiocephalic arterial wall 
and plaque of individual slides were examined (Figure 36B). The number of brown 
pixels, representative of positive staining, was then calculated. The positive staining 
was calculated as a percentage of the total region and was corrected for isotype 
control values. 
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Figure 36. Examples of brachiocephalic artery sections stained for VCAM-1 and approach to 
measurement of staining. (A)  VCAM-1 staining measured in specific areas of brachiocephalic artery 
or plaque. (B) VCAM-1 staining measured in the brachiocephalic artery and plaque  
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4.3.10 Elastin Van Geison (EVG) stain  
 
 EVG was used to stain elastin and collagen. This allows identification on the fibrous 
cap. Slides were taken out of the freezer and the following protocol was performed.  
Procedure  Duration  Purpose  
Air dry sections  30 minutes  
70% ethanol  15 minutes  Hydration  
Distilled water  1 minute   Rinse  
Potassium permanganate  10 minutes  Oxidising agent 
Distilled water  Until stain runs clear  Rinse  
1 % Oxalic acid  10 minutes  Decolourise  
Distilled water  5 minutes  Rinse  
Miller’s elastin  Overnight on Rocker  Stains elastic fibres 
blue/black 
70% ethanol Dunk 7 times   
Distilled water  1 minute  X 2  Rinse  
Van Gieson Solution  10 minutes Stains collagen red 
Blot slides dry   Get rid of most of stain  
Oven bake at 60°C 30 minutes  Increases adherence to 
slide 
70% ethanol 3 minutes  Dehydration 
90% ethanol 3 minutes Dehydration 
100% ethanol 3 minutes Dehydration 
100 % Xylene  5 minutes  Dehydration  
Mount with DPX and 
coverslip  
 To preserve stain 
 
Table 23. Protocol for Elastin Van Gieson Stain. 
 
4.3.11 Fibrous cap thickness analysis  
 
Image Pro-Analyser was used to measure the fibrous cap thickness, after staining 
with EVG. Five separate measurements were taken for each individual fibrous cap 
and the mean value was calculated for the best estimate. Fibrous cap thickness at 
the widest and thinnest part of the plaque were also recorded.  
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4.3.12 Serum 
 
Using a 25 gauge needle, approximately 1ml of whole blood was taken by cardiac 
puncture. This was placed into vacutainers coated with clot activator and stored on 
ice. Samples were then centrifuged at 1600g for 10 minutes at 4°C. The serum was 
then aliquoted in 50ul aliquots and stored at -80°C. Serum CCL2 and VCAM-1 were 
measured using duoset ELISA development kits from R&D systems in accordance 
with manufacturer’s instructions, at concentrations in Table 24. See Table 7 in 
general methods section for ELISA protolol for murine serum.  Serum was sent for 
analysis of total cholesterol, HDL, LDL, triglycerides and free fatty acids at the Medical 
Research Council Harwell laboratory, UK.  
 
 
Table 24. Concentrations of CCL2 and VCAM-1 antibodies and standards for ELISA. 
 
4.3.13 Statistical Analysis 
 
Analysis of statistical difference between the groups was carried out using a one way 
ANOVA with a Bonferroni post hoc test. p < 0.05 was considered significant. 
 
4.3.14 Sample Size Estimation 
 
Previous studies have shown that ApoE−/− increases atherosclerotic plaque by 0.4 + 
0.05 mm2 (Asquith et al, 2010). Six animals per group will have 90% statistical power 
to demonstrate a significant difference with p <0.05. 
Protein 
measured  
Capture antibody 
working 
concentration 
Detection antibody 
working 
concentration 
High standard 
concentration 
Mouse 
CCL2 
200 ng/ml 50 ng/ml 250 pg/ml 
Mouse 
VCAM-1 
1 µg/ml 100 ng/ml 8000 pg/ml 
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4.4 Results  
 
4.4.1 Lipid rich plaques present in ApoE-/- mice after 8 weeks of high fat feeding  
 
After 8 weeks of high fat feeding, 6 of 6 mice had plaques in the aortic root (Figure 
37) and brachiocephalic artery (Figure 38). In the brachiocephalic artery the mean 
plaque area was 0.014 + 0.0047 mm2 and mean plaque percentage was 7.72 + 1.51%. 
In the aortic root mean plaque size was 0.22 + 0.007 mm2and mean plaque 
percentage was 19.8 + 1.46%.  
 
 
 
 
 
 
 
 
 
 
Figure 37. Aortic root section from ApoE-/- mouse and wild type C57BL/6 mouse stained with Oil red O (A) 
Aortic root from ApoE-/- mouse fed high fat diet from 8 weeks and sacrificed at 16 weeks, lipid rich plaques 
seen. (B) Wild type C57BL/6 mouse at 16 weeks at the same level of the aortic root, no plaque seen. Both at 
X 4 magnification. P (Plaque), AVL (Aortic valve leaflets). Scale bars = 200 μm 
Figure 38. Brachiocephalic artery from ApoE-/- mouse stained with Oil red O. Lipid in plaque can be seen 
stained red. At X 10 magnification.  
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4.4.2 Skin irritation in mice administered Hyper-IL-6   
 
The following results are grouped for experiments 1 and 2. Three of 12 mice (25%) 
mice in the Hyper-IL-6 0.5 µg group and 1 of 6 (16.7%) of mice in the Hyper-IL-6 1 µg 
group developed signs of skin irritation that required the application of clay 
treatment. No other mice in other groups developed signs of skin irritation.  
 
4.4.3 Lower weight gain in mice administered Hyper-IL-6 1 µg 
 
Mice administered Hyper-IL-6 1 µg (mean weight gain 3.5 + 1.0 g) had significantly 
lower weight gain than those administered PBS (6.1 + 2.2 g), IL-6 (6.5 + 1.6 g) or 
Hyper-IL-6 0.5 µg (7.4 + 1.8 g) (Figure 39). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39. Weight gain in 16 week old ApoE-/- mice fed a high fat diet from 8 weeks and 
administered either PBS, IL-6, Hyper-IL-6 0.5µg or Hyper-IL-6 1µg twice weekly for 8 weeks. 
Weight gain was significantly lower in mice administered Hyper-IL-6 1µg than those 
administered PBS, IL-6 or Hyper-IL-6 0.5 µg.  *p < 0.05, **p < 0.01, ***p < 0.0001 
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4.4.4 No significant difference in aortic root plaque size between mice administered 
PBS, IL-6 or Hyper-IL-6  
 
There was no difference in aortic root plaque area or aortic plaque percentage 
between the groups. Mean plaque area for PBS (0.225 + 0.01 mm2), IL-6 (0.217 + 0.01 
mm2), Hyper-IL-6 0.5 µg (0.228 + 0.011 mm2), Hyper-IL-6 1 µg (0.218 + 0.001 mm2) 
(Figure 40A). Similarly, there was no significant difference in percentage plaque in 
the aortic root; mean percentage plaque for PBS (21.9 + 1.9 %), IL-6 (22.9 + 1.1 %), 
Hyper-IL-6 0.5 µg (25.0 + 1.5 %) , Hyper-IL-6 1 µg (24.1 + 0.1 %) (Figure 40B).  
 
 
 
4.4.5 Significantly larger plaque and plaque percentage in the brachiocephalic 
arteries of mice administered Hyper-IL-6 compared to IL-6 and PBS 
 
Mice treated with Hyper-IL-6 1µg had significantly larger brachiocephalic plaque size 
(0.73 + 0.04 mm2) than those administered PBS (0.018 + 0.01 mm2), p < 0.001, and 
IL-6 (0.033 + 0.017 mm2), p = 0.015 (Figure41A). Mice administered Hyper-IL-6 1µg 
Figure 40. No difference in aortic plaque area (A) or aortic plaque percentage (B) in ApoE-/- mice aged 16 
weeks fed a high fat diet and administered either PBS, IL-6, Hyper IL-6 0.5µg or Hyper-IL-6 1µg twice weekly 
for 8 weeks.  
127 
 
had significantly higher percentage plaque in the brachiocephalic artery (45.3 + 18.1 
%) compared to those administered PBS (10.38 + 6.7 %), p < 0.001 or IL-6 (20.1 + 10.2 
%), p = 0.002 (Figure 41B). Mice administered Hyper-IL-6 0.5µg had significantly 
higher percentage plaque (27.7 + 16.2 %) than PBS administered mice, p= 0.015. 
Examples of brachiocephalic cross sections from each group are shown in Figure 42. 
There was a significant negative correlation between weight gain and 
brachiocephalic plaque size and brachiocephalic plaque percentage area (Figure 43).  
 
 
 
Figure 41. Brachiocephalic plaque size and plaque percentage in 16 week old ApoE-/- mice fed high fat diet 
from age 8 weeks and administered either PBS, IL-6 or Hyper-IL6. (A) Significantly higher brachiocephalic 
plaque area in mice administered Hyper-IL- µg (mean plaque area 0.73 + 0.04 mm2) compared to those 
administered PBS (0.018 + 0.01 mm2), p < 0.001 or IL-6 (0.033 + 0.017 mm2), p = 0.015. (B) Significantly higher 
percentage plaque area in mice administered Hyper-IL-6 1 µg (45.3 + 18.1 %) compared to those administered 
PBS (10.38 + 6.7 %), p < 0.001or IL-6 (20.1 + 10.2 %), p = 0.002. Significantly higher percentage plaque in mice 
administered Hyper-IL-6 0.5 µg (27.7 + 16.2 %) compared to mice administered PBS p= 0.015. 
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Figure 42. Examples of cross sectional images from brachiocephalic arteries from ApoE-/- mice aged 16 weeks fed 
a high fat diet from age 8 weeks and administered the following drugs twice weekly for 8 weeks from age 8 weeks 
(A) Mice administered PBS (B) Mice administered IL-6 (C) Mice administered Hyper-IL-6 0.5 µg (D) Mice 
administered Hyper-IL-6 1 µg. 
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4.4.6 VCAM-1 staining in the brachiocephalic artery  
 
Firstly, brachiocephalic arteries of the same mouse were examined for VCAM-1 
staining. VCAM-1 staining was mostly localised to the artery wall underlying plaque. 
Some VCAM-1 staining was observed within plaque (especially the plaque cap) and 
in the arterial wall opposite the plaque (Figure 44). This was quantified in 8 mice, 2 
from each group. Mean percentage staining for VCAM-1 was significantly higher in 
the artery wall underlying plaque (33.7 + 11.0 %), then in the plaque itself (13.65 + 
7.0 %) and lowest in the arterial wall opposite the plaque (2.0 + 2.5 %) , p < 0.001 
(Figure 45).  
 Percentage VCAM-1 staining in the brachiocephalic artery from all mice in all groups 
was then compared. For this analysis the entire arterial wall and entire plaque in 
cross section was examined. Percentage VCAM-1 staining in the brachiocephalic 
sections (including vessel wall and plaque) was significantly higher in mice 
administered Hyper IL-6 0.5 µg and Hyper-IL-6 1 µg (mean percentage staining 11.7 
+ 4.07 % and 12.8 + 4.24 %) compared to mice administered PBS (mean 5.7 + 1.1 %) 
Figure 43. A) No significant correlation between weight gain and brachiocephalic plaque area in ApoE-/- 
mice aged 16 weeks fed high fat diet for 8 weeks R = -0.27, p = 0.08. (B) Significant negative correlation 
between weight gain and brachial plaque percentage in ApoE-/- mice aged 16 weeks fed high fat diet for 
8 weeks, r = -0.33, p= 0.03. 
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but not mice administered IL-6 (mean 10.2 + 2.5 %) (Figure 46). There was a 
significant positive correlation between percentage VCAM-1 staining in the 
brachiocephalic artery and both brachiocephalic plaque area (R = 0.44, p = 0.03) and 
brachiocephalic plaque percentage (R = 0.47, p = 0.02) (Figure 48). 
 
 
 
 
 
 
Figure 44. Brachiocephalic artery stained for VCAM-1 at (A) X 4 magnification. VCAM-1 
staining (brown) can be seen mostly in the arterial wall underlying the plaque, in the 
fibrous cap and some in the plaque. Little VCAM-1 staining in the arterial wall opposite 
plaque. (B) X 20 magnification. VCAM-1 staining (brown) can be seen mostly in the 
arterial wall underlying the plaque, in the fibrous cap and some in the plaque. 
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Figure 45. Comparison of percentage VCAM-1 staining in different areas of the brachiocephalic 
artery. Mean percentage staining for VCAM-1 was significantly higher in the artery wall underlying 
plaque (33.7 + 11.0 %), then in the plaque itself (13.65 + 7.0 %) and lowest in the arterial wall 
opposite the plaque (2.0 + 2.5 %) , *p < 0.05, *** p < 0.0001. 
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Figure 46. Percentage VCAM-1 staining in brachiocephalic artery and plaque in ApoE-/- mice aged 16 
weeks and fed a high fat diet for 8 weeks and administered either IP PBS, IL-6, Hyper-IL-6 0.5 µg or 
Hyper-IL-6 1 µg. Percentage staining for VCAM-1 significantly higher in mice administered Hyper IL-6 
0.5 µg and Hyper-IL-6 1 µg (mean percentage staining 11.7 + 4.07 % and 12.8 + 4.24 % respectively) 
compared to mice administered PBS (mean 5.7 + 1.1 %) but not mice administered IL-6 (mean 10.2 + 
2.5 %). 
 
Figure 47. Significant positive correlation between percentage VCAM-1 staining in the brachiocephalic 
artery of 16 week old ApoE-/- mice fed high fat diet for 8 weeks and (A) brachiocephalic plaque area R = 
0.44, p = 0.03 and (B) brachiocephalic plaque percentage R = 0.47, p = 0.02 
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4.4.7 Fibrous cap thickness  
 
There was no significant difference the in average fibrous cap thickness between the 
groups; mean fibrous cap thickness for PBS (5.08 + 1.4 µm), IL-6 (2.86 + 0.6 µm), 
Hyper-IL-6 0.5 µg (4.69 + 0.7 µm) and Hyper-IL-6 1 µg (10.5 + 3.6 µm) (Figure 48A). 
There was no significant difference in mean thickness of the widest part of the fibrous 
cap between groups; PBS (7.37 + 2.0 µm), IL-6 (4.17 + 1.3 µm), Hyper-IL-6 0.5µg (5.05 
+ 0.9 µm), Hyper-IL-6 1µg (10.54 + 2.6 µm) (Figure 48B). Mice administered Hyper-IL-
6 1 µg had significantly greater mean fibrous cap thickness at the thinnest part of the 
fibrous cap (5.21 + 0.9 µm) compared to mice administered IL-6 (1.94 + 0.5 µm), p = 
0.04 (Figure 48C). 
There were significant positive correlations between the mean fibrous cap thickness 
and mean brachiocephalic plaque size (R = 0.57, p = 0.0034) and brachiocephalic 
plaque percentage (R = 0.61, p = 0.0015) (Figure 49). There was a significant negative 
correlation between mean fibrous cap thickness and weight gain (Figure 50).  
Figure 51 shows examples of EVG staining of the fibrous cap. It was also noted that 
some large plaques also had fibrous cap internally and a necrotic core. (Figure 52).  
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Figure 48. Fibrous cap thickness measurements in ApoE-/- mice fed high fat diet for 8 weeks and administered 
either PBS, IL-6, Hyper-IL6 0.5µg or Hyper-IL-6 1µg. (A) No significant difference the mean fibrous cap thickness 
between PBS (5.08 + 1.4 µm), IL-6 (2.86 + 0.6 µm), Hyper-IL-6 0.5µg (4.69 + 0.7 µm), Hyper-IL-6 1µg (10.5 + 3.6 
µm) . (B) No significant difference in mean thickness of the widest part of the fibrous cap between groups; PBS 
(7.37 + 2.0 µm), IL-6 (4.17 + 1.3 µm), Hyper-IL-6 0.5µg (5.05 + 0.9 µm), Hyper-IL-6 1µg (10.54 + 2.6 µm). (C) 
Mean thinnest fibrous cap thickness was significantly greater in mice administered Hyper-IL-6 1µg (5.21 + 0.9 
µm) compared to mice administered IL-6 (1.94 + 0.5 µm), * p = 0.04.  
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Figure 49. Significant positive correlation between mean brachiocephalic fibrous cap thickness and (A) 
brachiocephalic plaque area, R = 0.57, p = 0.003 and (B) brachiocephalic plaque percentage, R = 0.61 p = 
0.0015 in ApoE-/- mice aged 16 weeks fed a high fat diet for 8 weeks. 
Figure 50. Significant negative correlation between weight gain and mean brachiocephalic fibrous 
cap thickness in 16 week old ApoE-/- mice fed high fat diet for 8 weeks. R = -0.52, p = 0.009 
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Figure 51. Brachiocephalic artery from ApoE-/- mice aged 16 weeks, fed high fat diet for 8 weeks. 
Arteries stained with EGV. (A) Example of larger plaque with thicker fibrous cap at X 10 and (B) X 20 
magnification. (C) Example of smaller plaque with thinner fibrous cap at X 10 and (D) X 20 
magnification. FC = fibrous cap 
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4.4.8 Lipid levels  
 
There was no significant difference in total cholesterol (Figure 53A), HDL (B), LDL (C), 
triglycerides (D), free fatty acids (E) or cholesterol: HDL ratio (F) between mice 
administered PBS, IL-6, or Hyper-IL6.  Mean lipid levels are shown in Table 25.   
 
 PBS 
Mean + SEM 
IL-6 
Mean + SEM 
Hyper-IL-6 0.5 µg 
Mean + SEM 
Hyper-IL-6 1µg 
Mean + SEM 
Total cholesterol 
(mmol/L) 
22.3 + 2.6 27.0 + 1.8 25.9 + 1.4 27.2 + 2.1 
HDL  (mmol/L) 
1.7 + 0.1 1.9 + 0.1 1.9 + 0.1 2.0 + 0.1 
LDL(mmol/L) 
16.7 + 1.8 20.0 + 1.2 19.1 + 0.9 20.6 + 1.5 
Triglycerides 
(mmol/L) 
1.7 + 0.3 1.8 + 0.2 1.8 + 0.2 1.7 + 0.2 
Free fatty acids 
(mmol/L) 
0.73 + 0.05 0.93 + 0.09 0.92 + 0.05 0.90 + 0.03 
Cholesterol:HDL 
ratio  
12.6 + 0.5 14.3 + 0.8 13.5 + 0.6 13.5 + 0.6 
 
Table 25. Mean lipid levels of ApoE-/- mice fed high fat diet for 8 weeks from age 8 weeks and 
administered either PBS, IL-6, Hyper-IL-6 0.5 µg or 1 µg. no significant differences 
between the groups. 
Figure 52. Brachiocephalic artery from ApoE-/- mouse aged 16 week fed high fat diet for 8 weeks. (A) Example 
of a complex plaque with internal fibrous material with the plaque at X 10 magnification and at (B) X 20 
magnification 
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Figure 53. No significant difference in (A) total cholesterol, (B) HDL, (C) LDL, (D) triglycerides, (E) 
free fatty acids or (F) Cholesterol: HDL ratio in 18-week-old mice fed high fat diet for 8 weeks and 
administered either PBS, IL-6, Hyper-IL-6 0.5 µg or Hyper-IL-6 1 µg IP twice weekly for 8 weeks. 
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4.4.9 No significant difference in serum VCAM-1 or CCL-2 between mice 
administered PBS, IL-6 or Hyper-IL-6  
 
There was no significant difference in serum VCAM-1 levels across the groups (Figure 
54). Mean serum VCAM-1 for mice administered PBS (4617 + 1393 ng/ml), IL-6 (4622 
+ 983 ng/ml), Hyper IL-6 0.5 µg (4648 + 1338 ng/ml), Hyper-IL-6 1 µg (4563 + 1618 
ng/ml), p = 0.999. There was no significant correlation between serum VCAM-1 and 
brachiocephalic plaque area or brachiocephalic percentage plaque (Figure 55) or 
significant correlation between VCAM-1 level and lipid levels. There was no 
significant correlation between serum VCAM-1 and brachiocephalic percentage 
staining of VCAM-1.  
There was no significant difference in serum CCL2 levels across the groups (Figure 
56). Mean serum CCL2 for mice administered PBS (124 + 41 pg/ml), IL-6 (149 + 77 
pg/ml), Hyper-IL-6 0.5 µg (88 + 40 pg/ml), Hyper-IL-6 1 µg (101 + 20 pg/ml) p = 0.051. 
There was a significant negative correlation between serum CCL2 and brachial plaque 
area (r = -0.3348, p = 0.030) and brachial percentage plaque (R= -0.362, p = 0.024) 
(Figure 57).  There was a significant positive correlation between serum VCAM-1 and 
serum CCL2, r = 0.355, p = 0.027. There was a significant negative correlation 
between serum CCL2 levels and serum triglyceride levels (r= -0.0343, p = 0.041) 
(Figure 58).   
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Figure 54. No significant difference in serum VCAM-1 between the groups. Mean serum 
VCAM-1 for PBS (4617 + 1393 ng/ml), IL-6 (4622 + 983 ng/ml), Hyper IL-6 0.5 µg (4648 + 1338 
ng/ml), Hyper-IL-6 1 µg (4563 + 1618 ng/ml), p = 0.999 
Figure 55. No significant correlation between serum VCAM-1 and percentage staining for 
VCAM-1 in the brachiocephalic artery in 16 weeks old ApoE-/- mice fed high fat diet for 8 
weeks 
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Figure 56. No significant difference in serum CCL2 between the groups. Mean serum CCL2 for ApoE-
/- mice administered PBS (124 + 41 pg/ml), IL-6 (149 + 77 pg/ml), Hyper-IL-6 0.5 µg (88 + 40 pg/ml), 
Hyper-IL-6 1 µg (101 + 20 pg/ml) p = 0.051 
Figure 57. Significant negative correlation between serum CCL2 and brachiocephalic plaque area (R = -
0.35, p = 0.03) and brachiocephalic plaque percentage (R = -0.36, p = 0.024) in ApoE-/- mice 
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4.5 Discussion  
 
We have shown that in our facility 18 week old ApoE-/- mice develop plaques in the 
brachiocephalic artery and the aortic root after 8 weeks of high fat feeding. The size 
of plaque seen in the aortic root is comparable with other centres under similar 
conditions (Jones et al, 2014). No information on plaque size in the brachiocephalic 
artery was found in the literature for the conditions used in this study.   In this 
chapter, mice were housed in conventional units which were not pathogen free. This 
was chosen to reflect the environment of RA patients.  
Mice administered Hyper-IL-6 1 µg had significantly reduced weight gain compared 
with those administered either PBS, IL-6 or Hyper-IL-6 0.5 µg. This could be due to 
systemic inflammation; in RA, chronic inflammation and reduced physical activity 
leads to muscle wasting but maintenance of the fat mass (Masuko, 2014). This is 
termed rheumatoid cachexia.  It is proposed that cytokines such as TNF-α and IL-6 
play pivotal roles here by activating NF-κB and leading to an increase in muscle 
proteolysis via the ubiquitin-proteasome pathway (Morley, 2006). Thus, the lower 
weight gain seen in mice administered Hyper-IL-6 in this experiment may be due to 
a reduction in muscle mass. To investigate this further it would be interesting to 
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Figure 58. Significant negative correlation between serum CCL2 and serum triglycerides, r = -0.3430, 
p = 0.00405 in ApoE-/- mice  
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measure the body composition of these mice at the time of sacrifice. Weight gain 
correlated negatively with brachiocephalic plaque percentage, so those mice with 
more weight gain had less atherosclerosis in the brachiocephalic artery. This perhaps 
reflects the role of inflammation on both parameters, high levels of inflammation are 
known to reduce weight gain and increase atherosclerosis. RA patients treated with 
Tocilizumab show both reduced levels of inflammation (as reflected by disease 
activity and CRP), and weight gain (Hirabayashi et al, 2010). Tocilizumab blocks both 
IL-6 classical and trans-signalling. Thus, IL-6- driven inflammatory pathways seem to 
play a role in body mass in both atherosclerosis-prone mice and in patients with RA.   
Here, for the first time, we demonstrate that enhanced IL-6 trans-signaling using 
Hyper-IL-6 increases atherosclerosis in an animal model. In the brachiocephalic 
artery Hyper-IL-6 significantly increased plaque percentage compared to PBS and IL-
6. IL-6 did not increase plaque size compared to PBS. Therefore, in this model, IL-6 
trans-signaling, rather than IL-6 classical signalling increased atherosclerosis. Our 
finding of no increase in plaque size when IL-6 was administered is conflicting to some 
reports in the literature. A previous study in ApoE-/- mice found that IL-6 
administration increased atherosclerotic lesion size in the aortic sinus (Huber et al, 
1999). The dose used in this study was 5000u weekly, less than the dose in this 
chapter.  However, in this study mice were fed high fat diet earlier than in this thesis, 
starting at 3 weeks of age for 6 weeks. Another study found that in a mouse model, 
serum cholesterol levels and atherosclerotic lesion formation were significantly 
increased in ApoE-/--IL-6-/- mice compared with ApoE-/- and wild-type (WT) mice 
(Schieffer et al, 2004). Plaques of ApoE-/--IL-6-/- mice showed significantly reduced 
transcript and protein levels of matrix metalloproteinase-9, tissue inhibitor of 
metalloproteinase-1, collagen I and V, and lysyl oxidase. Recruitment of 
macrophages and leukocytes into the atherosclerotic lesion was significantly reduced 
in ApoE-/--IL-6-/- mice. The transcript and serum protein levels of IL-10 were 
significantly reduced. Thus, from the literature, the role of IL-6 in atherosclerosis 
appears complex, with increased atherosclerosis in above physiological levels of IL-6, 
but also in the complete absence of IL-6. For the first time, the work in this chapter 
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shows that IL-6 trans-signaling, rather than IL-6 classical signaling, increases 
atherosclerosis in a mouse model.  
There was no difference in plaque size in the aortic root in those administered Hyper-
IL-6 (both doses) or IL-6 compared to PBS. A possible reason for the significant 
increase in plaque size in the brachiocephalic artery with Hyper-IL-6 but not in the 
aortic root may be that plaque develops in the aortic root before the brachiocephalic 
artery in ApoE-/- mice . In one study, at 10 weeks in ApoE-/- mice fed a high fat diet, 
atherosclerotic lesions were identified in 100% of all aortic roots and in 57% of 
brachiocephalic arteries (McAteer et al, 2004). Perhaps if mice had been sacrificed at 
an earlier age or fed a high fat diet for a shorter period, there may have been a 
difference in plaque size in the aortic root. In another study which compared plaque 
size in the aortic root with brachiocephalic artery, variables such as diet and strain of 
mouse used had greater effects on plaque size in the brachiocephalic artery than the 
aortic root (Teupser et al, 2003). Therefore, in the timeframe used in this thesis, the 
lesions in brachiocephalic artery may have been more sensitive to drug 
administration as they were likely to have been at earlier stages of atherosclerosis 
than those in the aortic root.  
From this work the brachiocephalic artery appears to be a useful site for 
quantification of atherosclerosis for the time point used in this work. However, using 
a cross sectional method has drawbacks, mainly that this does not show the volume 
of plaque. Although sections were taken at the same relative points in mice, it is 
possible that a short plaque could have been missed, or in fact the end of a plaque 
may have been sectioned, rather than its centre.  However, the cross sectional 
method has the advantage that other parameters can be measured, such a fibrous 
cap thickness and immunohistochemistry, which cannot be used with the en face 
method.  
The increase in plaque size in mice administered Hyper-IL-6 was associated with 
increase in expression of VCAM-1 in the artery of those administered Hyper-IL-6. 
There was no difference in VCAM-1 expression between those administered IL-6 and 
PBS. This suggests that IL-6 trans-signaling, rather than classical signalling, increases 
the expression of VCAM-1 in the vessel wall. VCAM-1 mediates the adhesion of 
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lymphocytes, monocytes, eosinophils, and basophils to vascular endothelium. 
VCAM-1 is of critical importance in the development of atherosclerosis, and VCAM-1 
has been shown to be rapidly induced by proatherosclerotic conditions (O’Brien et 
al, 1993). The ligand for VCAM-1 is Very Late Antigen Activation-4 (VLA-4), also called 
α4β1 integrin. Studies have shown that recruitment of peritoneal macrophages into 
atherosclerotic lesion of ApoE–/– mice can be inhibited by an α4 blocking antibody 
(Ley and Huo, 2001). Studies have attempted to investigate the effect of complete 
absence of VCAM-1 by using VCAM-1-/- mice. However, this has been very difficult as 
no or very few mice homozygous for the null allele are born; it appears this is 
necessary for placental development (Gurtner et al, 1995). Another study has 
disrupted its fourth Ig domain, producing the murine VCAM-1D4D allele (Cybulsky et 
al, 2001). VCAM-1D4D/D4D mice had significantly reduced atherosclerotic lesions, 
compared to wild type mice and ICAM-1-/- mice.   
In this chapter, we have shown that plaque size in the brachiocephalic artery 
correlates with arterial VCAM-1 expression. We have found that VCAM-1 staining in 
the brachiocephalic artery was highly prevalent in the artery wall underlying plaque. 
This is in agreement with the literature, O’Brien et al (1993) found high VCAM-1 
staining in inflammatory infiltrate at the base of plaques and also in areas of 
neovascularization.  This suggests that adhesion of monocytes, mediated by VCAM-
1, and subsequent infiltration of plaque occurs from the vasa vasorum of the arterial 
adventitia and media.  
Interestingly, there was no difference in serum VCAM-1 in mice administered Hyper-
IL-6 or IL-6 compared to PBS. This is unexpected, as VCAM-1 expression was higher 
in the brachiocephalic artery in mice administered Hyper-IL-6. Serum levels of VCAM-
1 were high in all groups, in fact mean levels in ApoE-/- mice were up to 4 times higher 
than serum levels seen in RA patients in Chapter 5 and approximately 1.5 times those 
seen in mice with CIA in Chapter 3. We have shown that in patients with RA, serum 
VCAM-1 is higher in those with high CV risk. What is not well defined is the 
relationship between soluble VCAM-1 and VCAM-1 on the endothelial cell surface. In 
this chapter there was no significant correlation between serum VCAM-1 and 
expression of VCAM-1 in the brachiocephalic artery. In vitro, soluble VCAM-1 levels 
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correlate with surface expression (Kjaergaard et al, 2013), however the relationship 
between the two in vivo, and the effect of soluble VCAM-1 appears to be context 
dependant. It has been proposed previously that soluble VCAM-1 could act as a 
competitive inhibitor of ligand binding (Rose et al, 2000); if there is an abundance of 
serum soluble VCAM-1 then this could bind to VLA-4 on monocytes, preventing their 
adhesion to cell surface VCAM-1 on the endothelium. Of note, Kitani et al (1996) 
found that in RA synovial fluid, the binding of soluble VCAM-1 to T cells inhibited their 
activation.  
There was no significant difference in serum CCL2 in mice administered IL-6, Hyper-
IL-6 or PBS. There was a significant negative correlation between serum CCL2 and 
brachiocephalic plaque size. This is unexpected given that CCL2 has been shown to 
correlate with CIMT in RA patients (Södergren et al, 2010) and elevated serum CCL2 
levels are found in patients with coronary artery disease or increased coronary risk 
factors (Martinovic et al, 2005). It would be interesting to measure CCL2 expression 
the brachiocephalic artery but this was not possible for this thesis due to time 
constraints.  
There was no difference in mean fibrous cap thickness in mice administered Hyper-
IL-6, IL-6 or PBS. Mice administered Hyper-IL-6 1 µg had greater mean fibrous cap 
thickness at the thinnest point of the cap compared to PBS and IL-6. This may be 
explained by the fact that there was also a positive correlation between fibrous cap 
thickness and plaque size, and plaque size was greater in those administered Hyper-
IL-6. To investigate this further mice could be grouped into those with similar sized 
plaques i.e. small, medium and large plaques, and then mean fibrous cap thickness 
compared within these plaque-size subgroups for PBS, IL-6 and Hyper-IL-6 
administered mice. However, numbers in these experiments were too small to make 
this comparison and very few plaques in the PBS groups were similar size to those 
administered Hyper-IL-6.  
Interestingly, there was no difference in the lipid profiles of mice administered IL-6 
or Hyper-IL-6 compared with PBS. It has previously been shown that IL-6 plays a role 
in lipid metabolism, though there are variable reports in the literature. For example 
in healthy volunteers, administration of IL-6 increased total cholesterol (Lyngso et al, 
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2002). However in middle-aged and old rhesus monkeys (Ettinger et al, 1995), and 
cancer patients (Veldhuis et al, 1995) IL-6 administration reduced total cholesterol 
levels. In patients with myocardial infarction (Brugada et al, 1996), those who have 
undergone major surgery (Akgun et al, 1998) and those on haemodialysis (Bologa et 
al, 1998), serum IL-6 levels correlate negatively with total cholesterol levels. In 
patients with renal disease undergoing haemodialysis low IL-6 levels have been 
shown to be the strongest predictor of mortality (Bologa et al, 1998). Overall, it 
appears that the effect of IL-6 on lipid levels depends somewhat on the inflammatory 
state of the patient or animal. Perhaps in the ApoE-/- mice used in this thesis, lipids 
levels (mostly LDL cholesterol) are already considerably raised so that the effect of 
additional inflammation in negligible. The absence of difference in lipid levels in mice 
administered Hyper-IL-6 compared to PBS is in keeping with previous work in LDLR-/- 
mice, where blockade of IL-6 trans-signaling, by administration of sgp130Fc, reduced 
atherosclerosis but did not affect serum lipid levels (Schuett et al, 2012). 
IL-6 increases VLDLR expression in several tissues (Hashizume et al, 2009) and this 
decreases triglyceride levels. Interestingly, in an in vitro study, IL-6 and sIL-6R 
significantly induced expression of VLDLR mRNA in VSMC but IL-6 or sIL-6R alone and 
TNF-α did not do so (Hashizume et al, 2009). In the same study IL-6 injection into 
mice increased the expression of VLDLR in heart, adipose tissue and liver and 
decreased TC and TG levels. This suggests that IL-6 trans-signaling in vitro, rather than 
IL-6 classical signaling, increases VLDLR expression. In the in-vitro part of this study, 
the administration of IL-6 may have increased both classical and trans-signaling, as 
there would have been sIL-6R in the circulation to bind to the IL-6, and therefore it is 
unclear which signaling mechanism is influencing this increase in VLDLR expression.  
Dyslipidaemia is commonly observed in patients with active RA. They have lower 
total cholesterol, HDL and LDL than people without RA (Robertson et al, 2013). When 
inflammation is supressed in these patients, for example with the use of DMARDs or 
biological agents, these lipid fractions increase. These changes in lipid profile can 
differ depending on the drugs used. It has been shown that IL-6 blockade using 
Tocilizumab increases serum total cholesterol, HDL, LDL and triglyceride levels in RA 
patients (Choy et al, 2014). Importantly LDL:HDL and Total cholestrerol:HDL ratios 
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remain relatively stable. These ratios have been shown to be more closely associated 
with CV risk than individual lipid measures (Natarajan et al, 2003).  
Previous research found that ApoE-/- mice were resistant to CIA (Asquith et al, 2010). 
In this study, ApoE-/- mice did not develop articular inflammation, but did develop 
anti-collagen antibody responses that are similar to those observed in C57BL/6 wild 
type mice that developed CIA. The authors concluded that the inflammatory burden 
of polyarticular disease may be crucial for vascular disease acceleration.  However, it 
is possible that as a result of the deletion of the ApoE gene, there are changes to 
serum proteins which may influence CIA development. In this study the authors 
found significantly lower IL-17 levels in the sera of ApoE−/− mice than in the sera of 
wild type C57BL/6 mice after CIA induction. Previous studies have shown that IL-17 
plays a crucial role in CIA development (Nakae et al, 2003).  Another possible reason 
for the lack of CIA development in ApoE-/- mice may be that hyperlipidaemia 
supressed CIA development. However, in the same study, high fat diet did not change 
arthritis severity compared to normal chow diet in wild type C57BL/6 mice. In 
addition, previous work has shown that in DBA-1 mice immunised with CIA, injection 
of 3H-cholesterol was associated with greater severity of CIA (Hamer et al, 2002). To 
further investigate the role of lipids in CIA development, CIA could be induced in 
other models, such as the LDLR-/- mouse.  
 
4.6 Conclusion  
 
Here, for the first time, we have shown that IL-6 trans-signalling using Hyper-IL-6 
increases plaque size in ApoE-/- mice. This accelerated atherosclerosis was not seen 
with IL-6 alone. This increase in plaque size with Hyper-IL-6 may be partly driven by 
the increased arterial and plaque expression of VCAM-1 in those administered Hyper-
IL-6. IL-6 trans-signaling did not effect fibrous cap thickness or lipid levels.  
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5 Chapter 5: The role of sIL6R-regulated CVD Candidate 
Proteins (SCCPs) in progression of subclinical atherosclerosis 
in patients with early RA and in cardiovascular risk in 
established RA. 
 
 
5.1 Introduction  
 
It has been shown that rapid progression of CVD occurs soon after RA onset (Kerola 
et al, 2012). Cardiovascular risk scores, even with modification as recommended by 
EULAR, underestimate CVD risk in RA patients (Rosales-Alexander et al, 2014). A 
prospective study of patients with early RA (classified as symptoms of less than 12 
months) followed up 442 patients over 5 years (Innala et al, 2011). At 5 years, 10.9% 
of patients had experienced a new cardiovascular event, 12 of these 48 events were 
fatal.  
 
Using cardiovascular events as an outcome for exploratory studies in this thesis is not 
appropriate, since the required sample size is prohibitively large. Several validated 
non-invasive imaging techniques are now available as surrogate markers for 
determining subclinical atherosclerosis in RA and were recently reviewed by Kerekes 
et al (2012). Of these, ultrasonographic assessment of carotid intima media thickness 
(CIMT) and the presence of plaques have been identified as most useful for stratifying 
RA patients with high CV risk. In a recent study, approximately 60% of patients 
identified as having moderate cardiovascular risk, according to the modified EULAR 
cardiovascular SCORE, had evidence of carotid plaques and/or CIMT >0.90 mm 
(Corrales et al, 2013)  (both considered factors indicative of poor cardiovascular 
prognosis in the general population). Furthermore, the proportion of patients 
identified as having high or very high cardiovascular risk increased from 9.2% with 
the modified EULAR SCORE to 47.7% with additional carotid ultrasound results 
(Corrales et al, 2013). However, the feasibility of performing these ultrasound 
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assessments within rheumatology clinics or in partnership with specialist cardiology 
clinics remains to be established. In particular, most cardiology departments do not 
have capacity to scan over 1000 RA patients annually. In this study, CIMT thickness 
and CIMT progression over time were used as a surrogate marker of CVD and CVD 
progression. If SCCPs are associated with progression of CVD then they could be used 
to identify high-risk patients; these patients could then be selected for more 
intensive investigation and treatment. This project will examine this hypothesis in a 
longitudinal study of patients with early RA using CIMT as a surrogate of CVD. In this 
chapter, CIMT > 0.90 mm and/or carotid plaques were used as the gold standard test 
for subclinical atherosclerosis and high CV risk (Corrales et al, 2013). However, this is 
a surrogate marker for CVD, thus there are limitations in applying this to other or 
additional CVD pathologies that RA patients can experience. Wald et al (2009) found 
that neither carotid plaque nor CIMT has a CVD screening performance that is 
sufficiently discriminatory between affected and unaffected individuals to be a 
worthwhile screening test in the general population.  
 
Due to inherent problems with recruitment and retainment of patients over a 
prolonged period of follow up, it was decided that both a cross sectional study in 
patients with established RA and a prospective study in patients with early RA would 
be performed. This enabled greater patient numbers to be recruited. In addition, 
differences in SCCPs could be assessed in those who had a history of CVD versus those 
that did not. 
 
 
5.2 Hypothesis and Aims  
 
Hypothesis: SCCPs are associated with cardiovascular risk in patients with established 
RA and progression of subclinical atherosclerosis in patients with early RA.  
 
In order to address this hypothesis the following aims were identified: 
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1. To investigate whether SCCPs are associated with RA disease activity in 
patients with established RA.  
2. To investigate whether SCCPs are associated with cardiovascular risk in 
patients with established RA.  
3. To investigate whether SCCPs are associated with previous CVD in established 
RA.  
4. To investigate whether SCCPs are associated with RA disease activity and with 
progression of disease activity in early RA.   
5. To investigate whether SCCPs are associated with presence and progression 
of subclinical atherosclerosis, using CIMT, in early RA. 
 
5.3 Methods  
 
5.3.1 Established RA recruitment and data collected 
 
Patients with established rheumatoid arthritis (duration greater than 1 year) were 
recruited from general rheumatology clinics in University Hospital of Wales (UHW).  
Research Ethics Committee for Wales ref no 12/WA/0045. After written consent 
was gained the following was collected: 
Data collected:  
 Gender 
 Age 
 Height  
 Ethnicity  
 Postcode  
 RA disease duration  
 Concomitant diseases  
 Family history of cardiovascular disease or stroke  
 History of chronic kidney disease (also checked by looking at renal 
function on the UHW clinical portal)  
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 History of atrial fibrillation  
 Smoking status  
 Alcohol intake  
 Medications 
 History of cardiovascular disease (ischaemic heart disease including 
angina and acute coronary syndrome, cerebrovascular accident or 
transient ischaemic attack, peripheral vascular disease) 
 
Data measured: 
 Blood pressure  
 Weight  
 Height  
 DAS28 
 As part of routine care ESR, CRP and lipid profile were requested via the 
laboratories at UHW.  
 
5.3.2 Early Arthritis Study recruitment and data collected  
 
Patients with early RA, defined by ACR/EULAR 2010 criteria (Aletaha et al 2010) and 
symptoms of less than 6 months were identified from rheumatology clinics and 
referral letters to the rheumatology department at UHW. Patients were assessed 6-
monthly for 12 months. Ethics and R&D approval was in place for a larger study: 
Inflammation and Immune Regulation in Early Inflammatory Arthritis (Research 
Ethics Committee for Wales ref no 11/WA/0326). An amendment to the protocol was 
successfully made to add carotid ultrasonography to assessments to determine CIMT 
and presence of plaques.  
 
Inclusion criteria  
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 Age 18 or over  
 Able and willing to give written consent and comply with the requirements of 
the study protocol  
 Duration of symptoms 4 weeks to 6 months 
 Synovitis in at least one joint    
 Meets criteria of 2010 Rheumatoid arthritis classification criteria: an 
American College of Rheumatology/European League Against Rheumatism 
collaborative initiative (Aletaha et al, 2010). 
 
 
Exclusion criteria  
 
 Definite other autoimmune rheumatic disease e.g. SLE, MCTD, scleroderma, 
polymyositis.  
 Functional class IV, defined by the ACR Classification of Functional Status in RA  
 Previous treatment with any biological agent.  
 Treatment with intravenous gamma globulin, plasmapheresis or Prosorba TM 
column within the past 6 months. 
 Current other inflammatory joint disease (e.g. gout, reactive arthritis, Lyme 
disease). 
 Previous cardiovascular disease (ischaemic heart disease including angina and 
acute coronary syndrome, cerebrovascular accident or transient ischaemic 
attack, peripheral vascular disease) 
 Concomitant diabetes mellitus 
 
Patients that fulfilled inclusion criteria were assessed in the Clinical Research Facility 
in UHW.  
 
Data collected:  
o Gender 
o Age 
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o Ethnicity  
o Postcode  
o Symptom duration  
o Concomitant diseases  
o Extra articular features i.e. rheumatoid nodules, eye, lung, cardiac or 
skin symptoms, Sjogren’s syndrome, neuropathy, vasculitis, back pain  
o Family history of cardiovascular disease or stroke  
o History of chronic kidney disease (also checked by looking at renal 
function on the UHW clinical portal)  
o History of atrial fibrillation  
o Smoking status  
o Alcohol intake  
o Employment status  
o Medications  
o Patient Visual Analogue Scale for arthritis severity  
 
Data measured:  
o Height  
o Weight  
o Body mass index  
o Blood pressure was measured in both arms while sitting, after the 
patient had rested for at least 30 minutes  
o Tender joint count  
o Swollen joint count  
o US 7 and 10 score  
o CIMT and presence of plaque using carotid US 
 
5.3.3 Assessment of cardiovascular risk   
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CV risk was calculated for each patient using the QRISK2, Framingham and SCORE 
algorithms. These risk algorithms are described in section 1.8, including the variables 
each uses to calculate risk.  
 
5.3.4 Calculation of DAS28  
 
From the tender and swollen joint counts, ESR and CRP, the DAS-28(ESR) (Prevoo et 
al 1995) and DAS-28(CRP) (Fransen et al 2003) were calculated using the standard 
formula. Patients were grouped by DAS28 (Prevoo et al, 1995) into severity, see Table 
26. 
 
DAS28 Score DAS28 group 
< 2.6 Remission 
2.6 –  3.2 Mild 
3.2 - 5.1 Moderate 
> 5.1 Severe 
 
Table 26. Stratification of disease activity by DAS28 score 
 
5.3.5 Musculoskeletal Ultrasound (US) assessments  
 
Ultrasound was performed of patients’ hands and feet, by two rheumatology 
registrars trained in musculoskeletal ultrasound (RD and CR). Images or clips were 
stored and later scored blind by both RD and CR using 7-joint ultrasound (Backhaus 
et al, 2009) (Figure 59) and 10-joint ultrasound (Larché et al, 2010) (Figure 60) scores. 
The US10 score was adapted from Larché et al (2010), to include semi quantitative 
measures of synovial thickness and vascularity. The original score also includes a 
quantitative measure of vascularity, the authors using an automated measurement 
of the number of colour pixels in a region of interest (ROI). However, we did not have 
access to this software and therefore this was omitted.  
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Figure 59. US7 score. Gray-scale ultrasound and power Doppler (PD) US performed 
for synovitis, tenosynovitis/paratenonitis, and erosions from the dorsal, palmar, and 
ulnar aspects of the wrist, metacarpophalangeal (MCP), proximal interphalangeal 
(PIP), and metatarsophalangeal (MTP) joints. From Backhaus et al, 2009.  
Figure 60. US 10 score. Gray-scale ultrasound and power Doppler US performed for 
synovial thickening and power Doppler activity for 10 MCP joints. Adapted from 
Larché et al, 2010. 
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5.3.6 Training in carotid ultrasound  
 
I was trained in carotid ultrasound by a senior vascular scientist with a strong track 
record in study set up, training and project management of vascular studies. I had 40 
hours of training over several weeks and 2 meetings per month to cover data review, 
quality control and trouble shooting. 
  
 Reproducibility of scanning  
 
To ensure reproducibility of images 5 healthy volunteers were scanned 
twice, approximately a week apart. Each scan was analysed. These were 
checked by a senior vascular scientist for:  
 
•         Correctly labelled images 
 
•         Images recorded in the correct order – i.e. right carotid first, starting 
with the   cross sectional loop. 
 
•         Image set up appropriately – suitable gain, focus point in appropriate 
position. 
 
•         Correct zoom 
 
•         Image quality - intima visible on both walls, presence of an analysable 
area, straight image 
 
•         Similarity of two images  
 
Reproducibly of analysis  
 
To ensure reproducibility of analysis 10 images were analysed twice, 1 week 
apart.  The following were checked by a trained vascular scientist:  
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•         Calibration 
 
•         Appropriate choice of waveforms (3 consecutive waveforms, all end-
diastolic diameters and systolic diameters within 0.1 mm of each other)  
 
•         Size of the analysis box  
 
•         Location from the carotid bifurcation  
 
•         Correct placement of detection lines 
  
 Coefficient of variation 
 
 
5.3.7 Assessment of CIMT using carotid ultrasound  
 
Patients were positioned supine after resting for at least 30 minutes. The left and 
right common carotid arteries were imaged longitudinally 1 cm proximal to the 
carotid bifurcation. Images were focused on the posterior (far) wall of the artery and 
then magnified. Several ten-second cine loops were recorded in DICOM format and 
then downloaded for offline analysis.  
 
5.3.8 Analysis of CIMT 
 
An automated carotid analyser (Carotid Analyzer, Medical Imaging Applications, Iowa 
City, IA) was used to measure CIMT. Three end-diastolic frames were selected and 
CIMT measured, defined as the interface between lumen-intima and media-
adventitia, for both right and left carotid arteries. The mean of the three end-diastolic 
frames was calculated, and then the mean of the left and right-sided readings was 
calculated. The internal and external carotid arteries and bifurcation were also 
scanned and presence or absence of plaque was noted.  
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CIMT > 0.90 mm and/or carotid plaques were used as the gold standard test for 
subclinical atherosclerosis and high CV risk (Corrales et al, 2013). These patients were 
classed as ‘US positive’. Those patients who did not have plaque or CIMT > 0.9 mm 
were ‘US negative’, Table 27. Plaque was defined as a focal structure that encroaches 
into the arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value or 
demonstrates a thickness of > 1.5 mm as measured from the media-adventitia 
interface to the intima-lumen interface (Touboul et al, 2004). 
 
 
Carotid US positive Carotid US negative 
Plaque present or CIMT > 0.9 mm No plaque and CIMT < 0.9 mm 
 
Table 27. Definition of carotid US positive and US negative patients. 
 
 
5.3.8.1 Definition of rapid progressor 
 
A previous study by Södergren et al (2010) in 27 patients with early RA found that 
mean increase in CIMT at 18 months was 0.05 + 0.15mm (mean + SD). For this study, 
rapid progression was defined as increase in CIMT >0.05 mm and patients were 
defined as per Table 28. 
 
 
Non-rapid Progressor  Rapid Progressor 
Increase in CIMT < 0.05mm  Increase in CIMT > 0.05mm  
 
Table 28. Definition of non-rapid and rapid progressor according to change in CIMT  
 
 
5.3.9 Measurement of carotid distensibility  
 
 
The Carotid Analyzer software was used as above. Three consecutive frames were 
selected and the end-diastolic and systolic diameters were recorded for left and right 
carotid arteries. The mean of these readings was calculated. Right and left arm blood 
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pressure was recorded and the respective pulse pressure calculated.  The following 
equation was used to calculate the distensibility coefficient (DC) in 10−3 kPa−1 (from 
Dijk et al, 2005):  
 
 
((2 X ΔD/ Dd)/ PP) X 1000  
 
 
ΔD = Mean carotid distension. (Systolic diameter- end diastolic diameter) 
Dd = End-diastolic diameter   
PP= Pulse pressure (in kPa)  
 
 
5.3.10 Assessment of cardiovascular risk status  
 
 
For each patient the SCORE, QRISK2, ACC/AHA and Framingham 10 year risk of 
cardiovascular event was calculated. Thresholds have previously been set by risk 
algorithm authors to define ‘high risk’ patients as per Table 29. If the patient’s 10-
year risk of cardiovascular event was greater than 10% using the QRISK2 then a letter 
was sent to the patient’s general practitioner to inform them, along with information 
about the patient’s blood pressure, lipid profile and BMI. Current NICE guidelines 
state that people with a greater than 10% ten year risk of cardiovascular disease 
should be offered atorvastatin 20 mg for the primary prevention of CVD (NICE 
guideline CG181, 2014). The patient was informed about their risk status and advised 
to make an appointment with their GP to discuss this further.  
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Variable  
Threshold used to 
define ‘high risk’ 
SCORE (Perk et al 2012)  > 5% 
QRISK2 (NICE  guideline 
CG181) 
>10% 
ACC/AHA (Goff et al 2013) >7.5% 
Framingham (National 
Cholesterol Education 
Program 2012) 
> 20% 
 
Table 29. Cardiovascular risk scores and thresholds used to define ‘high risk' for each score. 
 
 
5.3.11 Blood sampling  
 
Blood was sent to the laboratory at UHW for measurement of rheumatoid factor, 
anti-CCP antibodies, lipid profile (Total cholesterol, HDL cholesterol, LDL cholesterol, 
triglycerides), ESR and CRP. Anti CCP and Rheumatoid factor groups were included as 
there is data that citrullination is found in plaques. Also Pratt et al (2012) identified 
IL-6 mediated STAT-3 signalling in CD4 T cells  during the earliest clinical phase of RA, 
and was most prominent in anti-CCP negative patients who developed RA.  At the 
same time, blood was also taken for SCCP measurement. Blood was taken into 
Vacutainer® serum separation tubes (BD) and then centrifuged at 1500rpm for 5 
minutes at 4°C. Serum was aliquoted and frozen at -70°C.  
 
5.3.12 ELISA 
 
Levels of IL-6, sIL-6R, IL-6/sIL-6R complex and SCCPS were measured using duoset 
ELISA development kits from RnD Systems (Abingdon) in accordance with 
manufacturer’s instructions. See Table 8 in general methods section for protocol for 
ELISA on human serum. All ELISAs were read in a plate reader at OD 450 nm. 
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Standards and samples were assayed in duplicate. See Table 30 for concentrations 
used in each ELISA.  
 
Protein Capture antibody 
working 
concentration 
Detection antibody 
working 
concentration 
High standard 
concentration 
IL-6 
2 µg/mL 50 ng/mL 600 pg/mL 
sIL-6R 
2 µg/mL 100 ng/ml 1000 pg/ml 
Il-6/sIL-6R 
complex  
2 µg/mL   0.5 µg/mL  5000 pg/mL 
VCAM-1 
2 µg/mL 200 ng/ml 1000 pg/ml 
CCL2 
1 ug/ml 50 ng/ml 1000 pg/ml 
Tissue Factor 
4 ug/ml 200 ng/ml 500 pg/ml 
CXCL8 
4 ug/ml 20 ng/ml 2000 pg/ml 
M-CSF 
2 µg/mL 200 ng/ml 1000 pg/ml 
CXCL9 
1 µg/mL 200 ng/mL 4000 pg/mL 
Thrombomodulin 
2 µg/mL 1 µg/mL 2000 pg/mL 
MMP-1 
2 µg/mL 100 ng/mL 4000 pg/mL 
 
Table 30. Antibody and standard concentrations for SCCPs used in ELISA for human serum 
 
5.3.12.1 Statistics  
 
Statistics used were dependent on the data analysed. Where two groups were 
compared the paired means student’s t-test was used. Where multiple groups were 
compared, a one-way ANOVA and post hoc Bonferroni test were performed. All 
results were expressed as the mean + SEM. Binary logistic regression was used to 
examine the effect of multiple variables on particular outcomes.  Differences that 
were considered significant were p < 0.05.   
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Sample size estimation. A previous study showed that in early RA patients CIMT 
increased by 0.05 + 0.15 mm. For this study, rapid progression will be defined as 
increase in CIMT >0.05mm/year. In the absence of a biomarker, 50% of patients will 
have CIMT increase of at least 0.05mm. We expect SCCPs to improve the proportion 
of predicted patients by 50%. A sample size of 77 patients will give 80% power to 
detect an increase in the proportion of correctly predicted patients with an increase 
of CIMT >0.05 mm from 50% to 75%. Allowing 10% lost to follow up, we aim to recruit 
85 patients.  
 
 
5.4 Results 
 
5.4.1 Established rheumatoid arthritis 
 
182 patients with established RA were recruited, of which 67% were female. Patient 
characteristics are shown in Table 31. 27% of patients were in remission, 16% had 
mild disease activity, 35% had moderate disease activity and 22% had severe disease 
activity defined by the DAS28 score (Figure 61). 49% were taking Methotrexate and 
10% were taking Tocilizumab. Mean SCCP levels and comparison with those in the 
literature for RA are shown in Table 32.  
 
 
Variable 
 
Mean 
Age (years) 60 + 1.2 
Disease Duration (years) 13.1 + 1.0 
Rheumatoid factor 
positive (%) 
63.9 
Anti-CCP antibody 
Positive (%) 
66.3 
CRP 11.9 + 2.1 
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ESR (mm/hr) 22 + 1.7 
DAS28 3.6 + 0.2 
Systolic BP (mmHg) 129 + 2.2 
Cholesterol : HDL ratio 3.8 + 0.1 
QRISK2 (%) 16 + 1.5 
Framingham (%) 13 + 0.9 
 
Table 31. Demographics details for cross sectional study of 182 patients with established RA. 
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 Figure 61. DAS28 group in patients with established RA. 27% of patients were in 
remission, 16% had mild disease activity, 35% had moderate disease activity and 
22 % had severe disease activity. 
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SCCP 
 
Mean in this study  Value in RA in literature  
IL-6 (pg/ml) 19.8 + 2.9 1.5-234 (Robak et al 1998) (range) 
sIL-6R (ng/ml) 126 + 46 153.9 + 56.9 (Kohno et al 1998) 
IL-6/sIL-6R complex 
(pg/ml)  
348 + 201 
6800-8900l (De Benedetti et al 
1994) (range in systemic JIA, RA 
unknown) 
CCL2 (pg/ml) 199 + 14 
<0.08 – 179 (Green et al 2003)  
(range) 
CXCL8 (pg/ml) 40 + 8 17 – 49 (Slavić et al 2005) (range) 
CXCL9 (ng/ml) 0.8 + 0.1 
3.1 (1.2–4.9) (Kaun et al 2010) 
median and IQR 
MCSF (pg/ml) 4.3 + 1.8 
1.32 + 0.50 (Kawaji et al 1995) 
(mean) 
MMP-1 (ng/ml) 5.9 + 0.4 41.8 (Green et al 2003) (mean) 
Thrombomodulin 
(ng/ml) 
4.8 + 0.1 
5.9 + 2.2 (Abdul-Moniem et al 
2009) (mean) 
Tissue Factor (pg/ml) 29 + 7 unknown 
VCAM-1 (ng/ml) 855 + 53 
475 ± 258 (Navarro-Hernández et al 
2009) (mean) 
 
Table 32. Mean SCCP levels in patients with established RA in cross sectional study and in the 
literature 
 
 
5.4.1.1 Association of SCCPS with disease activity in established RA 
 
There was a significant positive correlation between DAS28 and VCAM-1 (Figure 62) 
but not with other SCCPs. There was no significant difference between DAS28 groups 
(remission, mild, moderate or severe) when IL-6, sIL-6R, IL-6/sIL-6R complex, CRP, IL-
8, MCSF, CCL2, CXCL9, thrombomodulin, MMP-1, or tissue factor were compared. 
ESR was significantly higher in severe RA groups compared to moderate, mild and 
remission groups and VCAM-1 was significantly higher in severe RA compared to 
moderate RA (Figure 63). 
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Figure 63. Significant difference in ESR and VCAM-1 between DAS28 groups. (A) ESR was significantly 
lower in RA remission (7.9 + 9.1 mm/hr), compared to mild (8.2 + 10.5 mm/hr), moderate (18.5 + 
12.2 mm/hr) and severe RA (40.3 + 26.4 mm/hr), p = 0.000. (B) VCAM-1 was significantly lower in 
moderate RA (780 + 412ng/ml) compared to severe RA (1349 + 880 ng/ml), p = 0.023. Mean VCAM-
1 for those in remission was 825 + 358 ng/ml and 955 + 865 ng/ml in mild RA.  
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Figure 62. Significant positive correlation between VCAM-1 and DAS28 in 
patients with established RA, r = 0.27, p = 0.017 
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5.4.1.2 Association of SCCPS with cardiovascular risk in established RA 
 
There was a significant positive correlation between the QRISK2 score and serum 
MMP-1 (r = 0.35, p = 0.0014), thrombomodulin (r = 0.32, p = 0.0034) and VCAM-1 (r 
= 0.32, p = 0.0025) (Figure 64). There was a significant positive correlation between 
the Framingham risk score and serum MMP-1 (r = 0.32, p = 0.0026) and 
thrombomodulin (r = 0.31, p = 0.0034) (Figure 65, Table 32). There was a significant 
correlation with age and MMP-1 (r = 0.25, p = 0.013), thrombomodulin (r = 0.318, p 
= 0.001) and VCAM-1 (r = 0.27, p = 0.002).  The QRISK2 and Framingham scores were 
significantly moderately correlated, r = 0.7, p < 0.0001 (Figure 66). Patients were 
classified according to the QRISK2 as having a low risk (< 10%) or high risk (> 10%) of 
cardiovascular event over the next 10 years. 52% of patients were high risk according 
to the QRISK2. Those classified as low risk had a significantly higher CRP than those 
at high risk (19.7 + 34.8 mg/L versus 8.2 + 8.5 mg/L), Table 33. Those classified as low 
risk had significantly lower serum thrombomodulin (4.6 + 1.2 ng/ml versus 5.4 + 1.6 
ng/ml) and VCAM-1 (977 + 600 ng/ml versus 1247 + 289 ng/ml) (Figure 67) than those 
classified as high risk (Table 34). 
 
 
Figure 64. Significant positive correlations between QRISK2 and (A) MMP-1 (r = 0.35, p = 0.0014), 
(B) Thrombomodulin (r = 0.32, p = 0.0034) and (C) VCAM-1 (R = 0.32, p = 0.0025). 
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Variable Correlation 
with QRISK2 ( 
r value) 
p value Correlation with 
Framingham  (R 
value) 
p Value 
CRP (mg/L) -0.139 ns -0.107 ns 
ESR (mm/hr) 0.211 ns 0.101 ns 
IL-6 (pg/ml) -0.078 ns 0.004 ns 
sIL-6R (ng/ml) 0.119 ns 0.128 ns 
IL-6/sIL-6R complex 
(pg/ml) 
-0.063 ns -0.021 ns 
CCL2 (pg/ml) 0.204 ns 0.098 ns 
CXCL8 (pg/ml) 0.113 ns 0.069 ns 
CXCL9 (ng/ml) 0.183 ns 0.054 ns 
MCSF (pg/ml) 0.111 ns 0.171 ns 
MMP-1 (ng/ml) 0.347 0.001 0.321 0.003 
Thrombomodulin 
(ng/ml) 
0.319 0.001 0.313 0.003 
Tissue Factor (pg/ml) -0.084 ns -0.241 ns 
VCAM-1 (ng/ml) 0.324 0.002 0.134 ns 
QRISK2  1  0.698 0.000 
Framingham  0.698 0.000 1  
Chol/HDL ratio -0.0076 ns 0.315 0.008 
Age  (years) 0.879 0.000 0.637 0.000 
Disease Duration (yrs) 0.054 ns 0.068 ns 
DAS-28 0.09          ns 0.011 ns 
BP (mmHg) 0.496 0.000 0.588 0.000 
 
Table 33. Correlation between SCCPs and CV risk variables with QRISK2 and Framingham scores 
Figure 65. Significant positive correlation between the Framingham risk score and (A) serum MMP-
1 (r = 0.32, p = 0.0026) and (B) serum thrombomodulin (r = 0.31, p = 0.0034) 
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Figure 66. Significant positive correlation between the QRISK2 and the Framingham score 
in patients with established RA, r = 0.7, p < 0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67. Serum VCAM-1 was significantly higher in those with a > 10% CV risk over the 
next 10 years according to both the QRISK2 and the Framingham score, compared to those 
with < 10% risk in patients with established RA. * p < 0.05  
R = 0.7, p < 0.0001 
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Table 34. Differences in SCCPs in those classified as low risk versus high risk of CVD according to 
the QRISK2 
 
 
5.4.1.3 Association of SCCPs with history of cardiovascular disease in established RA 
 
Twelve patients (9.6%) had previous CVD. Of these, seven (58.3%) were female. In 
those patients with a history of CV disease, mean serum CRP (3.9 + 5.7 mg/L versus 
13.3 + 24.5 mg/L), ESR (20 + 13.2 mm/hr versus 22 + 19.6 mm/hr), IL-6 (5.1 + 10.6 
pg/ml versus 22 + 39.8 pg/ml), sIL-6R (107 + 22 versus 128 + 53), MCSF (0 + 0 pg/ml 
versus 4.8 + 18.0 pg/ml) and tissue factor (0 + 0 pg/ml versus 50 + 82 pg/ml) were 
significantly lower than those with no history of CVD (Figure 68 and Table 35). All 
patients with a history of CVD had undectable levels of MSCF and tissue factor. There 
was no significant difference in serum VCAM-1 levels in those with history of CVD 
(1029 + 607 ng/ml) compared to those with no history of CVD (947 + 442 ng/ml). A 
further analysis of the subgroup of patients with previous CVD revealed that most 
Variable  Low risk QRISK2 High risk QRISK2 P value 
CRP (mg/L) 19.7 + 34.8 8.2 + 8.5 0.046 
ESR (mm/hr) 21.5 + 17.4 23.7 + 21.9 ns 
IL-6 (pg/ml) 24.0 + 46.8 16.2 + 29.1 ns 
SIL-6R (ng/ml) 123 + 51 113 + 42 ns 
Ratio IL-6 : sIL-6r 0.12 + 0.2 0.15 + 0.3 ns 
IL-6/sIL-6R complex 
(pg/ml) 
239.7 + 521 519 + 2630 ns 
CCL2 (pg/ml) 258 +134 242 + 146 ns 
CXCL8 (pg/ml) 27 + 28 42 + 70 ns 
CXCL9 (ng/ml) 0.78 +1.0 1.0 + 1.0 ns 
MCSF (pg/ml) 2.3 + 6.3 6.7 + 23.6 ns 
MMP-1 (ng/ml) 5.3 + 4.1 6.7 + 4.1 ns 
Thrombomodulin (ng/ml) 4.6 + 1.2 5.4 + 1.6 0.009 
Tissue Factor (pg/ml) 50.1 + 83.7 46.8 + 81.7 ns 
VCAM-1 (ng/ml) 977 + 600 1247 + 289 0.039 
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were on secondary prevention for CVD; 92% of patients with CVD were taking a 
statin, 80% were taking an antihypertensive. 
 
 
 
Figure 68. Significantly lower (A) CRP (3.9 + 5.7 mg/L versus 13 + 24.5 mg/L, p = 0.002), (B) sIL-6R 
(107 + 22 ng/ml versus 128 + 53 ng/ml p = 0.015 (C) IL-6 (5.1 + 10.6 pg/ml versus 22 + 39.8 pg/ml, p 
= 0.009) in those with history of CVD compared to those without history of CVD. (D) No significant 
difference in serum VCAM-1 levels in patients with history of CVD (1029 + 607 ng/ml) compared to 
those with no history of CVD (947 + 442 ng/ml). 
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Variable  History of CVD n = 
12 
No history of CVD n 
= 113 
P value 
CRP (mg/L)  3.9 + 5.7 13 + 24.5 ns 
ESR (mm/hr)  20 + 13.2 22 + 19.6 0.002 
IL-6 (pg/ml) 5.1 + 10.6 22 + 39.8 0.009 
Sil-6R (ng/ml) 107 + 22 128 + 53 0.015 
IL-6/sIL-6R complex 
(pg/ml) 
144.6 + 51.5 251.4 + 140.0 0.14 
CCL2 (pg/ml) 243 + 93 196 + 112 ns 
CXCL8 (pg/ml) 91 + 164 36 + 56 ns 
CXCL9 (ng/ml) 0.924 + 0.94 0.91 +  1.01 ns 
MCSF (pg/ml) 0 + 0 4.8 + 18.0 0.019 
MMP-1 (ng/ml) 5.0 + 5.2 5.9 + 4.1 ns 
Thrombomodulin (ng/ml) 4.5 + 0.7 5 + 1.5 ns 
Tissue Factor (pg/ml) 0 + 0 50 + 82 0.00 
VCAM-1 (ng/ml) 1029 + 442 947 + 607 ns 
QRISK2 score (%) 19 + 5.2 16 + 15 ns 
Framingham score (%) 18 + 8 13 + 9 ns 
Chol/HDL ratio 5.4 + 1.8 3.7 + 0.9 ns 
Age  (years) 61 + 10 60 + 14 ns 
Disease Duration (years) 12.8 + 6.5 13.4 + 11.2 ns 
 
Table 35. Levels of SCCPs in those with a history of cardiovascular disease and those without in 
patients with established RA  
 
 
5.4.1.4 Lower CRP in those taking statin  
 
As all patients who had CVD were taking a statin, a subgroup analysis was performed 
to investigate whether there was any difference in SCCP levels in those taking or not 
taking a statin. Mean serum CRP was significantly lower in those patients taking a 
statin (CRP 7.0 + 1.5 mg/L) compared to those not taking a statin (13.5 + 2.7 mg/L), p 
= 0.037 (Figure 69). There was no significant difference in SCCPs or disease activity in 
those taking statins and those not, Table 36. 
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Variable  Statin (n = 36) No Statin (n = 105) P value 
CRP (mg/L) 7.1 + 8.2 13.6 + 26.2 0.039 
ESR (mm/hr) 18.3 + 13.6 22.5 + 19.4 ns 
IL-6 (pg/ml) 21.8 + 31.9 19.3 + 40.1 ns 
Sil-6R (ng/ml) 132.4 + 69 124.2 + 44 ns 
Ratio IL-6 : sIL-6R 0.16 + 0.3 0.13 + 0.2 ns 
IL-6/sIL-6R complex (pg/ml) 130.5 + 212.5 491.5 + 2345 ns 
CCL2 (pg/ml) 227 + 123 255 + 142 ns 
CXCL8 (pg/ml) 76 + 129 30 + 33 ns 
CXCL9 (ng/ml) 1.29 + 1.3 0.76 + 0.88 ns 
MCSF (pg/ml) 9.5 + 30.5 2.8 + 10.1 ns 
MMP-1 (ng/ml) 5.0 + 4.1 6.0 + 1.2 ns 
Thrombomodulin (ng/ml) 5.4 + 1.7 4.8 + 1.3 ns 
Tissue Factor (pg/ml) 28.7 + 75 33.0 + 68 ns 
VCAM-1 (ng/ml) 1012 + 409 919 + 625 ns 
DAS28 3.57 + 1.43 3.60 + 1.76 ns 
 
Table 36. Differences in SCCPs and other variables in those taking and not taking a statin in 
patients with established RA. 
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Figure 69. Mean serum CRP levels significantly lower in patients taking a 
statin (7.0 + 1.5) than those not taking a statin (13.5 + 2.7) p = 0.037 in 
patients with established RA 
174 
 
5.4.1.5 Effect of methotrexate and tocilizumab on SCCPs 
 
There was no difference in SCCPs or DAS28 between those taking methotrexate and 
those not taking methotrexate (Table 37). Those patients on tocilizumab had 
significantly lower DAS28 (2.5 + 0.4 versus 3.8 + 0.2) (Figure 70) and serum ESR (8.7 
+ 3 mm/hr versus 24.3 + 1 mm/hr) than those not on tocilizumab (Figure 71, Table 
38). IL-6 was significantly higher in those taking tocilizumab than those not (845 + 27 
pg/ml versus 14 + 3 pg/ml, p = 0.034) (Figure 72). There was no difference in CRP 
between patients taking tocilizumab (mean CRP 11.3 + 6.3 mg/L) and patients not 
taking tocilizumab (mean CRP 12.0 + 2.2 mg/L).  
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Figure 70. DAS28 significantly higher in established RA patients not taking 
tocilizumab than those taking tocilizumab (3.8 + 0.2 versus 2.5 + 0.4) p = 
0.017  
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Figure 72. Serum IL-6 levels significantly higher in established RA patients taking 
tocilizumab than those not taking tocilizumab (845 + 27 versus 14 + 3 pg/ml, p = 
0.034). 
Figure 71. Serum ESR levels significantly higher in established RA patients 
not taking tocilizumab than those taking tocilizumab (24 + 2 mm/hr 
versus 9 + 4 mm/hr) p < 0.000 
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Variable  No Methotrexate (n = 67) Methotrexate (n = 75)  P value 
CRP (mg/L) 16 + 24 20 + 26 0.259 
ESR (mm/hr) 25 + 20 20 + 15 0.227 
IL-6 (pg/ml) 23 + 44 16 + 31 0.362 
SIL-6R (ng/ml) 119 + 51 116 + 43 0.728 
Ratio IL-6 : sIL-6R 0.13 + 0.2 0.14 + 0.3 0.884 
IL-6/sIL-6R complex (pg/ml) 217 + 493 541 + 2736 0.490 
CCL2 (pg/ml) 256 + 139 236 + 137 0.479 
CXCL8 (pg/ml) 32 + 34 48 + 94 0.317 
CXCL9 (ng/ml) 0.98 + 1.00 0.83 + 1.01 0.493 
MCSF (pg/ml) 2.5 + 6.7 6.2 + 23.2 0.312 
MMP-1 (ng/ml) 5.9 + 4.1 5.7 + 4.2 0.822 
Thrombomodulin (ng/ml) 4.99 + 1.6 4.9 + 1.2 0.854 
Tissue Factor (pg/ml) 40.3 + 83 24.5 + 56 0.340 
VCAM-1 (ng/ml) 1047 + 491 1184 + 673 0.268 
DAS28  3.65 + 1.61 3.54 + 1.74 0.78 
Cholesterol : HDL ratio  3.84 + 1.1 3.76 + 1.1 0.76 
 
Table 37. SCCP and other variables in established RA patients taking methotrexate versus those 
not taking methotrexate 
 
Variable  No Tocilizumab (n = 123) Tocilizumab (n = 19)  P value 
CRP (mg/L) 12 + 2 11 + 6 0.924 
ESR (mm/hr) 24 + 2 9 + 3 0.000 
IL-6 (pg/ml) 14 + 3 85 + 27 0.034 
SIL-6R (ng/ml) 124 + 5 148 + 16 0.172 
IL-6/sIL-6R complex (pg/ml) 359 + 253 564 + 323 0.625 
CCL2 (pg/ml) 194 + 14 258 + 30 0.107 
CXCL8 (pg/ml) 39 + 8 55 + 22 0.526 
CXCL9 (ng/ml) 0.8 + .1 1.3 + 0.5 0.368 
MCSF (pg/ml) 4.1 + 1.7 8.0 + 4.7 0.459 
MMP-1 (ng/ml) 6.1 + 0.4 4.1 + 1.5 0.241 
Thrombomodulin (ng/ml) 4.7 + 0.1 6.0 + 0.6  0.073 
Tissue Factor (pg/ml) 29.6 + 7.3 27.0 + 13.7 0.872 
VCAM-1 (ng/ml) 968 + 60 877 + 95 0.424 
DAS28  3.8 + 0.2 2.5 + 0.4 0.017 
Cholesterol : HDL ratio  3.7 + 0.1 4.0 + 0.4 0.567 
 
Table 38. SCCP and other variables in established RA patients taking tocilizumab versus those not 
taking tocilizumab 
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5.4.1.6 Effect of Rheumatoid Factor and anti–CCP status on SCCPs 
 
SIL-6R and MMP-1 were significantly higher in patients that were rheumatoid factor 
positive compared to those that were negative (Table 39). There was no significant 
difference between other SCCPs. Those patients that were anti-CCP positive had 
significantly lower CRP than those that were negative. There was no difference in 
other SCCPs (Table 40). 
 
Variable  RF positive (n = 78) RF negative (n = 44) P value 
CRP (mg/L) 9.8 + 18.4 15.4 + 30.4 0.284 
ESR (mm/hr) 20.3 + 14.9 23.4 + 21.4 0.401 
IL-6 (pg/ml) 21.5 + 24.2 18.2 + 33.5 0.687 
SIL-6R (ng/ml) 137 + 55 103 + 39 0.002 
Ratio IL-6 : sIL-6r 0.15 + 0.04 0.12 + 0.04 0.699 
IL-6/sIL-6R complex (pg/ml) 602 + 2577 99 + 290 0.223 
CCL2 (pg/ml) 250 + 142 245 + 129 0.877 
CXCL8 (pg/ml) 45 + 90 35 + 36 0.493 
CXCL9 (ng/ml) 0.82 + 0.95 0.88 + 1.07 0.789 
MCSF (pg/ml) 6.5 + 22.7 1.9 + 4.8 0.182 
MMP-1 (ng/ml) 7.0 + 4.6 4.7 + 3.5 0.008 
Thrombomodulin (ng/ml) 4.8 + 1.4 4.7 + 1.5 0.884 
Tissue Factor (pg/ml) 18.9 + 48.3 55 .5 + 95.2 0.071 
VCAM-1 (ng/ml) 943 + 560 936 + 649 0.955 
DAS28 3.65 + 1.71 3.39 + 1.54 0.496 
 
Table 39. SCCP and DAS28 levels in rheumatoid factor positive and negative established RA 
patients 
  
Variable  Anti-CCP  positive (n = 55) Anti-CCP  negative (n = 28) P value 
CRP 8.4 + 12.6 27.3 + 42.9 0.036 
ESR 18.3 + 14.7 27.5 + 23.6 0.074 
IL-6 (pg/ml) 15.3 + 26.3 26.5 + 57.8 0.367 
Sil-6R (ng/ml) 135 + 60 111 + 52 0.071 
Ratio IL-6 : sIL-6r 0.16 + 0.06 0.10 + 0.03 0.312 
IL-6/sIL-6R complex 
(pg/ml) 
525 + 2734 60 + 150 0.315 
CCL2 (pg/ml) 260 + 149 236 + 131 0.483 
CXCL8 (pg/ml) 32 + 37 30 + 30 0.751 
CXCL9 (ng/ml) 0.82 + 0.92 0.87 + 0.99 0.836 
MCSF (pg/ml) 3.86 + 15.01 1.97 + 5.51 0.463 
MMP-1 (ng/ml) 5.74 + 4.29 5.99 + 4.33 0.820 
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Thrombomodulin 
(ng/ml) 
4.96 + 1.27 4.68 + 1.34 0.411 
Tissue Factor (pg/ml) 10 + 23 48 + 84 0.075 
VCAM-1 (ng/ml) 989 + 528 1170 + 697 0.236 
DAS28 3.7 + 1.52 3.88 + 1.59 0.748 
 
Table 40. SCCPs and DAS28 levels in anti-CCP positive and negative established RA patients.  
 
 
5.4.2 Early Arthritis Study (EAS) results  
 
Forty-five patients were recruited. The baseline characteristics of the participants are 
presented in Table 41. 35 patients were followed up at 6 months, and 23 patients at 
12 months. 91% were Caucasian, 4% Indian, 2% Pakistani, and 2% Czech. Figure 73 
shows RA treatment at baseline, 6 months and 12 months. At baseline 63% were 
taking any DMARD, 58% of patients were taking methotrexate, 30% were taking two 
DMARDs, 26% were taking corticosteroids and 9% were taking two DMARDs plus 
corticosteroids (Figure 73). At 6 months, one patient and at 12 months, 2 patients 
were taking a biological drug (Tocilizumab). 52% of patients were not taking NSAIDs, 
26% were taking occasional NSAIDs and 22% were taking regular NSAIDS.  
 
 
Variable Mean 
Age (years) 56.1 + 2.2 
Female Sex (%) 75 
Disease Duration  
(months) 
4.0 + 0.2 
Rheumatoid factor positive (%) 59 
Anti-CCP antibody positive (%) 75 
CRP (mg/L) 11 + 2 
ESR (mm/hr) 24 + 3 
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DAS28 3.87 + 0.20 
Extra articular features (%) 15 
Systolic BP  
(mmHg) 
136 + 3.2 
QRISK2 (%) 16.9 + 2.5 
Smoking (%) 
      Never smoked  
      Former  
      Current 
 
39.5 
34.9 
25.6 
BMI 27.3 + 0.9 
HbA1c 40.2 + 1  
Family history of CVD  
< 60 years (%)  
18  
 
Table 41. Baseline characteristics of patients recruited in the early arthritis study. 
 
 
 
 
 
 
Figure 73. Medication for RA taken by early RA patients at (A) baseline, (B) 6 months and (C) 12 months 
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5.4.2.1 Association of SCCPs with disease activity in early RA  
 
Patients were grouped by DAS28 into severity, as in Table 26, Section 5.3.4. At 
baseline 18% were in remission, 43% had moderate disease activity, 18% had mild 
disease activity and 20% had severe disease activity (Figure 74). There was no 
significant correlation between baseline DAS28 and baseline IL-6, sIL-6R or SCCPs. To 
further assess the relationship between IL-6 and sIL-6R in this cohort, patients were 
grouped according to these serum cytokine concentrations, as per table 42. The 
mean serum level was calculated for IL-6 and sIL-6R and those below the mean were 
‘low’ and those above the mean were ‘high’.   
 
 Group 1 Group 2 Group 3 Group 4 
IL-6  Low  High Low High 
sIL-6R Low Low  High High  
 
Table 42. Patients with early RA grouped according to IL-6 and sIL-6R level. 
  
 
As expected, those in DAS28 remission at baseline had significantly lower ESR (10 + 
3 mm/hr) than those not in remission (27 + 3 mm/hr). However, there was no 
significant difference in CRP or IL-6 between these groups (Figure 75). There were 
significant positive correlations between DAS28 and ESR and CRP (Figure 76). There 
was a significant positive correlation between DAS28 and US7 score (Figure 77). 
There was no correlation between the DAS28 and US10 score. There were no 
significant correlations between either the US7 score or US10 score and SCCPs. There 
was no significant difference in CRP, ESR or SCCPs in those taking methotrexate and 
those not taking methotrexate. CXCL9 was significantly lower in those taking 
corticosteroids at baseline versus those not taking corticosteroids (119 + 48 pg/ml) 
versus 922 + 169  pg/ml), Figure 78. There was no difference in CRP, ESR or other 
SCCPs in these groups.  
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Mean SCCPs in early and established RA are shown in Table 43. In early RA, mean IL-
6, sIL-6R, CXCL8, thrombomodulin and VCAM-1 were significantly lower than 
established RA. MMP-1 and tissue factor were significantly higher in early RA than 
established RA. There was no significant difference in CCL2, CXCL9 or MSCF between 
early and established RA.  
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Figure 74. Percentage of patients in DAS28 categories at baseline. 18% of patients 
were in remission, 18% had mild disease activity, 43% had moderate disease 
activity and 20% had severe disease activity. 
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Figure 75 (A) No significant difference in baseline CRP in those in DAS28 remission (5 + 2 mg/L) and 
those not (35 + 2 mg/L). (B) Baseline ESR significantly lower in those in DAS28 remission (10 + 3 
mm/hr) compared to those not in remission (27 + 3 mm/hr), p < 0.05. (D) No significant difference 
in baseline IL-6 in those in remission (11 + 11 pg/ml) and those not at baseline (29 + 7 pg/ml).  
 
 
 
 
Figure 76. Significant positive correlation between baseline DAS28 and baseline ESR (r= 0.64, p <0.0001) and 
CRP (r= 0.53, p = 0.0003) in patients with early RA. 
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Figure 77. (A) Significant positive correlation between DAS28 and US7 score at baseline in patients 
with early RA, r = 0.37, p = 0.015. (B) No correlation between DAS28 and US10 score at baseline in 
patients with early RA, r =0.04, p = 0.82. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 78. Baseline CXCL-9 significantly lower in patients with early RA taking 
corticosteroids (119 + 48 pg/ml) compared to those not taking corticosteroids 
(922 + 169 pg/ml), p < 0.05 
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SCCP 
 
Mean in EAS  
Mean in 
established RA  
P value  
IL-6 (pg/ml) 7.7 + 2.5 19.8 + 2.9 <0.0001 
sIL-6R (ng/ml) 95 + 7 126 + 46 0.0002 
IL-6/sIL-6R complex 
(pg/ml)  
364 + 101 348 + 201 ns 
CCL2 (pg/ml) 209 + 21 199 + 14 ns 
CXCL8 (pg/ml) 2 + 2 40 + 8 0.0059 
CXCL9 (ng/ml) 788 + 144 826 + 92 ns 
MCSF (pg/ml) 15 + 13 4.3 + 1.8 ns 
MMP-1 (ng/ml) 11 + 1.5 5.9 + 0.4 P<0.0001 
Thrombomodulin 
(ng/ml) 
4.3 + 0.1  4.8 + 0.1 P<0.0001 
Tissue Factor (pg/ml) 50 + 25 29 + 7 P<0.0001 
VCAM-1 (ng/ml) 708 + 60 855 + 53 0.0115 
 
Table 43. Differences in serum SCCPs in early and established RA 
 
 
5.4.2.2 Disease activity and US10 score significantly reduced over time in patients 
with early RA 
 
DAS28 significantly reduced over time and was significantly lower at 12 months (2.75 
+ 0.39) and 6 months (3.02 + 0.22) compared to baseline (3.87 + 0.20), (Figure 79). 
At 6 months, those in DAS28 remission (DAS28 < 2.6) had significantly lower baseline 
CRP, ESR and IL-6 compared to those not in remission at 6 months (Figure 81). There 
was no significant difference in baseline CRP, ESR, IL-6 or other baseline SCCPs in 
those in remission versus those not in remission at 12 months. There was a significant 
reduction in mean US10 score at 12 months (2.3 + 0.7) compared to baseline (4.4 + 
185 
 
0.5) (Figure 82). There was no significant reduction in US7 score over time. Table 44 
summarises change in DAS28, US7 and US10 scores over time. There was a moderate 
positive correlation between baseline IL-6 and US7 score at 12 months (r=0.57, p = 
0.013) and strong positive correlation between baseline IL-6 and US10 score at 12 
months (r = 0.61, p = 0.0078) (Figure 83). There was no other significant correlation 
between baseline SCCPs and US scores at 12 months.  
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Figure 79. Mean DAS28 was significantly lower at 6 months (3.02 + 0.22) and 12 
months (2.75 + 0.39) than baseline (3.87 + 0.20) in patients with early RA * p < 
0.05, ** p < 0.01. 
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Figure 81. Significantly lower baseline CRP, ESR and IL-6 in patients with early RA in remission at 6 
months compared to those not in remission at 6 months. (A) Mean baseline CRP in remission was 
3.8 + 1.2 mg/L versus 12.1 + 2.6 mg/L. (B) Mean baseline ESR in remission was 14.5 + 3 mm/hr versus 
30.7 + 6 mm/hr. (C) Mean IL-6 in remission was 0.9 + 0.4 pg/ml versus 10.7 + 3.8 pg/ml, * p < 0.05. 
 
Figure 80. Percentage of patients in DAS28 groups at baseline, 6 month and 12 months 
187 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Baseline 
n =  44 
6 months 
n = 35 
12 months 
n = 23 
P  
DAS28 
3.87 + 0.20 3.02 + 0.22 2.75 + 0.39 
0.0016 
US7 Score 
6.7 + 0.6 5.1 + 0.7 5.5 + 1.2 
ns 
US10 Score  
4.4 + 0.5 3.2 + 0.4 2.3 + 0.7 
0.03 
 
Table 44. Mean DAS28 and US 7 and US 10 scores at baseline, 6 and 12 months in patients with 
early RA. 
Figure 82. Ultrasound scores over time in patients with early RA. (A) No significant change in US7 
score over time. (B) Significant reduction in US10 score at 12 months (2.3 + 0.7) compared to baseline 
(4.4 + 0.5), p < 0.05 
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5.4.2.3 Baseline CV risk scores and correlations with CIMT  
 
A summary of the CV risk scores and carotid ultrasound findings of patients at 
baseline is shown in Table 45. Table 46 summarises the percentage of EAS patients 
classified as high risk according to each CV risk algorithm. 58% of patients had a 
QRISK2 greater than 10% and according to NICE guidelines, should be offered a statin. 
Consequently, these patients and their General Practitioners were informed of this, 
if not already on a statin.  Of these patients with > 10% risk who returned at 6 months, 
29% were newly prescribed a statin, 50% were already on a statin and 21% should 
have been offered at statin but were not prescribed one. Table 47 shows the 
sensitivity and specificity of the risk scores in carotid US positive patients. The QRISK2 
score had the highest sensitivity and the SCORE had the highest specificity.   
All risks scores had a significant positive correlation with CIMT (Figure 84). The 
strongest correlation was with the Framingham risk score.  
 
Figure 83. Significant positive correlation between baseline IL-6 level and US7 (r = 0.57, p < 
0.05) and US10 score at 12 months (r = 0.61, p < 0.01) in patients with early RA. 
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Variable Mean  
QRISK2 
17.2 + 2.5 % 
SCORE 
2.1 +  0.4 % 
Framingham 
14.5 + 2.2 % 
ACC/AHA 
13.8 + 2.8 % 
% patients with 
CIMT > 0.9mm 
21.6 
Carotid plaque (% patients with 
plaque) 
29.7  
% patients classified as carotid US 
positive 
40.5  
% patients classified as carotid US 
negative 
59.5 
 
Table 45. CV risk scores and carotid US characteristics of EAS patients at baseline 
 
 
 
Variable  
Threshold used to 
define ‘high risk’ 
Percentage EAS patients 
classified as high risk (%) 
SCORE  > 5% 8 
QRISK2 >10% 54 
ACC/AHA >7.5% 43 
Framingham  > 20% 35 
 
 
Table 46. Cardiovascular risk scores, high CV risk definition according to algorithm used and 
percentage of patients with early RA defined as high risk. 
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Variable  US positive  
sensitivity (CI) 
US positive  
specificity 
QRISK2 > 10% 
87 (60-98%) 68 (45-86%) 
Framingham > 20% 
53 (27-79%) 77 (55-92%) 
SCORE  > 5%  
27 (8-55%) 95 (77-99.8%) 
ACC/AHA > 7.5% 
66 (38-88%) 94 (70-99.8%) 
 
Table 47. Sensitivity and specificity of cardiovascular risk scores in predicting carotid US 
positive patients in patients with early RA.  
 
 
 
 
Figure 84. Significant positive correlation between cardiovascular risk scores and CIMT in patients 
with early RA at baseline. Significant positive correlation between CIMT and (A) QRISK2 r = 0.74, p 
< 0.0001 (B) QRISK2 without adjustment for RA, r = 0.73, p < 0.0001 (C) Framingham r = 0.76 p < 
0.0001, (D) SCORE r = 0.66, p < 0.0001 and (E) ACC/AHA, r = 0.68, p < 0.0001 
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5.4.2.4 Association between CIMT and serum lipid levels and HbA1c 
 
There was a significant positive correlation between total cholesterol: HDL ratio (r = 
0.44, p < 0.01), total cholesterol (r = 0.38, p < 0.05) and LDL cholesterol (r = 0.47, p < 
0.01) and CIMT at baseline. There was no significant correlation between HDL 
cholesterol and CIMT. (Figure 85). There was a significant positive correlation 
between CIMT and HbA1c (r = 0.40, p = 0.04), Figure 86. 
 
 
Figure 85. Significant positive correlation between total cholesterol:HDL ratio (r = 0.44, p < 0.01), 
total cholesterol (r =  0.38, p < 0.05) and LDL cholesterol (r = 0.47, p < 0.01) and CIMT in patients 
with early RA. No significant correlation between HDL cholesterol and CIMT (r = -0.12, p =0.46).   
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Figure 86. Significant positive correlation between CIMT and HbA1c in patients with early 
RA, r = 0.397, p = 0.04 
 
 
5.4.2.5 Correlation of cardiovascular risk scores with distensibility coefficient 
 
There was a significant negative correlation between the distensibility coefficient and 
all cardiovascular risk scores at baseline (Figure 87). There were also significant 
negative correlations between the distensibility coefficient and CIMT, total 
cholesterol and LDL cholesterol at baseline (Figure 88) but no significant correlation 
between distensibility coefficient and CRP, ESR, SCCPs or DAS28.  
There was a significant negative correlation between baseline CXCL9 and 
distensibility coefficient at 12 months (Figure 89).  
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Figure 87. Significant negative correlations between distensibility coefficient and cardiovascular risk 
scores in patients with early RA. Significant negative correlation between distensibility coefficient 
and (A) QRISK2 r =-0.56, p < 0.0003, (B) QRISK2 without adjustment for RA, r = -0.55 p = 0.0005, (C) 
Framingham r = -0.59, p = 0.0002, (D) SCORE r= -0.49, p = 0.0019 and (E) ACC/AHA r= -0.52 p = 0.0051.  
 
 
Figure 88. Significant negative correlations between distensibility coefficient and CIMT (r = -0.51, p 
= 0.0011), Total cholesterol (r = -0.51, p = 0.0017) and LDL cholesterol (r = -0.49, p = 0.003) in 
patients with early RA. 
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Figure 89. Significant negative correlation between baseline CXCL9 and distensibility coefficient at 
12 months (r = -0.61, p = 0.0069).  
 
 
5.4.2.6 Differences in traditional risk factors and SCCPs in carotid US positive and 
negative patients 
 
41% of patients were carotid US positive. These patients had significantly higher age, 
BMI, systolic BP, total cholesterol, cholesterol: HDL ratio, LDL cholesterol, QRISK2, 
Framingham, SCORE, ACCAHA, thrombomodulin and CXCL9 than US negative 
patients (Table 48). Multivariate logistic regression analysis including age, BMI, 
systolic BP, total cholesterol, cholesterol:HDL ratio, LDL cholesterol, ESR and CXCL9 
as covariates found that total cholesterol, LDL cholesterol, age, BMI, systolic BP, 
thrombomodulin and CXCL9 were significant independent variables.  
 
Baseline variable  US negative n = 22 US positive n = 15 P value 
Age (years) 49 + 3 64 + 2 0.000 
BMI 24.6 + 0.8 30.8 + 1.8 0.005 
Systolic BP (mm 129 + 3 143 + 5 0.030 
Total Cholesterol (mmol/L) 5.0 + 0.3 5.9 + 0.2 0.011 
Cholesterol: HDL ratio 3.5 + 0.3 4.4 + 0.3 0.048 
LDL cholesterol (mmol/L)  2.9 + 0.2 3.8 + 0.2 0.002 
HDL cholesterol (mmol/L) 1.5 + 0.1 1.4 + 0.1 0.4080 
Triglycerides (mmol/L) 1.4 + 0.2 1.6 + 0.1 0.419 
Arterial distention coefficient 23 + 3 16 + 2 0.071 
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HbA1c 39.2 + 1 39.5 + 1.3 0.857 
QRISK2 8.3 + 2 26.9 + 5 0.003 
Framingham  8.8 + 2 22.2 + 4 0.007 
SCORE 1.2 + 0.4 3.2 + 0.8 0.028 
ACC/AHA 5.4 + 1.8 19.9 + 5.3 0.018 
Disease duration (months) 4.1 + 0.2 3.9 + 0.3 0.645 
DAS28 3.8 + 0.3 4.0 + 0.3 0.663 
CRP (mg/L)  8 + 2 14 + 4 0.212 
ESR (mm/hr) 19 + 3 32 + 7 0.086 
IL-6 (pg/ml) 6.8 + 4 11.7 + 15 0.432 
sIL-6R (ng/ml) 86 + 9 105 + 14 0.299 
IL-6/sIL-6R complex (pg/ml)  280 + 99 371 + 174 0.653 
CCL2 (pg/ml) 201 + 18 219 + 56 0.765 
CXCL8 (pg/ml) 5.2 + 5.2 1.4 + 1.4 0.494 
CXCL9 (ng/ml) 20 + 129 1122 + 284 0.043 
MCSF (pg/ml) 31.2 + 31 8.4 + 8.4 0.494 
MMP-1 (ng/ml) 12 + 2 11 + 4 0.810 
Thrombomodulin (ng/ml) 4.2 + 0.1 4.7 + 0.2 0.017 
Tissue Factor (pg/ml) 80 + 60 29 + 26 0.449 
VCAM-1 (ng/ml) 657 + 95 834 + 93 0.193 
 
Table 48. Difference in baseline variables and SCCPs in carotid US positive and US negative 
patients. 
 
5.4.2.7 No significant difference in CIMT at 12 months in patients with early RA  
 
There was no significant difference in CIMT at 12 months (0.706 + 0.048 mm) 
compared to 6 months (0.729 + 0.041 mm) or baseline (0.708 + 0.033 mm) ( Figure 
90).  Table 49 summarises the change in variables at baseline, 6 and 12 months.   
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Variable Baseline 
n =  44 
6 months 
n = 35 
12 months 
n = 18 
CIMT (mm) 
0.708 + 0.033 0.729 + 0.041 0.706 + 0.048 
Systolic BP (mmHg) 
136 + 3.2 132 + 3.8 132 + 4 
QRISK2 (%) 
16.9 + 2.5 14.1 + 3.1 12.4 + 2.8 
Distensibility 
coefficient (10−3 kPa−1) 
19.8 + 2.0 22.3 + 2.6 18.3 + 1.7 
Percentage taking 
statin 
12 % 24 % 19 % 
Cholesterol: HDL ratio 
3.8 + 0.2 4.0 + 0.3 3.7 + 0.3 
BMI 
27.3 + 0.9 27.1 + 1.3  27.0 + 1.5 
 
Table 49. Summary of characteristics at baseline, 6 and 12 months in patients with early RA. 
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Figure 90. No significant difference in mean CIMT at baseline (0.708 + 0.033 mm), 
6 months (0.729 + 0.041 mm) and 12 months (0.706 + 0.048 mm) in patients with 
early RA. 
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5.4.2.8 Baseline disease activity correlates with change in CIMT at 6 months in 
patients with early RA   
 
There were significant positive correlations between baseline DAS28, baseline CRP, 
baseline ESR and baseline QRISK2 and change in CIMT at 6 months (Figure 91). There 
was a significant difference in change in CIMT at 6 months (but not 12 months) in 
those in different IL-6 and sIL-6R groups (Figure 92), with the largest increase in those 
who had high IL-6 but low sIL-6R.  
 
 
 
 
Figure 91. Significant positive correlation between change in CIMT at 6 months and (A) Baseline 
DAS28 r = 0.50, p = 0.006, (B) Baseline CRP r = 0.51, p = 0.006, (C) Baseline QRISK2 r = 0.42, p = 
0.02, (D) Baseline ESR r = 0.45, p = 0.016. 
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Figure 92. Significant difference in change in CIMT at 6 months in patients with early RA in different 
IL-6/sIL-6R groups. G1 (IL-6 low and sIL-6R low), G2 (IL-6 high and sIL-6R low), G3 (IL-6 low and sIL-
6R high), G4 (IL-6 high and sIL-6R high). Largest increase in CIMT at 6 months in patients with a high 
IL-6 and low sIL-6R at baseline  
 
5.4.2.9 Rapid progressors at 12 months  
 
Rapid progressors were defined as those who had an increase > 0.05mm in CIMT. 3 
of 18 patients (17%) were classified as rapid progressors at 12 months. There was no 
significant difference in baseline BP, HDL cholesterol, triglycerides, CIMT, Age, BMI, 
disease duration, DAS28, CRP, IL-6, sIL-6R, IL-6/sIL-6R complex, CCL-2, CXCL8, CXCL9, 
Tissue factor, MCSF, Thrombomodulin and MMP-1 in rapid versus non-rapid 
progressors at 12 months (Table 50). Baseline total cholesterol, cholesterol:HDL 
ratio, LDL cholesterol, HbA1C and VCAM-1 were significantly higher in rapid 
progressors compared to non-rapid progressors (Figure 93). Baseline QRISK2, 
Framingham and SCORE were significantly higher in rapid progressors but ACC/AHA 
was not. Arterial distension coefficient was significantly lower in rapid progressors 
versus non-rapid progressors (Figure 93E). There was no significant difference in 
change in CIMT or change in distensibility coefficient in smokers at baseline versus 
non-smokers at baseline. Multivariate logistic regression analysis including baseline 
cholesterol, cholesterol:HDL ratio, age, VCAM-1 and HbA1c as covariates found that 
total cholesterol,, triglycerides and HbA1c were significant independent factor while 
VCAM-1 just failed to reach statistical significance at p=0.055. 
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Figure 93. Significantly higher baseline (A) Total cholesterol (6.7 + 0.2 versus 5.2 + 0.3 mmol/L) , (B) 
Cholesterol: HDL ratio (3.7 + 0.3 versus 5.5 + 0.7), (C) LDL cholesterol 3.1 + 0.3 mmol/L versus 4.4 + 
0.3 mmol/L) (D) VCAM-1 (734 + 126 ng/ml versus 1328 + 28 ng/ml) in rapid progressors compared 
to non-rapid progressors. (E) Significantly lower arterial distension coefficient in rapid progressors 
(18.8 + 1.8) compared to non-rapid progressors (11.2 + 2.2). *p < 0.05, ** p < 0.01, *** p < 0.001 
 
 
 
Baseline value 
 
Non-rapid 
 Progressor (n= 15) 
Rapid  
Progressor ( n = 3) 
P value  
CRP (mg/L)  9.5 + 2.5 5 + 3.1 0.30 
ESR (mm/hr) 22.4 + 3.8 11 + 3.0 0.2 
Systolic BP (mm 127 + 4 148 + 10 0.176 
Total Cholesterol (mmol/L) 5.2 + 0.3  6.7 + 0.2 0.002 
Cholesterol: HDL ratio 3.7 + 0.3 5.5 + 0.7 0.004 
LDL cholesterol (mmol/L)  3.1 + 0.3 4.4 + 0.3  0.018 
HDL cholesterol (mmol/L) 1.5 + 0.1 1.3 + 0.1 0.19 
Triglycerides (mmol/L) 1.3 + 0.2 2.4 + 0.4 0.08 
Arterial distention coefficient 18.8 + 1.8 11.2 + 2.2 0.04 
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Table 50. Baseline variables in rapid and non-rapid progressors in early RA patients 
 
 
5.4.2.10 Disease activity and CIMT in seropositive versus seronegative patients 
 
There was no significant difference in DAS28 at 12 months in either RF or anti-CCP 
positive or negative patients. There was no significant difference in CIMT at 0, 6 and 
12 months, or change in CIMT at 12 months in seropositive and seronegative 
patients, Table 51.  
 
 
 
 
HbA1c (mmol/mol) 38.7 + 1.4 47.7 + 1.3 0.002 
Baseline CIMT (mm) 0.64 + 0.05 0.84 + 0.14 0.30 
Age (years) 52.9 + 3.5 67.3 + 4.0 0.038 
BMI 27.4 + 2.0 27.4 + 2.3 0.995 
Disease duration  (months) 4.0 + 0.3 4.5 + 0.3 0.26 
DAS28 3.7 + 0.3 3.2 + 0.8 0.56 
QRISK2 (%) 10.5 + 2.9 25.8 + 3.1 0.01 
Framingham (%)  8 + 2 20 + 3 0.00 
SCORE (%) 1.1 + 0.5 4.3 + 0.6 0.00 
ACC/AHA (%) 6.5 + 2.2  22.4 + 2.9 0.10 
IL-6 ( pg/ml) 9 + 4 23 + 23 0.61 
SIL-6R (ng/ml)  96 + 8 120 + 37 0.59 
IL-6/sIL-6R  complex (pg/ml) 383 + 172 167 + 167  0.39 
VCAM-1 (ng/ml) 734 + 126 1328 + 28  0.000 
CCL2 (pg/ml) 181 + 25 197 + 80 0.78 
CXCL8 (pg/ml) 1.55 + 1.55 0 + 0  0.35 
CXCL9 (ng/ml) 843 + 287 658 + 258 0.65 
Tissue factor (pg/ml) 37 + 28 221 + 383 0.49 
MCSF (pg/ml) 9.3 + 9.3 0 + 0 0.35 
Thrombomodulin (ng/ml) 4.2 + 0.2 4.4 + 0.4 0.72 
MMP-1 (ng/ml) 12.5 + 2.5 14.1 + 5.1 0.78 
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RF negative RF positive p value  
Anti-CCP  
negative 
Anti-CCP  
positive 
p value  
DAS28 0 
months  
3.7 + 0.3 4.0 + 0.3 0.5 3.8 + 0.5 3.9 + 0.2 0.8 
DAS28 6 
months  
3.2 + 0.4 2.9 + 0.3 0.7 2.7 + 0.3 3.1 + 0.3 0.4 
DAS28 12 
months  
2.7 + 0.6 2.7 + 0.47 0.9 3.1 + 0.8 2.7 + 0.45 0.7 
Change in 
DAS28 at 12 
months  
-0.87 + 0.5 - 0.93 + 0.5 0.9 -0.55 + 0.94 - 0.99 + 0.42 0.4 
CIMT 0 
months 
(mm) 
0.77 + 0.04 0.66 + 0.05 0.1 0.822 + 0.07 0.67 + 0.19 0.07 
CIMT 6 
months 
(mm)  
0.81 + 0.05 0.66 +0.05 0.06 0.87 + 0.10 0.69 + 0.04 0.17 
CIMT 12 
months 
(mm)  
0.76 +0.07 0.66 + 0.07 0.3 0.73 + 0.14 0.70 + 0.05 0.84 
Change in 
CIMT at 12 
months 
(mm) 
0.03 + 0.02 0.01 + 0.01 0.4 0.03 + 0.02 0.02 + 0.01 0.80 
 
Table 51. Effect of RF and anti-CCP status on change in DAS28 and CIMT over time 
 
5.4.2.11 Effect of medication at baseline on change in DAS28 and CIMT  
 
Mean change in DAS28 at 12 months (but not 6 months) was greater in those taking 
methotrexate at baseline (-1.52 + 0.40) compared to those not taking methotrexate 
at baseline (0.31 + 0.63), p = 0.03 (Figure 94A). There was no significant difference in 
change in CIMT at 12 months in those taking methotrexate at baseline versus those 
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not taking methotrexate at baseline. Patients taking corticosteroids at baseline had 
a significantly greater change in DAS28 at 12 months (-2.2 + 0.7) (but not at 6 months) 
compared to those not taking corticosteroids at baseline (-0.39 + 0.4), p = 0.047 
(Figure 94B). There was no difference in change in CIMT at 12 months in those taking 
or not taking corticosteroids at baseline. There was no difference in change in CIMT 
or distensibility coefficient in those taking NSAIDS at baseline versus those not taking 
NSAIDS at baseline.  
At 6 months 1 patient was prescribed tocilizumab. There were no patients taking 
other biologic drugs e.g. anti-TNF.  At 12 months 2 patients were prescribed 
tocilizumab. Those on tocilizumab at 12 months had a greater reduction in DAS28 at 
12 months (-2.62 + 0.3) compared to those not taking tocilizumab (-0.80 + 0.4), p = 
0.010. Those taking tocilizumab had an increase in cholesterol/HDL ratio at 12 
months (0.6 + 0.1) compared to those not taking tocilizumab (-0.24 + 0.4), p = 0.045. 
There was no difference in change in CIMT in these patients.  
There was no significant difference in DAS28 or CIMT at 12 months or change in these 
variables in those taking or not taking statin at baseline. At 6 months, 4 patients were 
prescribed a statin that was ‘new’, i.e. statin introduced since baseline. As expected, 
these patients had a greater reduction in cholesterol: HDL ratio at 6 months than 
those who were not newly prescribed a statin (Figure 95). There was no significant 
difference in disease activity or change in CIMT in those newly prescribed a statin. At 
12 months, a further 2 patients were newly prescribed a statin compared to baseline. 
There was no significant difference in change in cholesterol: HDL ratio, CIMT or 
DAS28 at 12 months compared to baseline in those newly prescribed a statin 
compared to those not newly prescribed a statin.  
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Figure 94. (A) Patients with early RA taking methotrexate at baseline had a significantly greater 
change in DAS28 at 12 months (-1.52 + 0.4) compared to those not taking methotrexate at baseline 
(0.31 + 0.63), p = 0.03. (B) Patients taking corticosteroids at baseline had a significantly greater 
change in DAS28 at 12 months (-2.2 + 0.7) compared to those not taking corticosteroids at baseline 
(-0.39 + 0.4), p = 0.047 
 
 
Figure 95. Significantly greater reduction in mean cholesterol: HDL ratio at 6 months in those 
prescribed a new statin at 6 months (-1.4 + 0.4) compared to those not newly prescribed a statin 
(0.2 + 0.2) in patients with early RA * p < 0.05.  
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5.5 Discussion 
 
5.5.1 Established RA study 
 
The patient cohort was similar to those seen in the general population in the UK, in 
terms of age, gender and levels of inflammatory markers (Humphreys et al 2012). 
There was a significant but weak positive correlation between serum VCAM-1 and 
DAS28. This supports results from Chapter 3; there was a positive correlation 
between arthritis severity in mice and serum VCAM-1. Other studies in RA patients 
have shown correlations between serum VCAM-1 and ESR, CRP, number of swollen 
joints (Klimiuk et al 2002), and DAS28 (Navarro-Hernández et al 2009). As expected, 
ESR was highest in those with severe RA according to the DAS28. Those with severe 
RA also had higher VCAM-1 levels. 
There were significant positive correlations between the QRISK2 and serum MMP-1, 
thrombomodulin and VCAM-1. The Framingham risk score correlated positively with 
MMP-1 and thrombomodulin. In the general population, elevated MMP-1 was found 
to predict the presence of advanced CVD (Hwang et al 2009). However, 
thrombomodulin was shown to be reduced in CVD (Wei et al 2011) and its expression 
was reduced in atherosclerotic lesions compared to control arteries (Lasik et al 2001). 
In this thesis thrombomodulin (and VCAM-1 and MMP-1) correlated significantly but 
weakly with age, which may account partly for the discrepancy between my data and 
the literature on thrombomodulin.  
Over 50% of patients in this cohort were classified as high risk of having a CV event 
according to the QRISK2. This observation is supported by published literature that 
show RA patients have increased atherosclerosis in early RA (Hannawi et al 2007). 
Interestingly, in this thesis, those classified as low CV risk had a significantly higher 
CRP than those at high risk. This contradicts epidemiological studies which report 
that circulating CRP is associated with higher risk of CVD in the general population 
(Ridker and Cook 2004) and in RA (Graf et al 2009).  However, in this thesis, of those 
high risk patients, 34% were on a statin, while only 9% of low risk patients were taking 
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a statin. It is known that statins reduce the CRP (Zakynthinos and Pappa 2009), which 
may partly account for the difference seen here.  Patients with a low CV risk had 
significantly lower serum thrombomodulin. Studies of serum thrombomodulin in CV 
disease are conflicting: some found that soluble thrombomodulin showed a strong, 
inverse association with incident coronary heart disease (Salomaa et al 1999) and 
others that raised soluble thrombomodulin was predictive of the progression of 
atherosclerosis in patients with ischaemic heart disease. Another study reported that 
thrombomodulin expression reduced in atherosclerotic lesions (Lasik et al 2001). The 
role of thrombomodulin in predicting risk of CVD in RA or the general population is 
unclear in the light of such conflicting data.  
Patients classified as high CV risk had significantly higher VCAM-1 than those 
classified as low CV risk. A previous study found that VCAM-1 was higher in those 
who go on to develop CV events in the general population (Schmidt et al 2008). 
However, several other studies of the general population found VCAM-1 did not 
provide significant improvement in CVD risk assessment beyond conventional CVD 
risk factors (Kunutsor et al 2017) and was not significantly different in apparently 
healthy individuals that went on to develop CVD compared to those that did not (Luc 
et al 2003). However, these studies were in a non-RA population. It may be that in 
RA patients, atherosclerosis pathogenesis differs slightly to the general population. 
For example, previous studies have shown that RA patients have more inflammation 
in both their aorta (Greenberg et al 2012) and in atherosclerotic plaques (Aubry et al 
2007) compared with non-RA controls.  
In those patients with established RA and a history of CV disease serum CRP, ESR and 
sIL-6R, IL-6/sIL-6R complex, MCSF and Tissue factor were significantly lower than 
those with no history of CVD. There was no difference in VCAM-1 between these 
groups. These findings were unexpected because inflammation is a factor 
acknowledged for increasing CV risk. However, as these patients were known to have 
a history of CV disease most were on secondary prevention for CVD; 92% were taking 
a statin and 80% were taking an antihypertensive. Those taking a statin had a lower 
CRP. Other SCCPs were unchanged. It may also be the case that patients with a prior 
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history of CVD are treated more aggressively by their rheumatologists for RA, due to 
the increasingly well-recognised association of inflammation and CVD.   
There was no difference in SCCPs, IL-6, sIL-6R, IL-6/sIL-6R complex, CRP or ESR in 
those taking or not taking methotrexate. Serum IL-6 was higher in those prescribed 
Tocilizumab. This has been shown in previous studies (Nishimoto et al 2008). It is 
thought that this increase in serum IL-6 is due to the binding of Tocilizumab to sIL-
6R; therefore reducing the availability sIL-6R for IL-6 to bind to. Thus, more unbound 
IL-6 is detectable in the serum (Nishimoto et al 2008). Interestingly, CRP was not 
lower in those taking Tocilizumab. This is at odds with the literature whereby CRP is 
significantly reduced by Tocilizumab (Genovese et al 2008). However, in order to 
meet the criteria for Tocilizumab treatment, patients had by definition severe disease 
activity, and therefore likely higher CRP to begin with.  
SIL-6R and MMP-1 were significantly higher in those that were rheumatoid factor 
positive compared to those that were negative. A previous study did not show an 
association with sIL-6R level and rheumatoid factor positivity (Nishina et al 2013). It 
could be hypothesised that IL-6 and sIL-6R levels are higher in rheumatoid factor 
positive patients as IL-6 stimulates B cells to differentiate into plasma cells to produce 
immunoglobulins (Hirano et al 1988). There was no significant difference between 
other SCCPs. Those patients who were anti-CCP positive had significantly lower CRP 
than those who were negative. There was no difference in other SCCPS.  
 
 
5.5.2 Early arthritis study  
 
75% of those recruited were female, in line with female prevalence of RA in the 
general population (Humphreys et al 2012). Mean disease duration at the baseline 
visit, defined as the time from which the patient first developed symptoms of RA, 
was 4 months. However, there was a variable time between first diagnosis with RA 
and time recruited to the study. Therefore some patients were seen before DMARD 
207 
 
therapy was initiated, others after. This could have had a bearing on level of 
inflammation and progression of subclinical atherosclerosis before the patient was 
assessed. 52% of patients were followed for 12 months. Those who were lost to 
follow up included those who were uncontactable, had moved away, or did not reach 
the 12 month visit by the end of the study. Recruitment was lower than hoped; a 
large factor in this was that many patients were not eligible for recruitment as they 
had had symptoms of RA for greater than 6 months.   
Current UK NICE guidelines for RA state that patients should be offered a 
combination of DMARDs including methotrexate and short term glucocorticoids as 
first line treatment. This is the current practice in the early arthritis clinic in UHW. 
However, due to patient co-morbidities and patient choice this was not always 
possible. Only 9% of patients at baseline were taking this combination therapy but 
information about what was offered to patients in clinic was missing. Most patients 
at baseline were taking methotrexate. 
There was no significant correlation with baseline DAS28 and IL-6, sIL-6R or SCCPs. In 
the cross sectional study there was a significant positive correlation between DAS28 
and VCAM-1, perhaps reflecting greater patient numbers. There were also no 
significant correlations with baseline ultrasound scores and baseline SCCPs. There 
was a significant correlation between the DAS28 and US7 score but not US10 score. 
Interestingly, the US7 joint score has less joints in common with the DAS28 (5 joints 
in common) than the US10 score, which has 8 joints in common. However, the US7 
score includes more variables; tenosynovitis, paratenonitis, erosions, synovial 
thickening and vascularity, whereas the US10 score includes synovial vascularity and 
thickening only. Perhaps these extra markers included in the US7 reflect more closely 
the RA disease process, which may be reflected by the ESR and the patient VAS, both 
of which form part of the DAS28.  Of note, the original US10 score from Larché et al 
(2010) also includes a quantitative measure of vascularity which we did not include 
in this study as the software was not available.  
Disease activity significantly reduced at month 6 and 12. This was to be expected 
given treatment with DMARDs. At baseline there was no significant difference in CRP 
or IL-6 in those in DAS28 remission versus those not in remission. Those in DAS28 
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remission had significantly lower ESR, to be expected given that the ESR forms part 
of the DAS28. Interestingly, at 6 months those in DAS28 remission had significantly 
lower baseline CRP, ESR and IL-6. This may simply reflect the increased numbers of 
those in remission at 6 months compared to baseline (14 patients in remission at 6 
months versus 9 at baseline).  In addition, baseline IL-6 correlated significantly with 
US7 and US10 score at 12 months. These observations suggest the importance of 
inflammation at baseline in propagating the inflammatory response.  
There was no difference in CRP, ESR, IL-6 or SCCPs at baseline in those in remission 
at 12 months versus those not in remission. Baseline ESR, CRP and SCCPs were not 
significantly different in patients taking methotrexate versus those not taking 
methotrexate at baseline. CXCL9 at baseline was lower in those taking 
corticosteroids, other SCCPs, ESR and CRP were not different. In a study of patients 
with Adult Onset Stills disease, CXCL-9 fell significantly after treatment with 
corticosteroids (Han et al 2017). It may be expected that those taking corticosteroids 
would have lower CRP and ESR. However, those patients prescribed corticosteroids 
by a physician were likely to have had higher disease activity.  
54% patients had a greater than 10% risk of CV event over 10 years. This was similar 
to the rate found in the cross sectional study. These patients were advised to see 
their GP and a letter sent to the GP explaining this. Of these, only half were then 
subsequently started on a statin. Although no formal questionnaire was used to 
assess patients’ understanding of why no statin was prescribed, some stated that 
they discussed it with their GP and did not feel it was necessary, some did not visit 
their GP and some were not sure. The NICE guidelines were updated in 2014 to 
reduce the threshold for statin consideration from QRISK2 > 20% risk of CVD over 10 
years, to > 10% risk CVD over 10 years. Some GPs may not have been aware of the 
change in guidelines.  
CIMT > 0.90mm or the presence of plaques are predictors of CV events in RA as well 
as the general population (Gonzalez-Juanatey et al 2009). This definition was used to 
classify patients as carotid US positive in this study. A significant proportion (41%) of 
patients in this study were carotid US positive. Carotid US positive patients had 
several traditional risk factors which were significantly higher than carotid US 
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negative patients: age, BMI, systolic BP, total cholesterol, cholesterol:HDL ratio and 
LDL cholesterol. The QRISK2, Framingham, SCORE, ACCAHA were all significantly 
higher in carotid US positive patients. Of the SCCPs, only CXCL9 was higher in US 
positive patients. A previous study in the Yonsei Cardiovascular Genome Centre 
cohort measured CXCL9 and CIMT in 164 apparently healthy patients (Yu et al 2015) 
Of note, patients with cardiovascular disease, inflammatory disease and use of 
inflammatory medications were excluded. The authors found that CXCL-9 correlated 
significantly with CIMT after adjusting for confounding factors such as age, diabetes 
and smoking status, and medication. Patients with plaque on carotid US had 
significantly higher CXCL-9 than those without plaque. However, CXCL9 did not 
correlate with change in CIMT over the 2 year follow up. This is similar to the findings 
of this thesis. CXCL9 is a T cell chemoattractant which is produced by dendritic cells, 
B cells and macrophages and is induced by IFN-γ (Rosenblum et al 2010).  T cells 
contribute to atherosclerosis by propagating inflammation and plaque growth 
(Robertson and Hansson 2006).  
All cardiovascular risk scores had a strong correlation with CIMT. Interestingly, the 
Framingham risk score had a stronger correlation than the QRISK2, which is the only 
risk score to include RA as an independent risk factor for CVD. There was a very 
similar correlation between CIMT and QRISK2 value (r = 0.74) and CIMT and QRISK2 
value without adjustment for RA (r = 0.73) in patients with early RA. Of the CV risk 
scores, QRISK2 had the highest sensitivity but lowest specificity to detect carotid US 
positive patients. The SCORE had the lowest sensitivity but highest specificity to 
detect carotid US positive patients. Although the Framingham risk score had a strong 
correlation with CIMT, it did not perform well in sensitivity for US positive patients. 
This is likely to be due to the cut off used to define ‘high risk’ patients of > 20%.  
Another study by Ozen et al, 2016 found that the ACC/AHA score better identified 
high risk patients (using the same definition of carotid US positive patients as this 
thesis) compared to the QRISK2 and SCORE. They did not examine the Framingham 
risk score. However, this study was performed in patients with established RA in 
Turkey. Of note, the QRISK2 includes the Townsend deprivation index using a UK 
postcode, and such a measure would not have been included in the Turkish study.   
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There was no significant difference in CIMT at 6 and 12 months compared to baseline. 
There was a trend for CIMT to increase at month 6 and then reduce at month 12 
compared to baseline. Similarly, there was a trend for arterial stiffness and 
cholesterol:HDL ratio to increase at 6 months and then reduce at 12 months, again 
this was not significant. There are variable reports in the literature regarding changes 
in CIMT over time in RA patients. In a study of early RA patients in India, CIMT 
decreased significantly at 12 months from baseline, by an average of 0.07mm (Guin 
et al 2013). However, in this study RA patients had significantly higher DAS28 at 
baseline (5.61) and after 1 year (4.01) than in this thesis. In the study by Södergren 
et al (2010), mean CIMT increased by 0.05mm over 18 months, a longer period of 
time. The baseline mean DAS28 was 3.62, slightly lower than this thesis.  
This study found a moderate correlation between CIMT and cholesterol:HDL ratio 
and LDL cholesterol and a weak correlation between CIMT and total cholesterol. CV 
risk scores correlated more strongly with CIMT than with arterial distensibility. 
Distensibility coefficients were inversely associated with all cardiovascular risk 
scores, CIMT, total cholesterol and LDL cholesterol. Studies in animals have shown 
changes in arterial distensibility in the early stages of atherosclerosis (Hironaka et al 
1997). In humans, reduced distensibility is associated with CV risk factors (Dart et al 
1991) and can predict those at increased risk of future CV disease in healthy 
individuals (Mattace-Raso et al 2006). In Chapter 3 we found reduced aortic 
constriction in mice with CIA. There was a moderate inverse relationship between 
baseline CXCL9 and distensibility coefficient at 12 months. This finding has not been 
shown previously. Previous studies have shown that patients with acute coronary 
syndromes, those who developed events (death, nonfatal acute MI, and refractory 
unstable angina) had significantly higher CXCL9 than those who did not develop 
events (Dusi et al 2016). Studies have also shown increased expression of CXCL9 in 
human atherosclerotic plaques (Mach et al 1999).  
There was a significant relationship between change in CIMT at 6 months and 
baseline disease activity measured by DAS28, CRP and ESR. This suggests that 
inflammation is contributing to subclinical atherosclerosis progression in early RA. A 
study in the Netherlands found that while baseline DAS28 in patients with early RA 
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was not significantly different in those who had a CV event at 10 years versus those 
who did not, time-averaged DAS28 did have a significant effect on the risk of CVD 
(Arts et al 2014). In a prospective study in patients with inflammatory polyarthritis, 
CRP at baseline was found to predict death due to CVD (Goodson et al 2005). In 
another study of patients with longstanding RA, CRP correlated directly with the 
presence of atherosclerosis, as measured by CIMT, over an extended follow-up 
(Gonzalez-Gay et al 2005). In this thesis there was no difference in seropositivity and 
change in CIMT or DAS28 at 6 or 12 months. Interestingly, we found that increase in 
CIMT at 6 months was highest in those with high IL-6 and low sIL-6R level. The 
relationship between IL-6 and sIL-6R is complex and it is difficult to know whether 
this state would favour IL-6 classical or trans-signaling. Physiologically, there is more 
sIL-6R available in the serum than IL-6. IL-6 binds to sIL-6R and this complex is 
immediately neutralized by sgp130. Therefore, the sIL-6R and sgp130 constitute a 
buffer in the blood for circulating IL-6, which will only act systemically once the 
capacity of the buffer is exceeded (Calabrese and Rose-John 2014). Thus in this group 
of patients with high IL-6 and low sIL-6R, IL-6 trans-signaling may be more prominent. 
There did not seem to be a relationship between the complex of IL-6/sIL-6R and IL-6 
and sIL-6R individually. We found the IL-6/sIL-6R complex to be more unstable than 
other proteins detected by ELISA, for example more variation in levels measured by 
ELISA using the same sample at different time points. It may be more susceptible to 
environmental factors such as change in temperature. Also, IL-6/sIL-6R complex 
binds to sgp130 and therefore there may be more IL-6/sIL-6R complex in serum than 
detected by ELISA. 
 
Rapid progressors in this study had significantly higher baseline HbA1c, total 
cholesterol, cholesterol:HDL ratio, LDL cholesterol and VCAM-1. In a study by Arts et 
al RA patients who developed a CV event had significantly higher baseline (at the 
time of RA diagnosis) total cholesterol: HDL ratio (but not total cholesterol or LDL 
cholesterol) (Arts et al 2015). A complicating factor here is the lipid paradox; 
inflammation reduces total cholesterol, HDL cholesterol and LDL cholesterol in 
patients with RA (Gonzalez-Gay et al 2005). When inflammation improves, serum 
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cholesterol improves. This phenomenon was seen with tocilizumab treatment in this 
thesis and other studies have consistently shown that tocilizumab is associated with 
increased lipid levels in the context of decreased inflammatory markers (Ito and 
Takagi 2010, Emery et al 2008). The study by Arts et al (2015) also found significantly 
higher DAS28, ESR and CRP at baseline in those who developed CV events. Several of 
these variables, which are higher in rapid progressors (HbA1c and lipid levels) form 
part of the ‘metabolic syndrome’. The metabolic syndrome is defined most recently 
by the International Diabetes Foundation criteria (2005) (Zimmet et al 2005). This 
includes obesity, impaired fasting glucose, dyslipidaemia and hypertension. Central 
obesity is a prerequisite for this definition, which I did not measure. In this thesis, 
change in CIMT and change in distensibility over 12 months was not associated with 
smoking at baseline or ethnicity. Also, surprisingly, several of the traditional risk 
factors such as age, BP, BMI and serum triglyceride levels were not significantly 
higher in rapid progressors compared to non-rapid progressors. A prospective 5-year 
study of patients with early RA (classified as symptoms of less than 12 months) found 
that at 5 years, 10.9% of patients had experienced a new cardiovascular event, 12 of 
48 events were fatal. An increase in the hazard rate of a new CVE during follow up 
was predicted by some traditional risk factors: treated hypertension, higher 
triglyceride level, diabetes mellitus, greater age at disease onset, being male, having 
had a previous CV event, but also with higher cumulative disease activity and 
progression of extra articular disease. In this study, ESR at baseline had an 
unfavourable prognostic significance for a new CV event when evaluated together 
with CV risk factors and DMARD treatment (Innala et al 2011).  
This thesis found rapid progressors had significantly higher VCAM-1 than non-rapid 
progressors. This is a novel finding in RA patients. In the general population VCAM-1 
has been associated with CV disease. As previously mentioned, there are conflicting 
data in the literature regarding VCAM-1. In a six year observational study men with 
CV events during follow-up had higher baseline median serum ICAM-I and VCAM-I 
than those without CV events (Schmidt et al 2008). When the median serum ICAM-I 
and VCAM-1 were used as a cut off, those with levels above the cut-off value had an 
increased risk of having a plaque in the femoral artery. Another study found a 
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correlation between serum ICAM-1 and VCAM-1 and carotid IMT in the general 
population (Kondo et al 2005). However, a prospective cohort study found no 
association between elevated VCAM-1 and risk of future acute coronary event or 
angina pectoris in apparently healthy men aged 50-59 years over a 5 year follow up 
(Luc et al 2003). Studies have shown that VCAM-1 is rapidly induced by 
proatherosclerotic conditions, including early lesions. A study of 24 atherosclerotic 
plaques found that all contained some VCAM-1, compared to 45% of control 
segments (O’Brien et al 1993). The majority of VCAM-1 was found in areas of 
neovascularization and inflammatory infiltrate in the base of plaques compared to 
endothelial cells at the arterial lumen in control segments and in plaques. Most 
VCAM-1 was expressed by subsets of plaque smooth muscle cells and macrophages.  
 
There was no difference in change in CIMT at 1 year and methotrexate, 
corticosteroids or NSAID use. A prospective study of patients with early RA found that 
treatment with COX-2 inhibitors was significantly predictive of a new CV event at 5 
year follow up (Innala et al 2011). Another prospective study over 3 years of patients 
with established RA found no difference in CVD risk for patients taking NSAIDs but 
patients with RA who developed CVD were signiﬁcantly more often treated with COX-
2 inhibitors (Peters et al 2009).  Another study found that in RA patients with no 
history of CVD, corticosteroid use was associated with a 78% increased risk if CV 
death compared to those who did not receive corticosteroids (Maradit-Kremers et al 
2005b). However, in RA patients with a previous history of CVD, the risk of CV death 
was lower in those who received corticosteroids compared to those who did not. 
There is evidence that patients with RA have evidence of more unstable plaque and 
more inflammation within plaques, compared to controls (Aubry et al 2007). 
Perhaps, in this setting, corticosteroids play a role in plaque stabilisation.  
 
A few drawbacks of the present studies should be mentioned. There are inherent 
drawbacks with one-off measurements of SCCPs; they may change over a matter of 
days and can be altered by other medical conditions and intercurrent illness such as 
infection. To control for diurnal variation in several of the serum markers measured, 
214 
 
e.g. IL-6, patients were assessed in the morning between the hours of 9am and 11am. 
However, there is still some variability within this timeframe. In addition, there was 
a variable duration of RA at the time of baseline assessment. However, there were 
no correlations between disease duration and disease activity or atherosclerosis. We 
did not record physical activity levels of patients and this may also contribute to CV 
risk.  
There are several limitations to the methods used in this chapter. These are non-
controlled observational cohorts and disease is heterogenous. Also, patients were 
treated with different DMARDs, and some were treated with corticosteroids or 
NSAIDs. Thus, the sample may not be representative of the general RA population. 
In hindsight, the MSK US assessments (US7 and US10 scores) probably do not add 
much to information risk of CVD disease or subclinical atherosclerosis and the time 
used to perform these procedures may have been better used on other 
measurements of CV risk such as aortic pulse wave velocity. The definition of a rapid 
progressor (CIMT increase > 0.05mm) was made using results from Sodergren et al 
in the RA population. This is a fairly arbitrary cut off and is taken from a cohort of RA 
patients, not from the evidence base in the general population. 
 
5.6 Conclusions 
 
1. Over 50% of patients with established RA and early RA (at the time of 
diagnosis) are classified as being high risk of CVD according to the QRISK2.  
2. VCAM-1 correlated with disease activity and cardiovascular risk in patients 
with established RA.    
3. Several traditional CV risk factors predict CIMT progression. Inflammation 
from disease onset in CV susceptible individuals may accelerate 
atherosclerosis. In early RA baseline disease activity correlated significantly 
with change in CIMT at 6 months.  
4. Rapid progressors had significantly higher serum VCAM-1 at baseline than 
non-rapid progressors.  
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6 General discussion  
 
Cardiovascular mortality in patients with RA is up to 50% higher than the general 
population (Gabriel 2008). Although it is well established that incidence of CVD is 
increased in RA, the precise cause is unclear. There is increasing recognition that 
systemic inflammation is a major driver of this increased CV risk (Gabriel 2008, del 
Rincon et al 2001, Arts et al 2014). IL-6 has been implicated in CVD in the general 
population but its role in CVD in RA is not well defined. Of the two modes of IL-6 
signaling, there is increasing evidence that trans-signaling is pro-inflammatory 
whereas classical signaling has important regenerative or anti-inflammatory effects. 
In chapter 3, I show that IL-6 trans-signaling is implicated in vascular dysfunction in 
CIA. In chapter 4, I show that IL-6 trans-signaling leads to accelerated atherosclerosis 
in a susceptible animal model. In chapter 5, I show that VCAM-1, regulated by IL-6 
trans-signaling, is associated with progression of subclinical atherosclerosis in 
patients with early RA.  
 
Prior to the work carried out in this thesis it was known that CIA was associated with 
aortic contractile dysfunction. The work in this thesis validates this finding but, for 
the first time, I show that selective blockade of IL-6 trans-signaling, using intravenous 
sgp130Fc, reduces arthritis severity and restores the vascular dysfunction associated 
with CIA. This improvement in vascular function may be due to the effect of IL-6 
trans-signaling on macrophage recruitment into the vessel wall and surrounding 
adipose tissue. Previous work by Williams et al (2016) found mice with CIA have 
increased macrophages in the aorta and perivascular adipose tissue (PVAT). Another 
study by Kraakman et al (2015) found IL-6 trans-signaling recruited macrophages to 
adipose tissue in high fat diet-induced obesity in mice and that blocking IL-6 trans-
signaling with sgp130Fc in these mice prevented macrophage accumulation in 
adipose tissue.  The improvement in vascular function in mice treated with sgp130Fc 
in this thesis was associated with a reduction in serum CCL2 and VCAM-1. CCL2 
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recruits monocytes to sites of inflammation; these then differentiate into 
macrophages (Yang et al 2014). VCAM-1 induces immune-cell recruitment within 
vessel walls.  Previous work using the Biomap® system found that CCL2 and VCAM-1 
were regulated by IL-6 trans-signaling (Tan et al 2013). Thus, sgp130Fc may restore 
vascular function by decreasing CCL2 and VCAM-1-driven recruitment of 
macrophages into the aorta and PVAT. To further explore this hypothesis I could 
examine the effect of blockade of IL-6 trans-signaling on VCAM-1, CCL2 and 
macrophage expression in the aorta and PVAT in CIA.  
 
Also for the first time, I have shown that IL-6 trans-signaling using Hyper-IL-6 
increases plaque size in ApoE-/- mice. This accelerated atherosclerosis was not 
observed with IL-6 alone. There is conflicting evidence of the role of IL-6 in 
atherosclerosis in the literature. A previous study in ApoE-/- mice reported that IL-6 
administration increased atherosclerotic lesion size in the aortic sinus (Huber at al 
1999). However, another study found that serum cholesterol levels and 
atherosclerotic lesion formation were significantly increased in ApoE-/--IL-6-/- mice 
compared with ApoE-/- and wild-type mice (Schieffer et al 2004). Previous work in 
LDLr-/- mice showed that blockade of IL-6 trans-signaling, using sgp130Fc, reduced 
atherosclerosis (Schuett et al 2011). Overall, the role of IL-6 in atherosclerosis is 
complex; while a potent pro-inflammatory cytokine, IL-6 can have anti-
atherosclerotic effects, and its opposing effects may be explained in part by its two 
modes of signaling. For the first time, the work in this chapter shows that IL-6 trans-
signaling, rather than IL-6 classical signaling, increases atherosclerosis in a mouse 
model. This increase in plaque size with Hyper-IL-6 may be partly driven by the 
increased arterial and plaque expression of VCAM-1 in those administered Hyper-IL-
6. This increase in VCAM-1 was not seen with IL-6 administration. Plaque size in the 
brachiocephalic artery correlated with arterial VCAM-1 expression but not serum 
VCAM-1. The increase in plaque with Hyper-IL-6 was not accompanied by an increase 
in serum lipid levels. This is similar to findings in LDLr-/- mice, whereby sgp130Fc 
reduced atherosclerosis but did not affect serum lipid levels (Schuett et al 2011).  In 
RA patients, IL-6 blockade using Tocilizumab increases serum total cholesterol, HDL, 
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LDL and triglyceride levels (Choy et al 2014). In the ApoE-/- model used in this thesis 
lipid levels were considerably higher than in RA patients (total cholesterol 
approximately 4 times higher in ApoE-/- mice than in RA patients), so that any increase 
in lipid levels with additional inflammation may be negligible.  
 
In chapter 5, I found that over half of patients with established RA were classified as 
high risk of CVD over the next 10 years. These patients had significantly higher VCAM-
1 than those classified as low CV risk. This is a novel finding in RA. In the general 
population, there is conflicting evidence of the role of VCAM-1 in predicting those at 
high risk of CV events. Schmidt et al (2008) reported higher VCAM-1 in those who 
developed CV events in the general population. However, other studies of the 
general population found VCAM-1 did not provide significant improvement in CVD 
risk assessment beyond conventional CVD risk factors (Kunutsor et al 2017, Malik et 
al 2001) and was not significantly different in apparently healthy individuals that 
went on to develop CVD compared to those that did not (Luc et al 2003). These 
studies in the general population examined patients longitudinally and measured CV 
outcomes. To examine whether the finding of higher VCAM-1 in patients classified as 
high CV risk in this thesis is in fact predictive of CV events, these patients could be 
followed-up over the next 10 years and CV events recorded.  
 
In chapter 5, patients with early RA in DAS28 remission at 6 months had significantly 
lower baseline CRP, ESR and IL-6. In addition, baseline IL-6 correlated significantly 
with US7 and US10 scores at 12 months. A previous study reported a positive 
association between baseline IL-6 and radiographic progression of RA over 4 years 
(Klein-Wieringa et al 2011). To my knowledge, this is the first time that baseline IL-6 
has been shown to be positively associated with ultrasound scores at 12 months.  
These observations suggest the importance of inflammation at baseline in 
propagating the inflammatory response. I did not correlate SCCPs at baseline with 
radiologic damage at 12 months using established scoring systems such as the 
Sharp/van der Heijde scoring (SHS) method (van der Heijde 2000). This could be an 
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area for future work, as radiographic damage and joint deformity are major causes 
of disability for RA patients.   
 
It is known that in early RA, CV risk is increased. I have confirmed the high prevalence 
(41%) of subclinical atherosclerosis in patients with early RA. Carotid US positive 
patients had several traditional risk factors which were significantly higher than 
carotid US negative patients: age, BMI, systolic BP, total cholesterol, cholesterol/HDL 
ratio and LDL cholesterol. Ozen et al found that carotid US positive RA patients had 
higher cholesterol:HDL ratio and age, but not LDL cholesterol or BMI (Ozen et al 
2016). A novel finding of this chapter is that carotid US positive patients had higher 
CXCL9. This has been found previously in the general population (Yu et al 2015) but 
not in RA patients. Previous work using the Biomap® system found that CXCL9 is 
regulated by IL-6 trans-signaling. CXCL9 is a T cell chemoattractant; these cells 
contribute to atherosclerosis by propagating inflammation and plaque growth 
(Robertson and Hansson 2006). CXCL9 was not associated with progression of 
atherosclerosis over 12 months in this thesis but it would be interesting to follow 
these patients up over an extended period and examine the association between 
baseline CXCL9 and CV events.  
 
I have confirmed previous findings that some traditional risk factors (HbA1c, total 
cholesterol, cholesterol:HDL ratio and LDL cholesterol) predict CIMT progression in 
early RA. However, I also show the novel finding that baseline serum VCAM-1 is 
elevated in RA patients who become rapid progressors in terms of subclinical 
atherosclerosis. This adds weight to the finding in this thesis in the cross sectional 
study of patients with established RA that serum VCAM-1 was higher in those 
classified as high CV risk. I also show that baseline disease activity correlates with 
change in change in CIMT at 6 months. Taken together, these findings suggest that 
in RA, inflammation from disease onset may accelerate atherosclerosis in susceptible 
individuals, which confirms the data in ApoE-/- in Chapter 4. This proposed interaction 
between pre-existing CV risk factors and inflammation, autoimmunity and 
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dyslipidaemia at the onset of RA, or even before RA becomes apparent, is 
summarised in Figure 96.   
 
 
 
 
Figure 96. Summary of hypothesis of the effect of inflammation at RA onset on progression of 
atherosclerosis 
 
In all three results chapters, VCAM-1 was consistently associated with disease states. 
In chapter 3, restoration of vascular function in mice treated with sgp130Fc was 
associated with reduced serum VCAM-1. In chapter 4, the increase in plaque size 
seen in ApoE-/- mice with Hyper-IL-6 was associated with increased arterial and 
plaque expression of VCAM-1, which correlated with VCAM-1 arterial expression but 
not serum VCAM-1.  In chapter 3, serum VCAM-1 correlated with disease activity and 
cardiovascular risk in established RA, and in early RA baseline VCAM-1 was higher in 
patients who developed rapid progression of subclinical atherosclerosis.  What 
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remains to be elucidated is whether serum VCAM-1 can predict CV events in RA 
patients. It is also important to mention that inclusion of a biomarker in a risk model 
requires detailed knowledge of the biomarker level in the general population. In 
addition, these consistent findings of association of VCAM-1 in disease states prompt 
consideration about the potential role of blockade of VCAM-1 in the treatment of RA 
and atherosclerosis.   
 
The relationship between cell surface VCAM-1 and soluble serum VCAM-1 is complex 
and appears to be context dependent. In vitro, soluble VCAM-1 levels correlate with 
surface expression (Kjaergaard et al 2013). Of note in this thesis, there was no 
significant correlation between VCAM-1 expression in atherosclerotic plaque in 
ApoE-/- mice and serum VCAM-1. In RA patients, VCAM-1 synovial membrane 
expression does not correlate with serum or synovial fluid levels (Mulherin et al 
1996). Circulating soluble VCAM-1 results either from alternating splicing of mRNA 
or proteolysis of the membrane-bound protein form. The ligand for VCAM-1 is VLA-
4 (Navarro-Hernández et al 2009). Soluble VCAM-1 may act as a competitive inhibitor 
of ligand binding (Rose et al 2000). Of note, Kitani et al found that in RA synovial fluid, 
the binding of soluble VCAM-1 to T cells inhibited their activation (Kitani et al 1996).  
 
In view of its role in both RA and atherosclerosis, blockade of VCAM-1 may be 
beneficial in these diseases. Park et al (2013) found anti-VCAM-1 antibodies 
attenuated atherosclerosis in ApoE-/- mice. Carter et al found that neutralizing 
monoclonal antibody to VCAM-1 resulted in reduced severity, but not incidence of 
CIA in mice (Carter et al 2002). However, studies in patients with atherosclerosis have 
not been successful so far. A study in patients with ACS found that succinobucol (an 
agent which blocks VCAM-1 expression and has anti-oxidant effects) was not 
associated with a difference in the primary endpoint of CV death, cardiac arrest, MI, 
stroke, unstable angina, or coronary revascularization compared with placebo at 2-
year follow-up (Tardif et al 2008). Also, compared with placebo, succinobucol 
increased LDL cholesterol and systolic blood pressure, and decreased HDL cholesterol 
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and HbA1c. Natalizumab is a recombinant, humanized antibody which binds to VLA-
4 and blocks its interaction with VCAM-1. Natalizumab is licensed for treatment of 
highly active relapsing remitting multiple sclerosis (Torkildsen et al 2016) and 
refractory Crohn’s disease (Sandborn et al 2005). However, inhibition of the VLA-
4/VCAM-1 interaction affects the cellular immune response and there have been 
reports of progressive multifocal leukoencephalopathy (Ho et al 2017) and 
sarcoidosis (Parisinos et al 2011) in patients treated with Natalizumab.  
 
Other drugs that have recently been approved for the treatment of RA are the JAK 
inhibitors baricitinib and tofacitinib. Baricitinib inhibits JAK1 and JAK2 and tofacitinib 
inhibits JAK1 and JAK3. IL-6 signals through the JAK/STAT pathway, specifically JAK1 
and JAK2. Therefore both these drugs inhibit the action of IL-6, but also many other 
cytokines such as IFN-γ, IL-8 and IL-23 (Cutolo et al 2013). Both drugs have shown 
efficacy in RA in trials and have the benefit of being oral drugs, but side effects include 
serious infections, deranged liver function tests, neutropenia and increased serum 
lipid levels (Dougados et al 2017, Cutolo et al 2013). Similar to tocilizumab, despite 
the increase in lipids levels, so far there does not seem to be an increase in CV events 
(Weinblatt et al 2017, Charles-Schoeman et al 2016), although long terms effects 
remain to be elucidated. These drugs block downstream activities of both IL-6 
classical and trans-signaling. Selective blockade of IL-6 trans-signaling may offer an 
advantage over these drugs as this strategy offers a reduction in inflammation whilst 
allowing the regenerative and homeostatic effects of IL-6 classical signaling to 
continue.  
 
Overall, IL-6 trans-signaling appears to play a pivitol role in vascular dysfunction and 
atherosclerosis in mouse models. In humans, proteins regulated by IL-6 trans-
signaling are associated with progression of subclinical atherosclerosis in early RA. 
These findings suggest that blockade of IL-6 trans-signaling may be beneficial to 
patients with RA, and perhaps for atherosclerosis in the general population. 
Sgp130Fc successfully underwent phase I clinical trials in 2014 and is currently under 
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the name Olamkicept in phase II clinical trials for use in treatment of inflammatory 
bowel disease (Rose-John 2017), this could also have therapeutic applicability in the 
management of rheumatoid arthritis.  
 
Directions for future work  
To further explore the mechanisms of improved vascular function with IL-6 trans-
signalling blockade in CIA I could examine VCAM-1, CCL2 and macrophage expression 
in the aorta and PVAT. Another area of investigation would be to examine the effect 
of VCAM-1 blockade effect on vascular dysfunction in CIA. Another strategy would 
be to examine the effect of soluble VCAM-1 on atherosclerosis in the ApoE-/- and CIA 
model to determine if soluble VCAM-1 regulates inflammation. It would also be 
interesting to examine plaques from RA patients at autopsy and measure VCAM-1, 
CCL2, IL-6 and IL-6R and compare with those from the general population.  
As discussed, patients in both the cross sectional study and early RA study could be 
followed up over an extended period, perhaps 5 years, and onset of CVD or CV events 
measured. The association of SCCPs, particularly VCAM-1 and CXCL9 with CV 
outcomes could be examined. I could also examine joint radiological damage at 5 
years and correlate with baseline SCCPs.  
The relationship between serum IL-6, sIL-6R, the complex of IL-6/sIL-6R and sgp130 
is still not fully elucidated and there are likely to be complex mechanisms at play in 
RA patients, which change throughout the course of the disease. Serial 
measurements of these proteins over time and their response to treatment would 
be interesting to examine.   
Another area for future study, which has increasing recognition in the literature, is 
‘pre-RA’. It is known that even before RA diagnosis, patients have increased levels of 
inflammation and dyslipidaemia. To study these patients is inherently difficult, but 
studies on groups that are at increased risk of developing RA, such as those with a 
strong family history, would be of value. Measures of subclinical atherosclerosis and 
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measurement of SCCPs could be performed, and a longitudinal study examining RA 
and atherosclerosis development undertaken.  
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